

Peter Mac publications 2022

January

1. Agarwal N, Azad A, Shore ND, Carles J, Fay AP, Dunshee C, Karsh LI, Paccagnella ML, Santo ND, Elmeliogy M, Lin X, Czibere A, Fizazi K. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. *Future Oncol* 2022;18:425-36.
2. Aide N, Iravani A, Prigent K, Kottler D, Alipour R, Hicks RJ. PET/CT variants and pitfalls in malignant melanoma. *Cancer Imaging* 2022;22:3.
3. Anton A, Tran B. Global Disparity in Access to Novel Therapeutics for Metastatic Prostate Cancer. *JCO Oncol Pract* 2022;18:57-9.
4. Archer C, Veall J, Duggan LV, Downey A, Rose P. A comparison of patient and provider perceptions of awake tracheal intubations. *Can J Anaesth* 2022;69:179-81.
5. Barnes DR, Silvestri V, Leslie G, McGuffog L, Dennis J, Yang X, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arason A, Arnold N, Auber B, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Barwell J, Belotti M, Benitez J, Berthet P, Boonen SE, Borg Å, Bozsik A, Brady AF, Brennan P, Brewer C, Brunet J, Bucalo A, Buys SS, Caldés T, Caligo MA, Campbell I, Cassingham H, Christensen LL, Cini G, Claes KBM, Cook J, Coppa A, Cortesi L, Damante G, Darder E, Davidson R, de la Hoya M, De Leeneer K, de Putter R, Del Valle J, Diez O, Ding YC, Domchek SM, Donaldson A, Eason J, Eeles R, Engel C, Evans DG, Feliubadaló L, Fostira F, Frone M, Frost D, Gallagher D, Gehrig A, Giraud S, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gregory H, Gross E, Hahnen E, Hamann U, Hansen TVO, Hanson H, Hentschel J, Horvath J, Izatt L, Izquierdo A, James PA, Janavicius R, Jensen UB, Johannsson OT, John EM, Kramer G, Kroeldrup L, Kruse TA, Lautrup C, Lazaro C, Lesueur F, Lopez-Fernández A, Mai PL, Manoukian S, Matrai Z, Matricardi L, Maxwell KN, Mebirouk N, Meindl A, Montagna M, Monteiro AN, Morrison PJ, Muranen TA, Murray A, Nathanson KL, Neuhausen SL, Nevanlinna H, Nguyen-Dumont T, Niederacher D, Olah E, Olopade OI, Palli D, Parsons MT, Pedersen IS, Peissel B, Perez-Segura P, Peterlongo P, Petersen AH, Pinto P, Porteous ME, Pottinger C, Pujana MA, Radice P, Ramser J, Rantala J, Robson M, Rogers MT, Rønlund K, Rump A, Sánchez de Abajo AM, Shah PD, Sharif S, Side LE, Singer CF, Stadler Z, Steele L, Stoppa-Lyonnet D, Sutter C, Tan YY, Teixeira MR, Teulé A, Thull DL, Tischkowitz M, Toland AE, Tommasi S, Toss A, Trainer AH, Tripathi V, Valentini V, van Asperen CJ, Venturelli M, Viel A, Vijai J, Walker L, Wang-Gohrke S, Wappenschmidt B, Whaite A, Zanna I, Offit K, Thomassen M, Couch FJ, Schmutzler RK, Simard J, Easton DF, Chenevix-Trench G, Antoniou AC, Ottini L. Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. *J Natl Cancer Inst* 2022;114:109-22.
6. Body A, Wong R, Shapiro J, Jalali A, McLachlan SA, Ananda S, Lipton L, Cooray P, Gibbs P, Lee B, Lee M. Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia. *Intern Med J* 2022;52:49-56.
7. Bournazos AM, Riley LG, Bommireddipalli S, Ades L, Akesson LS, Al-Shinnag M, Alexander SI, Archibald AD, Balasubramaniam S, Berman Y, Beshay V, Boggs K, Bojadzieva J, Brown NJ, Bryen SJ, Buckley MF, Chong B, Davis MR, Dawes R, Delatycki M, Donaldson L, Downie L, Edwards C, Edwards M, Engel A, Evans LJ, Faiz F, Fennell A, Field M, Freckmann ML, Gallacher L, Gear R, Goel H, Goh S, Goodwin L, Hanna B, Harraway J, Higgins M, Ho G, Hopper BK, Horton AE, Hunter MF, Huq AJ, Josephi-Taylor S, Joshi H, Kirk E, Krzesinski E, Kumar KR, Lemckert F, Leventer RJ, Lindsey-Temple SE, Lunke S, Ma A, Macaskill S, Mallawaarachchi A, Marty M, Marum JE, McCarthy HJ, Menezes MP, McLean A, Milnes D, Mohammad S, Mowat D, Niaz A, Palmer EE, Patel C, Patel SG, Phelan D, Pinner JR, Rajagopalan S, Regan M, Rodgers J, Rodrigues M, Roxburgh RH, Sachdev R, Roscioli T, Samarasekera R, Sandaradura SA, Savva E, Schindler T, Shah M, Sinnerbrink IB, Smith JM, Smith RJ, Springer A, Stark Z, Strom SP, Sue CM, Tan K, Tan TY, Tantsis E, Tchan MC, Thompson BA, Trainer AH, van Spaendonck-Zwarts K, Walsh R, Warwick L, White S, White SM, Williams MG, Wilson MJ, Wong WK, Wright DC, Yap P, Yeung A, Young H, Jones KJ, Bennetts B, Cooper ST. Standardized practices for RNA diagnostics using clinically accessible specimens reclassifies 75% of putative splicing variants. *Genet Med* 2022;24:130-45.

8. Brodsky RA, Lee JW, Nishimura JI, Szer J. Lactate dehydrogenase versus haemoglobin: which one is the better marker in paroxysmal nocturnal haemoglobinuria? *Br J Haematol* 2022;196:264-5.
9. Brown L, Loveday B. Acute pancreatitis in Australian adults: can administrative data help with healthcare planning? *ANZ J Surg* 2022;92:8-9.
10. Buske C, Tedeschi A, Trotman J, García-Sanz R, MacDonald D, Leblond V, Mahe B, Herbaux C, Matous JV, Tam CS, Heffner LT, Varettoni M, Palomba ML, Shustik C, Kastritis E, Treon SP, Ping J, Hauns B, Arango-Hisijara I, Dimopoulos MA. Ibrutinib plus Rituximab Versus Placebo plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis from the Randomized Phase III iNOVATE Study. *J Clin Oncol* 2022;40:52-62.
11. Cameron LB, Hitchen N, Chandran E, Morris T, Manser R, Solomon BJ, Jordan V. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. *Cochrane Database Syst Rev* 2022;1:CD013453.
12. Carmichael L, Rocca R, Laing E, Ashford P, Collins J, Jackson L, McPherson L, Pendergast B, Kiss N. Early postoperative feeding following surgery for upper gastrointestinal cancer: A systematic review. *J Hum Nutr Diet* 2022;35:33-48.
13. Chau TCY, Baek S, Coxam B, Skoczylas R, Rondon-Galeano M, Bower NI, Wainwright EN, Stacker SA, Cooper HM, Koopman PA, Lagendijk AK, Harvey NL, François M, Hogan BM. Pkd1 and Wnt5a genetically interact to control lymphatic vascular morphogenesis in mice. *Dev Dyn* 2022;251:336-49.
14. Chen K, Murphy D, Lawrentschuk N. Active Surveillance for Low-Risk Prostate Cancer: The Uphill Battles and the Unnecessary Ones. *J Urol* 2022;207:265-7.
15. Chi LH, Burrows AD, Anderson RL. Can preclinical drug development help to predict adverse events in clinical trials? *Drug Discov Today* 2022;27:257-268.
16. Choi PY, Merriman E, Bennett A, Enjeti AK, Tan CW, Goncalves I, Hsu D, Bird R. Consensus guidelines for the management of adult immune thrombocytopenia in Australia and New Zealand. *Med J Aust* 2022;216:43-52.
17. Chong E, Ratnayake B, Dasari BVM, Loveday BPT, Siriwardena AK, Pandanaboyana S. Adjuvant Chemotherapy in the Treatment of Intraductal Papillary Mucinous Neoplasms of the Pancreas: Systematic Review and Meta-Analysis. *World J Surg* 2022;46:223-34.
18. Cousin S, Blay JY, Garcia IB, de Bono JS, Le Tourneau C, Moreno V, Trigo J, Hann CL, Azad AA, Im SA, Cassier PA, French CA, Italiano A, Keedy VL, Plummer R, Sablin MP, Hemming ML, Ferron-Brady G, Wyce A, Khaled A, Datta A, Foley SW, McCabe MT, Wu Y, Horner T, Kremer BE, Dhar A, O'Dwyer PJ, Shapiro GI, Piha-Paul SA. Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study. *Int J Cancer* 2022;150:993-1006.
19. Crowe J, Francis JJ, Edbrooke L, Loeliger J, Joyce T, Prickett C, Martin A, Khot A, Denehy L. Impact of an allied health prehabilitation service for haematologic patients receiving high-dose chemotherapy in a large cancer centre. *Support Care Cancer* 2022;30:1841-52.
20. Davidson NM, Chen Y, Sadras T, Ryland GL, Blombery P, Ekert PG, Göke J, Oshlack A. JAFFAL: detecting fusion genes with long-read transcriptome sequencing. *Genome Biol* 2022;23:10.
21. Deftereos I, Yeung JM, Arslan J, Carter VM, Isenring E, Kiss N. Adherence to ESPEN guidelines and associations with postoperative outcomes in upper gastrointestinal cancer resection: results from the multi-centre NOURISH point prevalence study. *Clin Nutr ESPEN* 2022;47:391-8.
22. Degeling K, IJzerman MJ, Groothuis-Oudshoorn CGM, Franken MD, Koopman M, Clements MS, Koffijberg H. Comparing Modeling Approaches for Discrete Event Simulations with Competing Risks Based on Censored Individual Patient Data: A Simulation Study and Illustration in Colorectal Cancer. *Value Health* 2022;25:104-15.

23. Delahunt B, Steigler A, Atkinson C, Christie D, Duchesne G, Egevad L, Joseph D, Kenwright DN, Matthews J, Murray JD, Oldmeadow C, Samaratinga H, Spry NA, Thunders MC, Hondermarck H, Denham JW. Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: 10-year data from the TROG 03.04 RADAR trial. *Pathology* 2022;54:49-54.
24. Delany C, Milch V, Keefe D, Wong ZW. COVID-19 recovery: implications for cancer care clinicians. *Support Care Cancer* 2022;30:1003-6.
25. Dervisevic E, Voelcker NH, Risbridger G, Tuck KL, Cadarso VJ. Colorimetric Detection of Extracellular Hydrogen Peroxide Using an Integrated Microfluidic Device. *Anal Chem* 2022;94:1726-32.
26. Diepstraten ST, Anderson MA, Czabotar PE, Lessene G, Strasser A, Kelly GL. The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. *Nat Rev Cancer* 2022;22:45-64.
27. Edbrooke L, Khaw P, Freimund A, Carpenter D, McNally O, Joubert L, Loeliger J, Traill A, Gough K, Mileskin L, Denehy L. ENhancing Lifestyle Behaviors in Endometrial CancEr (ENABLE): A Pilot Randomized Controlled Trial. *Integr Cancer Ther* 2022;21:15347354211069885.
28. Ewe KYH, Blyth CC, McLeod C, Borland ML, Bowen AC, Yeoh DK, Campbell AJ. Re-examining Hepatitis B Postexposure Prophylaxis Following Pediatric Community-acquired Needle-stick Injury in an Era of a National Immunization Registry. *Pediatr Infect Dis J* 2022;41:80-84.
29. Fennell DA, Griffiths G, Ottensmeier C, Hanna GG, Danson S, Szlosarek P, Nye M. CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply. *Lancet Oncol* 2022;23:e14-e15.
30. Fennell KA, Vassiliadis D, Lam EYN, Martelotto LG, Balic JJ, Hollizeck S, Weber TS, Semple T, Wang Q, Miles DC, MacPherson L, Chan YC, Guirguis AA, Kats LM, Wong ES, Dawson SJ, Naik SH, Dawson MA. Non-genetic determinants of malignant clonal fitness at single-cell resolution. *Nature* 2022;601:125-31.
31. Ferguson MT, Kusre S, Myles PS. Minimal clinically important difference in days at home up to 30 days after surgery. *Anaesthesia* 2022;77:196-200.
32. Fidelito G, Watt MJ, Taylor RA. Personalized Medicine for Prostate Cancer: Is Targeting Metabolism a Reality? *Front Oncol* 2022;11:778761.
33. Flood M, Narasimhan V, Wilson K, Lim WM, Ramsay R, Michael M, Heriot A. Organoids as a Robust Preclinical Model for Precision Medicine in Colorectal Cancer: A Systematic Review. *Ann Surg Oncol* 2022;29:47-59.
34. Flood M, Ramsay R, Heriot A. ASO Author Reflections: Organoid-Based Precision Medicine in Colorectal Cancer-Are We There Yet? *Ann Surg Oncol* 2022;29:60-1.
35. Forbes Shepherd R, Werner-Lin A, Keogh LA, Delatycki MB, Forrest LE. Reproduction and Genetic Responsibility: An Interpretive Description of Reproductive Decision-Making for Young People with Li-Fraumeni Syndrome. *Qual Health Res* 2022;32:168-181.
36. Gafita A, Wang H, Robertson A, Armstrong WR, Zaum R, Weber M, Yagubbayli F, Kratochwil C, Grogan TR, Nguyen K, Navarro F, Esfandiari R, Rauscher I, Menze B, Elashoff D, Delpassand ES, Herrmann K, Czernin J, Hofman MS, Calais J, Fendler WP, Eiber M. Tumor Sink Effect in ⁶⁸Ga-PSMA-11 PET: Myth or Reality? *J Nucl Med* 2022;63:226-32.
37. Gates P, Dhillon H, Gough K, Wilson C, Hawkes E, Scudder L, Cushion T, Krishnasamy M. Exploration of motivation to participate in a study of cancer-related cognitive impairment among patients with newly diagnosed aggressive lymphoma: a qualitative sub-study. *Support Care Cancer* 2022;30:1331-9.
38. Granger CL, Edbrooke L, Antippa P, Wright G, McDonald CF, Lamb KE, Irving L, Krishnasamy M, Abo S, Whish-Wilson GA, Truong D, Denehy L, Parry SM. Effect of a postoperative home-based exercise and self-management programme on physical function in people with lung cancer (CAPACITY): protocol for a randomised controlled trial. *BMJ Open Respir Res* 2022;9:e001189.

39. Guccione L, Gough K, Drosdowsky A, Price T, Pavlakis N, Wyld D, Ransom D, Michael M, Schofield P. The unmet supportive care needs, quality of life, and care experiences of patients with functioning and non-functioning neuroendocrine tumours (NETs) at early diagnosis. *Patient Educ Couns* 2022;105:212-20.
40. Hagberg CA, Nates JL, Riedel B, Gottumukkala VNR, Buggy D (Eds). *Perioperative Care of the Cancer Patient*. Elsevier, Cambridge, MA, USA, 2022.
41. Harvey M, Chislett B, Perera M, Lawrentschuk N, Bolton D, Jack G. Critical shortage in BCG immunotherapy: How did we get here and where will it take us? *Urol Oncol* 2022;40:1-3.
42. Hicks R, Czernin J, Herrmann K. Advancing Nuclear Medicine in Australia over 3 Decades: A Conversation Between Rodney Hicks, Johannes Czernin, and Ken Herrmann. *J Nucl Med* 2022;63:1-4.
43. Howard-Jones AR, Bowen AC, Danchin M, Koirala A, Sharma K, Yeoh DK, Burgner DP, Crawford NW, Goeman E, Gray PE, Hsu P, Kuek S, McMullan BJ, Tosif S, Wurzel D, Britton PN. COVID-19 in children: I. Epidemiology, prevention and indirect impacts. *J Paediatr Child Health* 2022 Jan;58:39-45.
44. Howard-Jones AR, Burgner DP, Crawford NW, Goeman E, Gray PE, Hsu P, Kuek S, McMullan BJ, Tosif S, Wurzel D, Bowen AC, Danchin M, Koirala A, Sharma K, Yeoh DK, Britton PN. COVID-19 in children. II: Pathogenesis, disease spectrum and management. *J Paediatr Child Health* 2022;58:46-53.
45. Jadvar H, Calais J, Fanti S, Feng F, Greene KL, Gulley JL, Hofman M, Koontz BF, Lin DW, Morris MJ, Rowe SP, Royce TJ, Salami S, Savir-Baruch B, Srinivas S, Hope TA. Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging. *J Nucl Med* 2022;63:59-68.
46. John T, Taylor A, Wang H, Eichinger C, Freeman C, Ahn MJ. Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes. *Cancer Epidemiol* 2022;76:102080.
47. Kok PS, Lee K, Lord S, John T, Marschner I, Wu YL, Mok TSK, Lee CK. Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer. *Lung Cancer* 2022;163:14-8.
48. Kusnadi EP, Timpone C, Topisirovic I, Larsson O, Furic L. Regulation of gene expression via translational buffering. *Biochim Biophys Acta Mol Cell Res* 2022;1869:119140.
49. Li H, Engel C, de la Hoya M, Peterlongo P, Yannoukakos D, Livraghi L, Radice P, Thomassen M, Hansen TVO, Gerdes AM, Nielsen HR, Caputo SM, Zambelli A, Borg A, Solano A, Thomas A, Parsons MT, Antoniou AC, Leslie G, Yang X, Chenevix-Trench G, Caldes T, Kwong A, Pedersen IS, Laurrup CK, John EM, Terry MB, Hopper JL, Southey MC, Andrulis IL, Tischkowitz M, Janavicius R, Boonen SE, Kroeldrup L, Varesco L, Hamann U, Vega A, Palmero EI, Garber J, Montagna M, Van Asperen CJ, Foretova L, Greene MH, Selkirk T, Moller P, Toland AE, Domchek SM, James PA, Thorne H, Eccles DM, Nielsen SM, Manoukian S, Pasini B, Caligo MA, Lazaro C, Kirk J, Wappenschmidt B, Spurdle AB, Couch FJ, Schmutzler R, Goldgar DE. Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants. *Genet Med* 2022;24:119-29.
50. Lim BWX, Li N, Rowley SM, Thompson ER, McInerney S, Zethoven M, Scott RJ, Devereux L, Sloan EK, James PA, Campbell IG. Integration of tumour sequencing and case-control data to assess pathogenicity of RAD51C missense variants in familial breast cancer. *NPJ Breast Cancer* 2022;8:10.
51. Lin T, Pham J, Paul E, Conron M, Wright G, Ball D, Mitchell P, Atkin N, Brand M, Zalcborg J, Stirling RG. Impacts of lung cancer multidisciplinary meeting presentation: Drivers and outcomes from a population registry retrospective cohort study. *Lung Cancer* 2022;163:69-76.
52. Lippey J, Keogh L, Campbell I, Mann GB, Forrest L. Development and pilot testing of an online decision aid for women considering risk-stratified breast screening. *J Community Genet* 2022;13:137-41.
53. Liu Z, Martin JH, Liauw W, McLachlan SA, Link E, Matera A, Thompson M, Jefford M, Hicks RJ, Cullinane C, Hatzimihalis A, Campbell I, Crowley S, Beale PJ, Karapetis CS, Price T, Burge ME, Michael M.

Evaluation of pharmacogenomics and hepatic nuclear imaging-related covariates by population pharmacokinetic models of irinotecan and its metabolites. *Eur J Clin Pharmacol* 2022;78:53-64.

54. Livingston PM, Russell L, Orellana L, Winter N, Jefford M, Girgis A, Austin D, O E, Mihalopoulos C, Ugalde A, Chambers R, Phipps-Nelson J, Herath D, Botti M, Rasmussen B, Whitfield K, Ftanou M, Smith AB, Pilatti K, Sara S, Wootten A, Gillan K, Singh M, Campbell D, Pillay B, White V. Efficacy and cost-effectiveness of an online mindfulness program (MindOnLine) to reduce fear of recurrence among people with cancer: study protocol for a randomised controlled trial. *BMJ Open* 2022;12:e057212.
55. Lloyd P, Hong A, Furrer MA, Lee EWY, Dev HS, Coret MH, Adshead JM, Baldwin P, Knight R, Shamash J, Alifrangis C, Stoneham S, Mazhar D, Wong H, Warren A, Tran B, Lawrentschuk N, Neal DE, Thomas BC. A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections. *World J Urol* 2022;40:119-126.
56. Loi S, Salgado R, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Drubay D, Lemonnier J, Sotiriou C, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, André F, Denkert C, Piccart M, Roblin E, Michiels S. Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. *NPJ Breast Cancer* 2022;8:3.
57. Lucas CG, Gupta R, Wu J, Shah K, Ravindranathan A, Barreto J, Gener M, Ginn KF, Prall OWJ, Xu H, Kee D, Ko HS, Yaqoob N, Zia N, Florez A, Cha S, Perry A, Clarke JL, Chang SM, Berger MS, Solomon DA. EWSR1-BEND2 fusion defines an epigenetically distinct subtype of astroblastoma. *Acta Neuropathol* 2022;143:109-13.
58. Masle-Farquhar E, Peters TJ, Miosge LA, Parish IA, Weigel C, Oakes CC, Reed JH, Goodnow CC. Uncontrolled CD21^{low} age-associated and B1 B cell accumulation caused by failure of an EGR2/3 tolerance checkpoint. *Cell Rep* 2022;38:110259.
59. Mato AR, Sharman JP, Biondo JML, Wu M, Mun Y, Kim SY, Humphrey K, Boyer M, Zhu Q, Seymour JF. The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study. *Haematologica* 2022;107:134-142.
60. McDowell L, Magarey M, Rischin D. Transoral surgery and deintensified adjuvant therapy: another step in determining its role in the management of human papillomavirus oropharyngeal cancer. *J Clin Oncol* 2022;40:114-117.
61. McLean LS, Lim AM, Webb A, Cavanagh K, Thai A, Magarey M, Fox C, Kleid S, Rischin D. Immunotherapy to Avoid Orbital Exenteration in Patients with Cutaneous Squamous Cell Carcinoma. *Front Oncol* 2022;11:796197.
62. Meiser B, Monnik M, Austin R, Nichols C, Cops E, Salmon L, Spurdle AB, Macrae F, Taylor N, Pachter N, James P, Kaur R. Stakeholder attitudes towards establishing a national genomics registry of inherited cancer predisposition: a qualitative study. *J Community Genet* 2022;13:59-73.
63. Mills G, Anderson MA, Tang C, Hamad N. The untold effect of the combined oral contraceptive pill on anticancer drugs. *Lancet Haematol* 2022;9:e10-e11.
64. Minson A, Hofman M, Dickinson M. A PET in a time of need: toward early PET-adapted therapy in DLBCL in first relapse. *Leuk Lymphoma* 2022;63:1-4.
65. Muraro E, De Zorzi M, Miolo G, Lombardi D, Scalone S, Spazzapan S, Massarut S, Perin T, Dolcetti R, Steffan A, De Re V. KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients with HER2-Positive Breast Cancer. *Front Immunol* 2022;12:791958.
66. Nguyen M, Segelov E, Goldstein D, Pavlakis N, Shapiro J, Price TJ, Nagrial A, Chantrill L, Leong T, Chen J, Burge M, Karapetis CS, Chau I, Lordick F, Renouf D, Tebbutt N, Roy AC. Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. *Expert Rev Anticancer Ther* 2022;22:39-51.

67. Nguyen TK, Chin L, Sahgal A, Dagan R, Eppinga W, Guckenberger M, Kim JH, Lo SS, Redmond KJ, Siva S, Stish BJ, Chan R, Lawrence L, Lau A, Tseng CL. International Multi-institutional Patterns of Contouring Practice and Clinical Target Volume Recommendations for Stereotactic Body Radiation Therapy for Non-Spine Bone Metastases. *Int J Radiat Oncol Biol Phys* 2022;112:351-60.
68. Perera MPJ, Thomas PB, Risbridger GP, Taylor R, Azad A, Hofman MS, Williams ED, Vela I. Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer. *Cancers* 2022;14:503.
69. Piotin A, Godet J, Trubiano JA, Grandbastien M, Guénard-Bilbault L, de Blay F, Metz-Favre C. Predictive factors of amoxicillin immediate hypersensitivity and validation of PEN-FAST clinical decision rule. *Ann Allergy Asthma Immunol* 2022;128:27-32.
70. Pitiyarachchi O, Phillips KA, Friedlander M. Pregnancy induced hyperplasia of residual breast tissue following risk reducing contralateral mastectomy - simply interesting or a clinically important observation. *Cancer Treat Res Commun* 2022;30:100504.
71. Qin VM, Haynes NM, D'Souza C, Neeson PJ, Zhu JJ. CAR-T plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors. *Front Immunol* 2022;12:813832.
72. Reifels L, Krishnamoorthy S, Kölves K, Francis J. Implementation Science in Suicide Prevention. *Crisis* 2022;43:1-7.
73. Rischin KJ, Mostaghim M, Rao A, Smith B, O'Brien TA, Trubiano JA, Frith K, McMullan B. ESCAPE-Allergy: Evaluating screening for children and adolescents with penicillin allergy. *J Paediatr Child Health* 2022;58:83-9.
74. Sammut SJ, Crispin-Ortuzar M, Chin SF, Provenzano E, Bardwell HA, Ma W, Cope W, Dariush A, Dawson SJ, Abraham JE, Dunn J, Hiller L, Thomas J, Cameron DA, Bartlett JMS, Hayward L, Pharoah PD, Markowitz F, Rueda OM, Earl HM, Caldas C. Multi-omic machine learning predictor of breast cancer therapy response. *Nature* 2022;601:623-9.
75. Scolyer RA, Atkinson V, Gyorki DE, Lambie D, O'Toole S, Saw RPM, Amanuel B, Angel CM, Button-Sloan AE, Carlino MS, Ch'ng S, Colebatch AJ, Daneshvar D, Pires da Silva I, Dawson T, Ferguson PM, Foster-Smith E, Fox SB, Gill AJ, Gupta R, Henderson MA, Hong AM, Howle JR, Jackett LA, James C, Lee CS, Lochhead A, Loh D, McArthur GA, McLean CA, Menzies AM, Nieweg OE, O'Brien BH, Pennington TE, Potter AJ, Prakash S, Rawson RV, Read RL, Rtshiladze MA, Shannon KF, Smithers BM, Spillane AJ, Stretch JR, Thompson JF, Tucker P, Varey AHR, Vilain RE, Wood BA, Long GV. BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. *Pathology* 2022;54:6-19.
76. Seth N, Seth I, Bulloch G, Siu AHY, Guo A, Chatterjee R, MacManus M, Donnan L. ¹⁸F-FDG PET and PET/CT as a diagnostic method for Ewing sarcoma: A systematic review and meta-analysis. *Pediatr Blood Cancer* 2022;69:e29415.
77. Seymour JF. CLL12: a positive answer to a poorly phrased question. *Blood* 2022;139:151-2.
78. Shembrey C, Smith J, Grandin M, Williams N, Cho HJ, Mølck C, Behrenbruch C, Thomson BN, Heriot AG, Merino D, Hollande F. Longitudinal Monitoring of Intra-Tumoural Heterogeneity Using Optical Barcoding of Patient-Derived Colorectal Tumour Models. *Cancers* 2022;14:581.
79. Swan D, Routledge D, Harrison S. The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies. *Br J Haematol* 2022;196:488-506.
80. Szer J. The Journal in 2021. *Intern Med J* 2022;52:5-6.
81. Tammemägi MC, Ruparel M, Tremblay A, Myers R, Mayo J, Yee J, Atkar-Khattra S, Yuan R, Cressman S, English J, Bedard E, MacEachern P, Burrowes P, Quaipe SL, Marshall H, Yang I, Bowman R, Passmore L, McWilliams A, Brims F, Lim KP, Mo L, Melsom S, Saffar B, Teh M, Sheehan R, Kuok Y, Manser R, Irving L, Steinfort D, McCusker M, Pascoe D, Fogarty P, Stone E, Lam DCL, Ng MY, Vardhanabhuti V, Berg CD, Hung RJ, Janes SM, Fong K, Lam S. USPSTF2013 versus PLCOm2012 lung cancer screening eligibility

criteria (International Lung Screening Trial): interim analysis of a prospective cohort study. *Lancet Oncol* 2022;23:138-48.

82. Tan DS, Thomas M, Kim DW, Szpakowski S, Urban P, Mehra R, Chow LQM, Sharma S, Solomon BJ, Felip E, Camidge DR, Vansteenkiste J, Petruzzelli L, Pantano S, Shaw AT. Genetic landscape of patients with ALK-rearranged non-small-cell lung cancer (NSCLC) and response to ceritinib in ASCEND-1 study. *Lung Cancer* 2022;163:7-13.
83. Taylor EV, Lyford M, Parsons L, Holloway M, Gough K, Sabesan S, Thompson SC. Putting Policy into Practice: How Three Cancer Services Perform against Indigenous Health and Cancer Frameworks. *Int J Environ Res Public Health* 2022;19:633.
84. Tellambura M, Cumberbatch M, Goad J. A case of acute-colonic pseudo-obstruction (Ogilvie Syndrome) post robot-assisted radical prostatectomy. *Urol Case Rep* 2022;40:101878.
85. Thompson ER, Nguyen T, Kankanige Y, Markham JF, Anderson MA, Handunnetti SM, Thijssen R, Yeh PS, Tam CS, Seymour JF, Roberts AW, Westerman DA, Blombery P. Single-cell sequencing demonstrates complex resistance landscape in CLL and MCL treated with BTK and BCL2 inhibitors. *Blood Adv* 2022;6:503-8.
86. Tino RB, Yeo AU, Brandt M, Leary M, Kron T. A customizable anthropomorphic phantom for dosimetric verification of 3D-printed lung, tissue, and bone density materials. *Med Phys* 2022;49:52-69.
87. Toivanen R, Porter LH, Li Z, Clouston D, Risbridger GP, Taylor RA. Hidden clues in prostate cancer - Lessons learned from clinical and pre-clinical approaches on diagnosis and risk stratification. *Cancer Lett* 2022;524:182-92.
88. Vasina EN, Greer P, Thwaites D, Kron T, Lehmann J. A system for real-time monitoring of breath-hold via assessment of internal anatomy in tangential breast radiotherapy. *J Appl Clin Med Phys* 2022;23:e13473.
89. Vervoort SJ, Devlin JR, Kwiatkowski N, Teng M, Gray NS, Johnstone RW. Targeting transcription cycles in cancer. *Nat Rev Cancer* 2022;22:5-24.
90. Visan KS, Lobb RJ, Wen SW, Bedo J, Lima LG, Krumeich S, Palma C, Ferguson K, Green B, Niland C, Cloonan N, Simpson PT, McCart Reed AE, Everitt SJ, MacManus MP, Hartel G, Salomon C, Lakhani SR, Fielding D, Möller A. Blood-Derived Extracellular Vesicle-Associated miR-3182 Detects Non-Small Cell Lung Cancer Patients. *Cancers* 2022;14:257.
91. Wellinger LC, Hogg SJ, Newman DM, Friess T, Geiss D, Michie J, Ramsbottom KM, Bacac M, Fauti T, Marbach D, Jarassier L, Thienger P, Paehler A, Cluse LA, Kearney CJ, Vervoort SJ, Trapani JA, Oliaro J, Shortt J, Ruefli-Brasse A, Rohle D, Johnstone RW. BET Inhibition Enhances TNF-Mediated Antitumor Immunity. *Cancer Immunol Res* 2022;10:87-107.
92. Wheeler JCW, Keogh L, Sierra MA, Devereux L, Jones K, IJzerman MJ, Trainer AH. Heterogeneity in how women value risk-stratified breast screening. *Genet Med* 2022;24:146-56.
93. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. Long-Term Outcomes with Nivolumab plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients with Advanced Melanoma. *J Clin Oncol* 2022;40:127-37.
94. Wong AKY, Collins A, Ng A, Buizen L, Philip J, Le B. Evaluation of a Large Scale Advance Care Planning Co-Design Education Program for Chinese-Speaking People in Australia. *Am J Hosp Palliat Care* 2022;39:178-83.
95. Wortman BG, Post CCB, Powell ME, Khaw P, Fyles A, D'Amico R, Haie-Meder C, Jürgenliemk-Schulz IM, McCormack M, Do V, Katsaros D, Bessette P, Baron MH, Nout RA, Whitmarsh K, Mileskin L, Lutgens L, Kitchener HC, Brooks S, Nijman HW, Astreinidou E, Putter H, Creutzberg CL, de Boer SM. Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-

Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy. *Int J Radiat Oncol Biol Phys* 2022;112:390-9.

96. Zidan L, Iravani A, Oleinikov K, Ben-Haim S, Gross DJ, Meirovitz A, Maimon O, Akhurst T, Michael M, Hicks RJ, Grozinsky-Glasberg S, Kong G. Efficacy and Safety of ¹⁷⁷Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicerter study. *J Nucl Med* 2022;63:218-25.
97. Zinzani PL, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, de Oliveira JSR, Buccheri V, Perini GF, Dickinson M, McDonald A, Özcan M, Sekiguchi N, Zhu Y, Raut M, Saretsky TL, Nahar A, Kuruvilla J. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. *Blood Adv* 2022;6:590-9.

February

1. Antill Y, Buchanan DD, Scott CL. Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer. *Cancer* 2022;128:1157-61.
2. Archer M, Dasari P, Walsh D, Britt KL, Evdokiou A, Ingman WV. Immune Regulation of Mammary Fibroblasts and the Impact of Mammographic Density. *J Clin Med* 2022;11:799.
3. Bartl AJ, Mahoney M, Hennon MW, Yendamuri S, Videtic GMM, Stephans KL, Siva S, Farrugia MK, Ma SJ, Singh AK. Systematic Review of Single-Fraction Stereotactic Body Radiation Therapy for Early Stage Non-Small-Cell Lung Cancer and Lung Oligometastases: How to Stop Worrying and Love One and Done. *Cancers* 2022;14:790.
4. Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Muller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jager U, Borchmann P, Westin JR. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. *N Engl J Med* 2022;386:629-39.
5. Blombery P, Lew TE, Dengler MA, Thompson ER, Lin VS, Chen X, Nguyen T, Panigrahi A, Handunnetti SM, Carney DA, Westerman DA, Tam CS, Adams JM, Wei AH, Huang DCS, Seymour JF, Roberts AW, Anderson MA. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. *Blood* 2022;139:1198-207.
6. Brieger KK, Phung MT, Mukherjee B, Bakulski KM, Anton-Culver H, Bandera EV, Bowtell DDL, Cramer DW, DeFazio A, Doherty JA, Fereday S, Fortner RT, Gentry-Maharaj A, Goode EL, Goodman MT, Harris HR, Matsuo K, Menon U, Modugno F, Moysich KB, Qin B, Ramus SJ, Risch HA, Rossing MA, Schildkraut JM, Trabert B, Vierkant RA, Winham SJ, Wentzensen N, Wu AH, Ziogas A, Khoja L, Cho KR, McLean K, Richardson J, Grout B, Chase A, Deurloo CM, Odunsi K, Nelson BH, Brenton JD, Terry KL, Pharoah PDP, Berchuck A, Hanley GE, Webb PM, Pike MC, Pearce CL, Ovarian Cancer Association Consortium. High prediagnosis inflammation-related risk score associated with decreased ovarian cancer survival. *Cancer Epidemiol Biomarkers Prev* 2022;31:443-452.
7. Bröske AE, Korfi K, Belousov A, Wilson S, Ooi CH, Bolen CR, Canamero M, Alcaide EG, James I, Piccione EC, Carlile DJ, Dimier N, Umana P, Bacac M, Weisser M, Dickinson M. Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma. *Blood Adv* 2022;6:1025-37.
8. Bucknell NW, Gyorki DE, Bressel M, Estall V, Webb A, Henderson M, Chua MS, Rischin D, Tiong A. Cutaneous squamous cell carcinoma metastatic to the axilla and groin: Outcomes and prognostic factors. *Australas J Dermatol* 2022;63:43-52.
9. Chan S, Godsell J, Horton M, Farchione A, Howson LJ, Margetts M, Jin C, Chatelier J, Yong M, Sasadeusz J, Douglass JA, Slade CA, Bryant VL. Case Report: Cytomegalovirus Disease Is an Under-Recognized

Contributor to Morbidity and Mortality in Common Variable Immunodeficiency. *Front Immunol* 2022;13:815193.

10. Cheung YT, Chan A, Charalambous A, Darling HS, Eng L, Grech L, van den Hurk CJG, Kirk D, Mitchell SA, Poprawski D, Rammant E, Ramsey I, Fitch MI, Chan RJ. The use of patient-reported outcomes in routine cancer care: preliminary insights from a multinational scoping survey of oncology practitioners. *Support Care Cancer* 2022;30:1427-1439.
11. Cochrane T, Enrico A, Gomez-Almaguer D, Hadjiev E, Lech-Maranda E, Masszi T, Nikitin E, Robak T, Weinkove R, Wu SJ, Sail KR, Pesko J, Pai M, Komlosi V, Anderson MA. Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. *Leuk Lymphoma* 2022;63:304-14.
12. Cribb BI, Kong J, McCormick J, Warriar SK, Heriot AG. Functional outcomes after lateral pelvic lymph node dissection for rectal cancer: a systematic review and meta-analysis. *Int J Colorectal Dis* 2022;37:583-95.
13. Cull G, Burger JA, Opat S, Gottlieb D, Verner E, Trotman J, Marlton P, Munoz J, Johnston P, Simpson D, Stern JC, Prathikanti R, Wu K, Novotny W, Huang J, Tam CS. Zanubrutinib for treatment-naive and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. *Br J Haematol* 2022;196:1209-18.
14. Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey LA, Gelmon K, Hortobagyi GN, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. *Ann Oncol* 2022;33:321-9.
15. Curtis AR, Livingstone KM, Daly RM, Marchese LE, Kiss N. Associations between Dietary Patterns and Malnutrition, Low Muscle Mass and Sarcopenia in Adults with Cancer: A Scoping Review. *Int J Environ Res Public Health* 2022;19:1769.
16. Deftereos I, Hitch D, Butzkueven S, Carter V, Fetterplace K, Fox K, Ottaway A, Pierce K, Steer B, Varghese J, Kiss N, Yeung JM. Implementing a standardised perioperative nutrition care pathway in upper gastrointestinal cancer surgery: a mixed-methods analysis of implementation using the Consolidated Framework for Implementation Research. *BMC Health Serv Res* 2022;22:256.
17. Dinh P, Graham JD, Elder EN, Kabir M, Doan TB, French J, Meybodi F, Hui R, Wilcken NR, Harnett PR, Hsu J, Stuart KE, Wang T, Ahern V, Brennan M, Fox SB, Dear RF, Lim E, White M, Mann GB, Pathmanathan N. Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing. *Breast Cancer Res Treat* 2022;191:501-511.
18. Feehan DD, Jamil K, Polyak MJ, Ogbomo H, Hasell M, Li SS, Xiang RF, Parkins M, Trapani JA, Harrison JJ, Mody CH. Natural killer cells kill extracellular *Pseudomonas aeruginosa* using contact-dependent release of granzymes B and H. *PLoS Pathog* 2022;18:e1010325.
19. Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJM, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Zia A, Awasthi R, Masood A, Anak O, Schuster SJ, Thieblemont C. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. *Nat Med* 2022;28:325-332.
20. Gee G, Sheridan S, Charles L, Dayne L, Joyce L, Stevens J, Paradies Y, Hulbert C, Haslam N, Thorpe R, Thorpe L, Thorpe A, Stewart P, Austin L, Lyons L, Belfrage M, Warber R, Paxton A, Thompson L. The Her Tribe and His Tribe Aboriginal-Designed Empowerment Programs. *Int J Environ Res Public Health* 2022;19:2381.

21. Goh PK, Wiede F, Zeissig MN, Britt KL, Liang S, Molloy T, Goode N, Xu R, Loi S, Muller M, Humbert PO, McLean C, Tiganis T. PTPN2 elicits cell autonomous and non-cell autonomous effects on antitumor immunity in triple-negative breast cancer. *Sci Adv* 2022;8:eabk3338.
22. Goldinger SM, Buder-Bakhaya K, Lo SN, Forschner A, McKean M, Zimmer L, Khoo C, Dummer R, Eroglu Z, Buchbinder EI, Ascierto PA, Gutzmer R, Rozeman EA, Hoeller C, Johnson DB, Gesierich A, Kölblinger P, Bennannoune N, Cohen JV, Kähler KC, Wilson MA, Cebon J, Atkinson V, Smith JL, Michielin O, Long GV, Hassel JC, Weide B, Haydu LE, Schadendorf D, McArthur G, Ott PA, Blank C, Robert C, Sullivan R, Hauschild A, Carlino MS, Garbe C, Davies MA, Menzies AM. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis. *Eur J Cancer* 2022;162:22-33.
23. Gregory G, Das Gupta K, Meiser B, Barlow-Stewart K, Geelan-Small P, Kaur R, Scheepers-Joynt M, McInerney S, Taylor S, Antill Y, Salmon L, Smyth C, Young MA, James PA, Yanes T. Polygenic risk in familial breast cancer: Changing the dynamics of communicating genetic risk. *J Genet Couns* 2022;31:120-129.
24. Hoskins C, Tutty E, Purvis R, Shanahan M, Boussioutas A, Forrest L. Young people's experiences of a CDH1 pathogenic variant: Decision-making about gastric cancer risk management. *J Genet Couns* 2022;31:242-251.
25. Huang JY, Steele P, Dabscheck E, Smallwood N. Nasal High Flow Therapy For Symptom Management in People Receiving Palliative Care. *J Pain Symptom Manage* 2022;63:e237-e245.
26. Ivanova ME, Lukoyanova N, Malhotra S, Topf M, Trapani JA, Voskoboinik I, Saibil HR. The pore conformation of lymphocyte perforin. *Sci Adv* 2022;8:eabk3147.
27. Kader T, Zethoven M, Gorringer KL. Evaluating statistical approaches to define clonal origin of tumours using bulk DNA sequencing: context is everything. *Genome Biol* 2022;23:43.
28. Kennedy OJ, Kicinski M, Valpione S, Gandini S, Suci S, Blank CU, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Robert C, Eggermont AMM, Lorigan P, Mandala M. Prognostic and predictive value of β -blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. *Eur J Cancer* 2022;165:97-112.
29. Khaw P, Do V, Lim K, Cunnigham J, Dixon J, Vassie J, Bailey M, Johnson C, Kahl K, Gordon C, Cook O, Foo K, Fyles A, Powell M, Haie-Meder C, D'Amico R, Bessette P, Mileskin L, Creutzberg CL, Moore A. Radiotherapy Quality Assurance in the PORTEC-3 (TROC 08.04) Trial. *Clin Oncol* 2022;34:198-204.
30. Kim SY, Kissane DW, Richardson G, Senior J, Morgan J, Gregory P, Birks S, Ooi C, Lipton L, Antill Y, Vereker M, Michael N, Bobevski I. The role of depression and other psychological factors in work ability among breast cancer survivors in Australia. *Psychooncology* 2022;31:167-175.
31. Kwok MM, Virk JS, Michael M, McKinley M, Magarey MJR. Cervical Nodal Metastatic Pituitary Carcinoma: A Case Report. *Ear Nose Throat J* 2022;101:110-113.
32. Larach JT, Flynn J, Wright T, Rajkomar AKS, McCormick JJ, Kong J, Smart PJ, Heriot AG, Warriar SK. Robotic complete mesocolic excision versus conventional robotic right colectomy for right-sided colon cancer: a comparative study of perioperative outcomes. *Surg Endosc* 2022;36:2113-20.
33. Lawrentschuk N. Editorial Comment. *J Urol* 2022;207:580.
34. Le BH, Aggarwal G, Douglas C, Green M, Nicoll A, Ahmedzai S. Oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe, chronic cancer pain: Challenges in the context of hepatic impairment. *Asia Pac J Clin Oncol* 2022;18:13-18.
35. Lickliter JD, Voskoboinik M, Mileskin L, Gan HK, Kichenadasse G, Zhang K, Zhang M, Tang Z, Millward M. Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours. *Br J Cancer* 2022;126:576-85.

36. Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Munoz J, Farooq U, van Meerten T, Reagan PM, Surenda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR, All ZUMA-7 Investigators, Contributing Kite Members. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. *N Engl J Med* 2022;386:640-54.
37. MacManus M, Hegi-Johnson F. Overcoming immunotherapy resistance in NSCLC. *Lancet Oncol* 2022;23:191-3.
38. Malorni L, Tyekucheva S, Hilbers FS, Ignatiadis M, Neven P, Colleoni M, Henry S, Ballestrero A, Bonetti A, Jerusalem G, Papadimitriou K, Bernardo A, Seles E, Duhoux FP, MacPherson IR, Thomson A, Davies DM, Bergqvist M, Migliaccio I, Gebhart G, Zoppoli G, Bliss JM, Benelli M, McCartney A, Kammler R, De Swert H, Ruepp B, Fumagalli D, Maibach R, Cameron D, Loi S, Piccart M, Regan MM. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. *Eur J Cancer* 2022;164:39-51.
39. Mascarenhas J, Passamonti F, Burbury K, El-Galaly TC, Gerds A, Gupta V, Higgins B, Wonde K, Jamois C, Kovic B, Huw LY, Katakam S, Maffioli M, Mesa R, Palmer J, Bellini M, Ross DM, Vannucchi AM, Yacoub A. The MDM2 antagonist idasanutlin in patients with polycythemia vera: results from a single-arm phase 2 study. *Blood Adv* 2022;6:1162-74.
40. Mato AR, Davids MS, Sharman J, Roeker LE, Kay N, Kater AP, Rogers K, Thompson MC, Rhodes J, Goy A, Skarbnik A, Schuster SJ, Tam CS, Eyre TA, O'Brien S, Nabhan C, Lamanna N, Sun C, Shadman M, Pagel JM, Ujjani C, Brander D, Coombs CC, Jain N, Cheah CY, Brown JR, Seymour JF, Woyach JA. Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: "What's Past Is Prologue" (Shakespeare). *Clin Cancer Res* 2022;28:603-8.
41. Mazariego C, Jefford M, Chan RJ, Roberts N, Millar L, Anazodo A, Hayes S, Brown B, Saunders C, Webber K, Vardy J, Girgis A, Koczwara B, COSA PRO Working Group. Priority recommendations for the implementation of patient-reported outcomes in clinical cancer care: a Delphi study. *J Cancer Surviv* 2022;16:33-43.
42. McDowell L, Bossi P. The Burning Question: Prophylactic Gabapentin for Mucositis-Related Pain in Patients Undergoing Chemoradiation Therapy for Head and Neck Cancer? *Int J Radiat Oncol Biol Phys* 2022;112:938-41.
43. McDowell L, Rischin D, Gough K, Henson C. Health-Related Quality of Life, Psychosocial Distress and Unmet Needs in Older Patients with Head and Neck Cancer. *Front Oncol* 2022;12:834068.
44. Meric-Bernstam F, Bahleda R, Hierro C, Sanson M, Bridgewater J, Arkenau HT, Tran B, Kelley RK, Park JO, Javle M, He Y, Benhadji KA, Goyal L. Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study. *Cancer Discov* 2022;12:402-415.
45. Miles LF, Soo VP, Braat S, Heritier S, Burbury KL, Story DA. A protocol for prospective observational study to determine if non-anaemic iron deficiency worsens postoperative outcome in adult patients undergoing elective cardiac surgery: the IDOCS study. *Perioper Med* 2022;11:4.
46. Mohan H, Larach JT, Suhardja T, Wang J, Lawrentschuk N, Heriot A, Warriar S. Robotic ultralow anterior resection, en bloc hysterectomy, unilateral ureterectomy and pelvic side wall clearance with selective anterior internal iliac artery resection - A video vignette. *Colorectal Dis* 2022;24:243.
47. Nan Tie E, Kok DL. Merkel cell carcinoma: is sentinel lymph node biopsy crucial? *Intern Med J* 2022;52:330-331.
48. Nedumannil R, Juneja S. Large granular lymphocytosis: A novel association with immunotherapy. *Hematol Oncol* 2022;40:119-121.
49. O'Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, Miller WH Jr, Safra T, Italiano A, Mileshkin L, Xu L, Jin F, Norwood K, Maio M. Pembrolizumab in Patients with

Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. *J Clin Oncol* 2022;40:752-61.

50. Ong WL, Milne RL, Foroudi F, Millar JL. Changing pattern of radiation therapy for bone metastases in an Australian population-based cohort of men with prostate cancer. *Clin Genitourin Cancer* 2022;20:e7-e15.
51. Parker A, Dash S, Bourke M, Patten R, Craike M, Baldwin P, Hosking W, Levinger I, Apostolopoulos V, de Courten M, Sharples J, Naslund M, Stavropoulos V, Woessner M, Sonn C, Stansen C, Pascoe M. A Brief, Daily, Online Mental Health and Well-being Intervention for University Staff During the COVID-19 Pandemic: Program Description and Outcomes Using a Mixed Methods Design. *JMIR Form Res* 2022;6:e35776.
52. Pearson EJ. Fatigue - a substantial problem in hematology, but what can be done? *Leuk Lymphoma* 2022;63:263-264.
53. Peters S, Thompson BA, Perrin M, James P, Zentner D, Kalman JM, Vandenberg JI, Fatkin D. Arrhythmic Phenotypes Are a Defining Feature of Dilated Cardiomyopathy-Associated *SCN5A* Variants: A Systematic Review. *Circ Genom Precis Med* 2022;15:e003432.
54. Rambhatla JS, Tonkin-Hill GQ, Takashima E, Tsuboi T, Noviyanti R, Trianty L, Sebayang BF, Lampah DA, Marfurt J, Price RN, Anstey NM, Papenfuss AT, Damelang T, Chung AW, Duffy MF, Rogerson SJ. Identifying Targets of Protective Antibodies against Severe Malaria in Papua, Indonesia, Using Locally Expressed Domains of *Plasmodium falciparum* Erythrocyte Membrane Protein 1. *Infect Immun* 2022;90:e0043521.
55. Rechtman M, Forbes A, Millar JL, Evans M, Dodds L, Murphy DG, Evans SM. Comparison of urinary and sexual patient-reported outcomes between open radical prostatectomy and robot-assisted radical prostatectomy: a propensity score matched, population-based study in Victoria. *BMC Urol* 2022;22:18.
56. Rowlands CF, Taylor A, Rice G, Whiffin N, Hall HN, Newman WG, Black GCM, kConFab Investigators, O'Keefe RT, Hubbard S, Douglas AGL, Baralle D, Briggs TA, Ellingford JM. MRSD: A quantitative approach for assessing suitability of RNA-seq in the investigation of mis-splicing in Mendelian disease. *Am J Hum Genet* 2022;109:210-22.
57. Sexton A, James PA. Metaphors and why these are important in all aspects of genetic counseling. *J Genet Couns* 2022;31:34-40.
58. Seymour JF. Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i. *Blood Adv* 2022;6:1365-70.
59. Smith AL, Hart NH, Jefford M, Chan RJ. Survivorship Research for People with Metastatic or Advanced Cancer: A time for action. *Asia Pac J Oncol Nurs* 2022;9:185-186.
60. Solomon BJ, Loong HH, Summers Y, Thomas ZM, French P, Lin BK, Sashegyi A, Wolf J, Yang JC, Drilon A. Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations. *ESMO Open* 2022;7:100398.
61. Subhash VV, Huang L, Kamili A, Wong M, Chen D, Venn NC, Atkinson C, Mayoh C, Venkat P, Tyrrell V, Marshall GM, Cowley MJ, Ekert PG, Norris MD, Haber M, Henderson MJ, Sutton R, Fletcher JI, Trahair TN. Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma. *Br J Cancer* 2022;126:482-491.
62. Tai A, Prakash S, Lade S, McCormack CJ, Goh MSY. Two cases of acquired perforating dermatosis successfully treated with allopurinol. *Australas J Dermatol* 2022;63:121-124.
63. Tam CS, Dimopoulos M, Garcia-Sanz R, Trotman J, Opat S, Roberts AW, Owen R, Song Y, Xu W, Zhu J, Li J, Qiu L, D'Sa S, Jurczak W, Cull G, Marlton P, Gottlieb D, Munoz J, Phillips T, Du C, Ji M, Zhou L, Guo H,

Zhu H, Chan WY, Cohen A, Novotny W, Huang J, Tedeschi A. Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies. *Blood Adv* 2022;6:1296-308.

64. Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A, Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Survival with Cemiplimab in Recurrent Cervical Cancer. *N Engl J Med* 2022;386:544-55.
65. Trubiano JA, Vogrin S, Copaescu A, Nasra M, Douglas A, Holmes NE, Chua KYL. Direct oral penicillin challenge for penicillin allergy delabeling as a health services intervention: A multicenter cohort study. *Allergy* 2022;77:1038-42.

March

1. Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, Oudard S, Saad F, Soares A, Benzaghoul F, Kerloeguen Y, Kimura A, Mohamed N, Panneerselvam A, Wang F, Pal S. A Phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. *Future Oncol* 2022;18:1185-98.
2. Albarakati H, Jackson P, Gulal O, Ramachandran P, Osbourne G, Liu M, Kron T, Geso M. Dose assessment for daily cone-beam CT in lung radiotherapy patients and its combination with treatment planning. *Phys Eng Sci Med* 2022;45:231-7.
3. Arber DA, Hasserjian RP, Orazi A, Mathews V, Roberts AW, Schiffer CA, Roug AS, Cazzola M, Döhner H, Tefferi A. Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach. *Am J Hematol* 2022;97:514-8.
4. Asfia A, Deepak B, Novak JI, Rolfe B, Kron T. Multi-jet fusion for additive manufacturing of radiotherapy immobilization devices: Effects of color, thickness, and orientation on surface dose and tensile strength. *J Appl Clin Med Phys* 2022;23:e13548.
5. Aung E, Pasanen L, LeGautier R, McLachlan SA, Collins A, Philip J. The role of telehealth in oncology care: A qualitative exploration of patient and clinician perspectives. *Eur J Cancer Care* 2022;31:e13563.
6. Bandala-Sanchez E, Roth-Schulze AJ, Oakey H, Penno MAS, Bediaga NG, Naselli G, Ngui KM, Smith AD, Huang D, Zozaya-Valdes E, Thomson RL, Brown JD, Vuillermin PJ, Barry SC, Craig ME, Rawlinson WD, Davis EA, Harris M, Soldatos G, Colman PG, Wentworth JM, Haynes A, Morahan G, Sinnott RO, Papenfuss AT, Couper JJ, Harrison LC, ENDIA Study Group. Women with type 1 diabetes exhibit a progressive increase in gut *Saccharomyces cerevisiae* in pregnancy associated with evidence of gut inflammation. *Diabetes Res Clin Pract* 2022;184:109189.
7. Bean HR, Diggins J, Ftanou M, Alexander M, Stafford L, Bei B, Francis PA, Wiley JF. Light enhanced cognitive behavioral therapy for insomnia and fatigue during chemotherapy for breast cancer: a randomized controlled trial. *Sleep* 2022;45:zsab246.
8. Bensley JG, Dhillon HM, Evans SM, Evans M, Bolton D, Davis ID, Dodds L, Frydenberg M, Kearns P, Lawrentschuk N, Murphy DG, Millar JL, Papa N. Self-reported lack of energy or feeling depressed 12 months after treatment in men diagnosed with prostate cancer within a population-based registry. *Psychooncology* 2022;31:496-503.
9. Bergin ART. Insights into the Demands on a Clinical Oncologist in Sri Lanka. *JCO Glob Oncol* 2022;8:e2100429.
10. Bishop E, Miller C, Miller S, McKellar C. How staying in a single room affects the experiences of haematology inpatients in an Australian cancer hospital. *Br J Nurs* 2022;31:S22-S29.

11. Brackman D, Eckert D, Menon R, Salem AH, Potluri J, Smith BD, Wei AH, Hayslip J, Miles D, Mensing S, Gopalakrishnan S, Zha J. Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy. *Hematol Oncol* 2022;40:269-79.
12. Breast Cancer Association Consortium, Mavaddat N, Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Keeman R, Bolla MK, Dennis J, Wang Q, Ahearn TU, Andrulis IL, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Briceno I, Bruning T, Camp NJ, Campbell A, Castela JE, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Christiansen H, Czene K, Dork T, Eriksson M, Evans DG, Fasching PA, Figueroa JD, Flyger H, Gabrielson M, Gago-Dominguez M, Geisler J, Giles GG, Guenel P, Hadjisavvas A, Hahnen E, Hall P, Hamann U, Hartikainen JM, Hartman M, Hoppe R, Howell A, Jakubowska A, Jung A, Khusnutdinova EK, Kristensen VN, Li J, Lim SH, Lindblom A, Loizidou MA, Lophatananon A, Lubinski J, Madsen MJ, Mannermaa A, Manoochehri M, Margolin S, Mavroudis D, Milne RL, Mohd Taib NA, Morra A, Muir K, Obi N, Osorio A, Park-Simon TW, Peterlongo P, Radice P, Saloustros E, Sawyer EJ, Schmutzler RK, Shah M, Sim X, Southey MC, Thorne H, Tomlinson I, Torres D, Truong T, Yip CH, Spurdle AB, Vreeswijk MPG, Dunning AM, Garcia-Closas M, Pharoah PDP, Kvist A, Muranen TA, Nevanlinna H, Teo SH, Devilee P, Schmidt MK, Easton DF. Pathology of Tumors Associated with Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. *JAMA Oncol* 2022;8:e216744.
13. Busch K, Davidson A, Di Ieva A, Assaad N, Butlin M, Avolio A, Kiat H. Significant venous flow alterations following brain arteriovenous malformation Surgery: Assessment by transcranial colour duplex. *J Clin Neurosci* 2022;99:268-74.
14. Castiblanco D, Rudd-Schmidt JA, Noori T, Sutton VR, Hung YH, Flinsenbergh TWH, Hodel AW, Young ND, Smith N, Bratkovic D, Peters H, Walterfang M, Trapani JA, Brennan AJ, Voskoboinik I. Severely impaired CTL killing is a feature of the neurological disorder Niemann-Pick disease type C1. *Blood* 2022;139:1833-49.
15. Chan RJ, Agbejule OA, Yates PM, Emery J, Jefford M, Koczwara B, Hart NH, Crichton M, Nekhlyudov L. Outcomes of cancer survivorship education and training for primary care providers: a systematic review. *J Cancer Surviv* 2022;16:279-302.
16. Chang D, Moore A, van Dyk S, Khaw P. Why quality assurance is necessary in gynecologic radiation oncology. *Int J Gynecol Cancer* 2022;32:402-406.
17. Chee L, Ritchie D, Ludford-Menting M, Ripley J, Chung J, Park D, Norton S, Kenealy M, Koldej R. Dysregulation of immune cell and cytokine signalling correlates with clinical outcomes in myelodysplastic syndrome (MDS). *Eur J Haematol* 2022;108:342-53.
18. Chic N, Luen SJ, Nuciforo P, Salgado R, Fumagalli D, Hilbers F, Wang Y, de Azambuja E, Láng I, Di Cosimo S, Saura C, Huober J, Prat A, Loi S. Tumor Cellularity and Infiltrating Lymphocytes as a Survival Surrogate in HER2-Positive Breast Cancer. *J Natl Cancer Inst* 2022;114:467-70.
19. Cohen PA, Webb PM, King M, Obermair A, GebSKI V, Butow P, Morton R, Lawson W, Yates P, Campbell R, Meniawy T, McMullen M, Dean A, Goh J, McNally O, Mileskin L, Beale P, Beach R, Hill J, Dixon C, Hegarty S, Codde J, Ives A, Lee YC, Brand A, Mellon A, Bilic S, Black I, Jeffares S, Friedlander M. Getting the MOST out of follow-up: a randomized controlled trial comparing 3 monthly nurse led follow-up via telehealth, including monitoring CA125 and patient reported outcomes using the MOST (Measure of Ovarian Symptoms and Treatment concerns) with routine clinic based or telehealth follow-up, after completion of first line chemotherapy in patients with epithelial ovarian cancer. *Int J Gynecol Cancer* 2022;32:560-5.
20. Comberlato A, Koga MM, Nüssing S, Parish IA, Bastings MMC. Spatially Controlled Activation of Toll-like Receptor 9 with DNA-Based Nanomaterials. *Nano Lett* 2022;22:2506-13.
21. Crawford-Williams F, Koczwara B, Chan RJ, Vardy J, Lisy K, Morris J, Iddawela M, Mackay G, Jefford M. Defining research and infrastructure priorities for cancer survivorship in Australia: a modified Delphi study. *Support Care Cancer* 2022;30:3805-15.

22. Dall GV, Hamilton A, Ratnayake G, Scott C, Barker H. Interrogating the Genomic Landscape of Uterine Leiomyosarcoma: A Potential for Patient Benefit. *Cancers* 2022;14:1561.
23. Dareng EO, Tyrer JP, Barnes DR, Jones MR, Yang X, Aben KKH, Adank MA, Agata S, Andrulis IL, Anton-Culver H, Antonenkova NN, Aravantinos G, Arun BK, Augustinsson A, Balmana J, Bandera EV, Barkardottir RB, Barrowdale D, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Bjorge L, Black A, Bogdanova NV, Bonanni B, Borg A, Brenton JD, Budzilowska A, Butzow R, Buys SS, Cai H, Caligo MA, Campbell I, Cannioto R, Cassingham H, Chang-Claude J, Chanock SJ, Chen K, Chiew YE, Chung WK, Claes KBM, Colonna S, GEMO Study Collaborators, GC-HBOC Study Collaborators, EMBRACE Collaborators, Cook LS, Couch FJ, Daly MB, Dao F, Davies E, de la Hoya M, de Putter R, Dennis J, DePersia A, Devilee P, Diez O, Ding YC, Doherty JA, Domchek SM, Dork T, du Bois A, Durst M, Eccles DM, Eliassen HA, Engel C, Evans GD, Fasching PA, Flanagan JM, Fortner RT, Machackova E, Friedman E, Ganz PA, Garber J, Gensini F, Giles GG, Glendon G, Godwin AK, Goodman MT, Greene MH, Gronwald J, OPAL Study Group, AOCs Group, Hahnen E, Haiman CA, Hakansson N, Hamann U, Hansen TVO, Harris HR, Hartman M, Heitz F, Hildebrandt MAT, Hogdall E, Hogdall CK, Hopper JL, Huang RY, Huff C, Hulick PJ, Huntsman DG, Imyanitov EN, Investigators KC, Investigators H, Isaacs C, Jakubowska A, James PA, Janavicius R, Jensen A, Johannsson OT, John EM, Jones ME, Kang D, Karlan BY, Karnezis A, Kelemen LE, Khusnutdinova E, Kiemeny LA, Kim BG, Kjaer SK, Komenaka I, Kupryjanczyk J, Kurian AW, Kwong A, Lambrechts D, Larson MC, Lazaro C, Le ND, Leslie G, Lester J, Lesueur F, Levine DA, Li L, Li J, Loud JT, Lu KH, Lubinski J, Mai PL, Manoukian S, Marks JR, Matsuno RK, Matsuo K, May T, McGuffog L, McLaughlin JR, McNeish IA, Mebirouk N, Menon U, Miller A, Milne RL, Minlikeeva A, Modugno F, Montagna M, Moysich KB, Munro E, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nielsen HR, Nielsen FC, Nikitina-Zake L, Odunsi K, Offit K, Olah E, Olbrecht S, Olopade OI, Olson SH, Olsson H, Osorio A, Papi L, Park SK, Parsons MT, Pathak H, Pedersen IS, Peixoto A, Pejovic T, Perez-Segura P, Permuth JB, Peshkin B, Peterlongo P, Piskorz A, Prokofyeva D, Radice P, Rantala J, Riggan MJ, Risch HA, Rodriguez-Antona C, Ross E, Rossing MA, Runnebaum I, Sandler DP, Santamarina M, Soucy P, Schmutzler RK, Setiawan VW, Shan K, Sieh W, Simard J, Singer CF, Sokolenko AP, Song H, Southey MC, Steed H, Stoppa-Lyonnet D, Sutphen R, Swerdlow AJ, Tan YY, Teixeira MR, Teo SH, Terry KL, Terry MB, Consortium O, Consortium C, Thomassen M, Thompson PJ, Thomsen LCV, Thull DL, Tischkowitz M, Titus L, Toland AE, Torres D, Trabert B, Travis R, Tung N, Tworoger SS, Valen E, van Altena AM, van der Hout AH, Van Nieuwenhuysen E, van Rensburg EJ, Vega A, Edwards DV, Vierkant RA, Wang F, Wappenschmidt B, Webb PM, Weinberg CR, Weitzel JN, Wentzensen N, White E, Whittemore AS, Winham SJ, Wolk A, Woo YL, Wu AH, Yan L, Yannoukakos D, Zavaglia KM, Zheng W, Ziogas A, Zorn KK, Kleibl Z, Easton D, Lawrenson K, DeFazio A, Sellers TA, Ramus SJ, Pearce CL, Monteiro AN, Cunningham J, Goode EL, Schildkraut JM, Berchuck A, Chenevix-Trench G, Gayther SA, Antoniou AC, Pharoah PDP. Polygenic risk modeling for prediction of epithelial ovarian cancer risk. *Eur J Hum Genet* 2022;30:349-62.
24. Dark C, Cheung S, Cheng LY. Analyzing cachectic phenotypes in the muscle and fat body of *Drosophila* larvae. *STAR Protoc* 2022;3:101230.
25. Davies A, Mathur N, Lau T, Crossett M, Lau KK. Venous air embolism in CT coronary angiography. *J Med Imaging Radiat Oncol* 2022;66:351-6.
26. Demetri GD, De Braud F, Drilon A, Siena S, Patel MR, Cho BC, Liu SV, Ahn MJ, Chiu CH, Lin JJ, Goto K, Lee J, Bazhenova L, John T, Fakih M, Chawla SP, Dziadziuszko R, Seto T, Heinzmann S, Pitcher B, Chen D, Wilson TR, Rolfo C. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors. *Clin Cancer Res* 2022;28:1302-12.
27. Doig KD, Fellowes A, Scott P, Fox SB. Tumour mutational burden: an overview for pathologists. *Pathology* 2022;54:249-53.
28. Doig KD, Love CG, Conway T, Seleznev A, Ma D, Fellowes A, Blombery P, Fox SB. Findings from precision oncology in the clinic: rare, novel variants are a significant contributor to scaling molecular diagnostics. *BMC Med Genomics* 2022;15:70.

29. Dromain C, Vullierme MP, Hicks RJ, Prasad V, O'Toole D, de Herder WW, Pavel M, Faggiano A, Kos-Kudla B, Öberg K, Krejs GJ, Grande E, Niederle B, Sundin A. ENETS standardized (synoptic) reporting for radiological imaging in neuroendocrine tumours. *J Neuroendocrinol* 2022;34:e13044.
30. Du X, Darcy PK, Wiede F, Tiganis T. Targeting Protein Tyrosine Phosphatase 22 Does Not Enhance the Efficacy of Chimeric Antigen Receptor T Cells in Solid Tumors. *Mol Cell Biol* 2022;42:e0044921.
31. Dunn J, McCuaig RD, Tan AHY, Tu WJ, Wu F, Wagstaff KM, Zafar A, Ali S, Diwakar H, Dahlstrom JE, Bean EG, Forwood JK, Tsimbalyuk S, Cross EM, Hardy K, Bain AL, Ahern E, Dolcetti R, Mazziere R, Yip D, Eastgate M, Malik L, Milburn P, Jans DA, Rao S. Selective Targeting of Protein Kinase C (PKC)- θ Nuclear Translocation Reduces Mesenchymal Gene Signatures and Reinvigorates Dysfunctional CD8+ T Cells in Immunotherapy-Resistant and Metastatic Cancers. *Cancers* 2022;14:1596.
32. Finnegan RN, Reynolds HM, Ebert MA, Sun Y, Holloway L, Sykes JR, Dowling J, Mitchell C, Williams SG, Murphy DG, Haworth A. A statistical, voxelised model of prostate cancer for biologically optimised radiotherapy. *Phys Imaging Radiat Oncol* 2022;21:136-45.
33. Foo T, Goldstein D, Segelov E, Shapiro J, Pavlakis N, Desai J, Yip D, Zalcborg J, Price TJ, Nagrial A, Chantrill L, Burge M, Karapetis CS, Tebbutt N, Roy AC. The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours. *Target Oncol* 2022;17:95-110.
34. Fortuno C, McGoldrick K, Pesaran T, Dolinsky J, Hoang L, Weitzel JN, Beshay V, San Leong H, James PA, Spurdle AB. Suspected clonal hematopoiesis as a natural functional assay of TP53 germline variant pathogenicity. *Genet Med* 2022;24:673-680.
35. Freifeld Y, Pedrosa I, McLaughlin M, Correa RM, Louie AV, Maldonado JA, Tang C, Kadow B, Kutikov A, Uzzo RG, Porta C, Bucknell NW, Siva S, Brugarolas J, Margulis V, Timmerman R, Hannan R. Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus. *Urol Oncol* 2022;40:166.e9-166.e13.
36. Gambell P, Rowley G, Pham TAT, Dang TL, Mulumba H, Smith L, Lakos G. Accurate white blood cell differential by Alinity hq: A comparison with flow cytometry and manual differential. *Int J Lab Hematol* 2022;44:288-95.
37. Garciaz S, Guirguis AA, Müller S, Brown FC, Chan YC, Motazedian A, Rowe CL, Kuzich JA, Chan KL, Tran K, Smith L, MacPherson L, Liddicoat B, Lam EYN, Cañeque T, Burr ML, Litalien V, Pomilio G, Poplineau M, Duprez E, Dawson SJ, Ramm G, Cox AG, Brown KK, Huang DCS, Wei AH, McArthur K, Rodriguez R, Dawson MA. Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death. *Cancer Discov* 2022;12:774-791.
38. Gasperoni JG, Fuller JN, Darido C, Wilanowski T, Dworkin S. Grainyhead-like (Grhl) Target Genes in Development and Cancer. *Int J Mol Sci* 2022;23:2735.
39. Gelber RD, Wang XV, Cole BF, Cameron D, Cardoso F, Tjan-Heijnen V, Krop I, Loi S, Salgado R, Kiermaier A, Frank E, Fumagalli D, Caballero C, de Azambuja E, Procter M, Clark E, Restuccia E, Heeson S, Bines J, Loibl S, Piccart-Gebhart M. Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. *Eur J Cancer* 2022;166:219-28.
40. Gill JG, Leef SN, Ramesh V, Martin-Sandoval MS, Rao AD, West L, Muh S, Gu W, Zhao Z, Hosler GA, Vandergriff TW, Durham AB, Mathews TP, Aurora AB. A Short Isoform of Spermatogenic Enzyme GAPDHS Functions as a Metabolic Switch and Limits Metastasis in Melanoma. *Cancer Res* 2022;82:1251-66.
41. Goh Y, Kim D, Kim JY, Kim HS, Jeong JH, Lee SU, Youn SH, Oh ES, Ha BR, Yeo AU, Kim M, Shin D, Lee SB, Kim YJ, Kim TH, Lim YK. Active small bowel sparing in intracavitary brachytherapy for cervical cancer. *Jpn J Clin Oncol* 2022;52:266-73.
42. Gondoputro W, Thompson J, Evans M, Bolton D, Frydenberg M, Murphy DG, Haynes AM, Agrawal S, Stricker P, Papa N. How Does Age Affect Urinary Continence following Robot-Assisted Radical

Prostatectomy? A Prospective Multi-Institutional Study Using Independently Collected, Validated Questionnaires. *J Urol* 2022;207:1048-56.

43. Gough K, Pascoe MC, Bergin R, Drosdowsky A, Schofield P. Differential adherence to peer and nurse components of a supportive care package—The appeal of peer support may be related to women's health and psychological status. *Patient Educ Couns* 2022;105:762-768.
44. Grobler AC, Lee KJ, Wong A, Currow DC, Braat S. Handling Missing Data and Drop Out in Hospice/Palliative Care Trials Through the Estimand Framework. *J Pain Symptom Manage* 2022;63:e431-9.
45. Hardcastle N, Hughes J, Siva S, Kron T. Dose calculation and reporting with a linear Boltzman transport equation solver in vertebral SABR. *Phys Eng Sci Med* 2022;45:43-48.
46. Harden SV, Chiew KL, Millar J, Vinod SK. Quality indicators for radiation oncology. *J Med Imaging Radiat Oncol* 2022;66:249-257.
47. Hatten SJ Jr, Lehrer EJ, Liao J, Sha CM, Trifiletti DM, Siva S, McBride SM, Palma D, Holder SL, Zaorsky NG. A Patient-Level Data Meta-analysis of the Abscopal Effect. *Adv Radiat Oncol* 2022;7:100909.
48. Heazlewood SY, Ahmad T, Mohenska M, Guo BB, Gangatirkar P, Josefsson EC, Ellis SL, Ratnadiwakara M, Cao H, Cao B, Heazlewood CK, Williams B, Fulton M, White JF, Ramialison M, Nilsson SK, Änkö ML. The RNA-binding protein SRSF3 has an essential role in megakaryocyte maturation and platelet production. *Blood* 2022;139:1359-73.
49. Hegarty S, Hardcastle N, Korte J, Kron T, Everitt S, Rahim S, Hegi-Johnson F, Franich R. Please Place Your Seat in the Full Upright Position: A Technical Framework for Landing Upright Radiation Therapy in the 21st Century. *Front Oncol* 2022;12:821887.
50. Hegi-Johnson F, Rudd S, Hicks RJ, De Ruyscher D, Trapani JA, John T, Donnelly P, Blyth B, Hanna G, Everitt S, Roselt P, MacManus MP. Imaging immunity in patients with cancer using positron emission tomography. *NPJ Precis Oncol* 2022;6:24.
51. Heinze K, Nazeran TM, Lee S, Krämer P, Cairns ES, Chiu DS, Leung SC, Kang EY, Meagher NS, Kennedy CJ, Boros J, Kommos F, Vollert HW, Heitz F, du Bois A, Harter P, Grube M, Kraemer B, Staebler A, Kommos FK, Heublein S, Sinn HP, Singh N, Laslavic A, Elishaev E, Olawaiye A, Moysich K, Modugno F, Sharma R, Brand AH, Harnett PR, DeFazio A, Fortner RT, Lubinski J, Lener M, Tołoczko-Grabarek A, Cybulski C, Gronwald H, Gronwald J, Coulson P, El-Bahrawy MA, Jones ME, Schoemaker MJ, Swerdlow AJ, Gorringer KL, Campbell I, Cook L, Gayther SA, Carney ME, Shvetsov YB, Hernandez BY, Wilkens LR, Goodman MT, Mateoiu C, Linder A, Sundfeldt K, Kelemen LE, Gentry-Maharaj A, Widschwendter M, Menon U, Bolton KL, Alsop J, Shah M, Jimenez-Linan M, Pharoah PD, Brenton JD, Cushing-Haugen KL, Harris HR, Doherty JA, Gilks B, Ghatage P, Huntsman DG, Nelson GS, Tinker AV, Lee CH, Goode EL, Nelson BH, Ramus SJ, Kommos S, Talhouk A, Köbel M, Anglesio MS. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas. *J Pathol* 2022;256:388-401.
52. Heitink L, Whittle JR, Vaillant F, Capaldo BD, Dekkers JF, Dawson CA, Milevskiy MJG, Surgenor E, Tsai M, Chen HR, Christie M, Chen Y, Smyth GK, Herold MJ, Strasser A, Lindeman GJ, Visvader JE. In vivo genome-editing screen identifies tumor suppressor genes that cooperate with Trp53 loss during mammary tumorigenesis. *Mol Oncol* 2022;16:1119-31.
53. Hicks RJ, Dromain C, de Herder WW, Costa FP, Deroose CM, Frilling A, Koumarianou A, Krenning EP, Raymond E, Bodei L, Sorbye H, Welin S, Wiedenmann B, Wild D, Howe JR, Yao J, O'Toole D, Sundin A, Prasad V. ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. *J Neuroendocrinol* 2022;34:e13040.
54. Holliday H, Yang J, Dodson E, Nikolic I, Kamili A, Wheatley M, Deng N, Alexandrou S, Davis TP, Kavallaris M, Caldon CE, McCarroll J, De Preter K, Mestdagh P, Marshall GM, Simpson KJ, Fletcher J, Swarbrick A.

miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma. *Mol Ther* 2022;30:1119-34.

55. Horeweg N, Workel HH, Loiero D, Church DN, Vermij L, Léon-Castillo A, Krog RT, de Boer SM, Nout RA, Powell ME, Mileskin LR, MacKay H, Leary A, Singh N, Jürgenliemk-Schulz IM, Smit V, Creutzberg CL, Koelzer VH, Nijman HW, Bosse T, de Bruyn M. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. *Nat Commun* 2022;13:1373.
56. Hübner M, Alyami M, Villeneuve L, Cortés-Guiral D, Nowacki M, So J, Sgarbura O. Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: Technical aspects and treatment protocols. *Eur J Surg Oncol* 2022;48:789-94.
57. Ierano C, Rajkhowa A, Gotterson F, Marshall C, Peel T, Ayton D, Thursky K. Opportunities for nurse involvement in surgical antimicrobial stewardship strategies: A qualitative study. *Int J Nurs Stud* 2022;128:104186.
58. Jackson P, Hofman M, McIntosh L, Buteau JP, Ravi Kumar A. Radiation Dosimetry in ¹⁷⁷Lu-PSMA-617 Therapy. *Semin Nucl Med* 2022;52:243-54.
59. Jackson TD, Cramer JJ, Muellner-Wong L, Frazier AE, Palmer CS, Formosa LE, Hock DH, Fujihara KM, Stait T, Sharpe AJ, Thorburn DR, Ryan MT, Stroud DA, Stojanovski D. Sideroflexin 4 is a complex I assembly factor that interacts with the MCIA complex and is required for the assembly of the ND2 module. *Proc Natl Acad Sci USA* 2022;119:e2115566119.
60. Jalali A, Gard G, Banks S, Dunn C, Wong HL, Wong R, Lee M, Gately L, Loft M, Shapiro JD, Kosmider S, Tie J, Ananda S, Yeung JM, Jennens R, Lee B, McKendrick J, Lim L, Khattak A, Gibbs P. Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer. *Curr Probl Cancer* 2022;46:100793.
61. Jepp CK, Foley DA, Chua IJ, Kwong JC, Payne MS, Davis J, Yeoh DK. Ureaplasma urealyticum meningitis complicated by hydrocephalus in a preterm neonate. *J Paediatr Child Health* 2022;58:529-531.
62. Jiang W, Lokuhetty N, Mohan HM, Larach JT, Waters P, Heriot AG, Warriar SK. How to do a robotic lateral pelvic side wall dissection for rectal cancer. *ANZ J Surg* 2022;92:540-2.
63. Johnson DN, Ruan Z, Petley EV, Devi S, Holz LE, Uldrich AP, Mak JYW, Hor JL, Mueller SN, McCluskey J, Fairlie DP, Darcy PK, Beavis PA, Heath WR, Godfrey DI. Differential location of NKT and MAIT cells within lymphoid tissue. *Sci Rep* 2022;12:4034.
64. Jones ME, Mohan HM, Rajkomar AKS, Larach JT, Warriar SK. Refining the art of the robotic TAMIS - A video vignette. *Colorectal Dis* 2022;24:339-340.
65. Kim S, Pitson G, Koh TL, Chao M, Byrne K, Hornby C, Foroudi F, Millar J, Ong WL. Increasing use of post-mastectomy hypofractionated radiation therapy for breast cancer in Victoria. *J Med Imaging Radiat Oncol* 2022;66:428-35.
66. Kolka CM, Webster J, Lepletier A, Winterford C, Brown I, Richards RS, Zelek WM, Cao Y, Khamis R, Shanmugasundaram KB, Wuethrich A, Trau M, Brosda S, Barbour A, Shah AK, Eslick GD, Clemons NJ, Morgan BP, Hill MM. C5b-9 Membrane Attack Complex Formation and Extracellular Vesicle Shedding in Barrett's Esophagus and Esophageal Adenocarcinoma. *Front Immunol* 2022;13:842023.
67. Koo K, Papa N, Evans M, Jefford M, IJerman M, White V, Evans SM, Ristevski E, Emery J, Millar J. Mapping disadvantage: identifying inequities in functional outcomes for prostate cancer survivors based on geography. *BMC Cancer* 2022;22:283.
68. Kron T. Cui Bono, Proton Radiotherapy? *Clin Oncol* 2022;34:258-60.
69. Kron T, Fox C, Ebert MA, Thwaites D. Quality management in radiotherapy treatment delivery. *J Med Imaging Radiat Oncol* 2022;66:279-290.
70. Kwan EM, Spain L, Anton A, Gan CL, Garrett L, Chang D, Liow E, Bennett C, Zheng T, Yu J, Dai C, Du P, Jia S, Fettke H, Abou-Seif C, Kothari G, Shaw M, Parente P, Pezaro C, Tran B, Siva S, Azad AA. Avelumab

Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial. *Eur Urol* 2022;81:253-262.

71. Larkins KM, Soucisse ML, Larach JT, Heriot A, Warriar SK. Multidisciplinary management of rare cancers: Recurrent neuroendocrine carcinoma of the appendix. *ANZ J Surg* 2022;92:598-600.
72. Lasocki A, Seymour JF. Central nervous system manifestations of systemic haematological malignancies and key differentials. *Clin Radiol* 2022;77:328-36.
73. Lau LMS, Mayoh C, Xie J, Barahona P, MacKenzie KL, Wong M, Kamili A, Tsoli M, Failes TW, Kumar A, Mould EVA, Gifford A, Chow SO, Pinese M, Fletcher JI, Arndt GM, Khuong-Quang DA, Wadham C, Batey D, Eden G, Trebilcock P, Joshi S, Alfred S, Gopalakrishnan A, Khan A, Grebert Wade D, Strong PA, Manouvrier E, Morgan LT, Span M, Lim JY, Cadiz R, Ung C, Thomas DM, Tucker KM, Warby M, McCowage GB, Dalla-Pozza L, Byrne JA, Saletta F, Fellowes A, Fox SB, Norris MD, Tyrrell V, Trahair TN, Lock RB, Cowley MJ, Ekert PG, Haber M, Ziegler DS, Marshall GM. In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer. *EMBO Mol Med* 2022;14:e14608.
74. Lau SYC, Choy KT, Yang TWW, Heriot A, Warriar SK, Guest GD, Kong JC. Defining the learning curve of transanal total mesorectal excision: a systematic review and meta-analysis. *ANZ J Surg* 2022;92:355-364.
75. Lawther AJ, Phillips AJK, Chung NC, Chang A, Ziegler AI, Debs S, Sloan EK, Walker AK. Disrupting circadian rhythms promotes cancer-induced inflammation in mice. *Brain Behav Immun Health* 2022;21:100428.
76. Lo AC, James LP, Prica A, Raymakers A, Peacock S, Qu M, Louie AV, Savage KJ, Sehn LH, Hodgson D, Yang JC, Eich HTT, Wirth A, Hunink MGM. PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma. *J Nucl Med* 2022;63:543-8.
77. Lokuhetty N, Mohan HM, Kong JC, Heriot AG, Warriar SK. Lateral pelvic sidewall dissection in rectal cancer: case selection and training to optimize outcomes. *Br J Surg* 2022;109:306-7.
78. Mak B, Lin HM, Kwan EM, Fettke H, Tran B, Davis ID, Mahon K, Stockler MR, Briscoe K, Marx G, Zhang A, Crumbaker M, Tan W, Huynh K, Meikle TG, Mellett NA, Hoy AJ, Du P, Yu J, Jia S, Joshua AM, Waugh DJ, Butler LM, Kohli M, Meikle PJ, Azad AA, Horvath LG. Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer. *BMC Med* 2022;20:112.
79. Maleki S, Glewis S, Fua T, Liu C, Rischin D, Alexander M, Na L, Lingaratnam S. A randomised controlled trial of clinical pharmacy intervention versus standard care to improve medication adherence in outpatients with head and neck cancer receiving radiotherapy. *Support Care Cancer* 2022;30:4243-53.
80. McQuilten ZK, Busija L, Seymour JF, Stanworth S, Wood EM, Kenealy M, Weinkove R, Australasian Leukaemia and Lymphoma Group (ALLG). Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia. *Leuk Lymphoma* 2022;63:676-683.
81. Meiser B, Woodward P, Gleeson M, Kentwell M, Fan HM, Antill Y, Butow PN, Boyle F, Best M, Taylor N, Bell K, Tucker K. Pilot study of an online training program to increase genetic literacy and communication skills in oncology healthcare professionals discussing BRCA1/2 genetic testing with breast and ovarian cancer patients. *Fam Cancer* 2022;21:157-66.
82. Mendis S, To YH, Tie J. Biomarkers in Locally Advanced Rectal Cancer: A Review. *Clin Colorectal Cancer* 2022;21:36-44.
83. Minson A, Tam C, Dickinson M, Seymour JF. Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas. *Cancers* 2022;14:1276.
84. Nedumannil R, Leitinger E, Juneja S. Extreme Thrombocytosis in Refractory ITP Post-Splenectomy with Associated Fatal Thromboembolism. *Clin Pathol* 2022;15:2632010x221083218.

85. Ng SP, Ngan SY, Leong T. Current State of Neoadjuvant Radiotherapy for Rectal Cancer. *Clin Colorectal Cancer* 2022;21:63-70.
86. Osong B, Masciocchi C, Damiani A, Bermejo I, Meldolesi E, Chiloiro G, Berbee M, Lee SH, Dekker A, Valentini V, Gerard JP, Rödel C, Bujko K, van de Velde C, Folkesson J, Sainato A, Glynn-Jones R, Ngan S, Brændengen M, Sebag-Montefiore D, van Soest J. Bayesian network structure for predicting local tumor recurrence in rectal cancer patients treated with neoadjuvant chemoradiation followed by surgery. *Phys Imaging Radiat Oncol* 2022;22:1-7.
87. Ou SI, Solomon BJ, Shaw AT, Gadgeel SM, Besse B, Soo RA, Abbattista A, Toffalorio F, Wiltshire R, Bearz A. Continuation of Lorlatinib in ALK-Positive NSCLC Beyond Progressive Disease. *J Thorac Oncol* 2022;17:568-77.
88. Pathmanandavel S, Crumbaker M, Yam AO, Nguyen A, Rofe C, Hovey E, Gedye C, Kwan EM, Hauser C, Azad AA, Eu P, Martin AJ, Joshua AM, Emmett L. ¹⁷⁷Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial. *J Nucl Med* 2022;63:560-6.
89. Philip J, Le B, Pasanen L, Rosens E, Wong A, Mendis R, Boughey M, Coperchini M, Moran J, Hynson J, Weil J, Rosenthal M. Palliative Care Clinical Trials: Building Capability and Capacity. *J Palliat Med* 2022;25(3):421-427.
90. Pirie K, Doane MA, Riedel B, Myles PS. Analgesia for major laparoscopic abdominal surgery: a randomised feasibility trial using intrathecal morphine. *Anaesthesia* 2022;77:428-37.
91. Prabahan A, Koldej R, Chee L, Ritchie D. Clinical features, pathophysiology, and therapy of poor graft function post-allogeneic stem cell transplantation. *Blood Adv* 2022;6:1947-59.
92. Prabhakaran S, Yang TWW, Johnson N, Bell S, Chin M, Simpson P, Carne P, Farmer C, Skinner S, Warriar SK, Kong JC. Latest evidence on the management of early-stage and locally advanced rectal cancer: a narrative review. *ANZ J Surg* 2022;92:365-72.
93. Prall OWJ, Browning J, Nastevski V, Caporarello S, Bates B, Hewitt CA, Arenas A, Lamb G, Howlett K, Arnolda R, Adeloju R, Stuart S, Xu H, Fellowes A, Fox SB. ROS1 rearrangements in non-small cell lung cancer: screening by immunohistochemistry using proportion of cells staining without intensity and excluding cases with MAPK pathway drivers improves test performance. *Pathology* 2022;54:279-85.
94. Rischin D, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Braña I, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Ishak WZW, Hong RL, Mendoza RG, Jia L, Chirovsky D, Norquist J, Jin F, Burtness B. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. *Oral Oncol* 2022;128:105815.
95. Runacres F, Steele P, Hudson J, Bills M, Poon P. 'We couldn't have managed without your team': A collaborative palliative care response to the COVID-19 pandemic in residential aged care. *Australas J Ageing* 2022;41:147-152.
96. Salem ME, El-Refai SM, Sha W, Puccini A, Grothey A, George TJ, Hwang JJ, O'Neil B, Barrett AS, Kadakia KC, Musselwhite LW, Raghavan D, Van Cutsem E, Tabernero J, Tie J. Landscape of KRAS^{G12C}, Associated Genomic Alterations, and Interrelation with Immuno-Oncology Biomarkers in KRAS-Mutated Cancers. *JCO Precis Oncol* 2022;6:e2100245.
97. Sapkaroski D, Mundy M, Dimmock MR. Immersive virtual reality simulated learning environment versus role-play for empathic clinical communication training. *J Med Radiat Sci* 2022;69:56-65.
98. Seidel C, Hentrich M, Zschabitz S, Paffenholz P, Heidenreich A, Nestler T, Tran B, Fischer S, Daugaard G, Ochsenreither S, Brito M, Zengerling F, Schwab C, Bokemeyer C, Oing C. Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG). *World J Urol* 2022;40:355-61.

99. Singh J, Gorniak M, Grigoriadis G, Westerman D, McBean M, Venn N, Law T, Sutton R, Morgan S, Fleming S. Correlation between a 10-color flow cytometric measurable residual disease (MRD) analysis and molecular MRD in adult B-acute lymphoblastic leukemia. *Cytometry B Clin Cytom* 2022;102:115-122.
100. Siva S, Ali M, Guckenberger M. Pre-emptive or reactive? PROMPT spinal screening in metastatic castration-resistant prostate cancer. *Lancet Oncol* 2022;23:443-4.
101. Siva S, Bressel M, Wood ST, Shaw MG, Loi S, Sandhu SK, Tran B, A AA, Lewin JH, Cuff KE, Liu HY, Moon D, Goad J, Wong LM, LimJoon M, Mooi J, Chander S, Murphy DG, Lawrentschuk N, Pryor D. Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPOR Trial. *Eur Urol* 2022;81:364-72.
102. Siva S, Louie AV. Substituting SABR for systemic therapy in oligometastatic renal cell carcinoma - buying time or time to change? *Nat Rev Urol* 2022;19:197-8.
103. Smith LK, Parmenter T, Kleinschmidt M, Kusnadi EP, Kang J, Martin CA, Lau P, Patel R, Lorent J, Papadopoli D, Trigou A, Ward T, Rao AD, Lelliott EJ, Sheppard KE, Goode D, Hicks RJ, Tiganis T, Simpson KJ, Larsson O, Blythe B, Cullinane C, Wickramasinghe VO, Pearson RB, McArthur GA. Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAF^{V600} melanoma. *Nat Commun* 2022;13:1100.
104. Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN Jr, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, Urtishak KA, Francis P, Lopez-Gitlitz A, Fizazi K, GALAHAD investigators. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. *Lancet Oncol* 2022;23:362-73.
105. Soh KT, Came N, Otteson GE, Jevremovic D, Shi M, Olteanu H, Natoni A, Lagoo A, Theakston E, Oskarsson J, Gorniak M, Grigoriadis G, Arroz M, Fletcher M, Lin P, Ludwig P, Tembhare P, Matuzeviciene R, Radzevicius M, Kay S, Chen W, Cabrita C, Wallace PK. Evaluation of multiple myeloma measurable residual disease by high sensitivity flow cytometry: An international harmonized approach for data analysis. *Cytometry B Clin Cytom* 2022;102:88-106.
106. Stockler MR, Martin AJ, Davis ID, Dhillon HM, Begbie SD, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx GM, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar WR, Pook DW, Reaume MN, Sandhu S, Tan A, Tan TH, Thomson A, Vera-Badillo F, Williams SG, Winter DG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ, ENZAMET Trial Investigators, Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP. *J Clin Oncol* 2022;40:837-46.
107. Tabernero J, Andre F, Blay JY, Bustillos A, Fear S, Ganta S, Jaeger D, Maio M, Mileskin L, Melero I. Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers. *ESMO Open* 2022;7:100419.
108. Teh JSK, Coussement J, Neoh ZCF, Spelman T, Lazarakis S, Slavin MA, Teh BW. Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis. *Blood Adv* 2022;6:2014-34.
109. Thompson JR, Smith AL, Lo SN, Kasparian NA, Saw RP, Dieng M, Seaman L, Martin LK, Guitera P, Milne D, Schmid H, Cust AE, Bartula I. Protocol for the implementation of a stepped-care model to address fear of cancer recurrence in patients previously diagnosed with early-stage (0-II) melanoma. *BMJ Open* 2022;12:e054337.
110. Tjokrowidjaja A, Lord SJ, John T, Lewis CR, Kok PS, Marschner IC, Lee CK. Pre- and on-treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non-small cell lung cancer. *Cancer* 2022;128:1574-83.

111. Tjong MC, Louie AV, Singh AK, Videtic G, Stephans K, Plumridge N, Harden S, Slotman BJ, Alongi F, Guckenberger M, Siva S. Single-Fraction Stereotactic Ablative Body Radiotherapy to the Lung - The Knockout Punch. *Clin Oncol* 2022;34:e183-94.
112. Tobar LE, Farnsworth RH, Stacker SA. Brain Vascular Microenvironments in Cancer Metastasis. *Biomolecules* 2022;12:401.
113. Tun Min S, Roohullah A, Tognela A, Jalali A, Lee M, Wong R, Shapiro J, Burge M, Yip D, Nott L, Zimet A, Lee B, Dean A, Steel S, Wong HL, Gibbs P, Lim SH. Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: Real-world data in an Australian population. *Asia Pac J Clin Oncol* 2022;18:e56-e63.
114. Udovicich C, Ng SP, Tange D, Bailey N, Haghighi N. From Postoperative to Preoperative: A Case Series of Hypofractionated and Single-Fraction Neoadjuvant Stereotactic Radiosurgery for Brain Metastases. *Oper Neurosurg* 2022;22:208-14.
115. Vaidyanathan S, Salmi TM, Sathiqu RM, McConville MJ, Cox AG, Brown KK. YAP regulates an SGK1/mTORC1/SREBP-dependent lipogenic program to support proliferation and tissue growth. *Dev Cell* 2022;57:719-31.
116. van de Ven M, Ijzerman M, Retèl V, van Harten W, Koffijberg H. Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer. *BMC Med Res Methodol* 2022;22:83.
117. Vatandoust S, Wattchow D, Sposato L, Michael MZ, Leung J, Gormly K, Chen G, Symonds EL, Tie J, Papanicolaou LE, Woods S, Gebiski V, Mead K, Kuruni A, Karapetis CS. A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol. *BMC Cancer* 2022;22:222.
118. Vaz SC, Adam JA, Delgado Bolton RC, Vera P, van Elmpt W, Herrmann K, Hicks RJ, Lievens Y, Santos A, Schöder H, Dubray B, Visvikis D, Troost EGC, de Geus-Oei LF. Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[¹⁸F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0. *Eur J Nucl Med Mol Imaging* 2022;49:1386-1406.
119. Vaz SC, Adam JA, Delgado Bolton RC, Vera P, van Elmpt W, Herrmann K, Hicks RJ, Lievens Y, Santos A, Schöder H, Dubray B, Visvikis D, Troost EGC, de Geus-Oei LF. Perspective paper about the joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[¹⁸F]FDG-PET/CT external beam radiation treatment planning in lung cancer. *Radiother Oncol* 2022;168:37-39.
120. Walls GM, Osman SOS, Brown KH, Butterworth KT, Hanna GG, Hounsell AR, McGarry CK, Leijenaar RTH, Lambin P, Cole AJ, Jain S. Radiomics for Predicting Lung Cancer Outcomes Following Radiotherapy: A Systematic Review. *Clin Oncol* 2022;34:e107-e122.
121. Wang M, Zadeh S, Pizzolla A, Thia K, Gyorki DE, McArthur GA, Scolyer RA, Long G, Wilmott JS, Andrews MC, Au-Yeung G, Weppler A, Sandhu S, Trapani JA, Davis MJ, Neeson PJ. Characterization of the treatment-naïve immune microenvironment in melanoma with BRAF mutation. *J Immunother Cancer* 2022;10:e004095.
122. Watt AC, Goel S. Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. *Breast Cancer Res* 2022;24:17.
123. Weld-Blundell IV, Grech L, Learmonth YC, Marck CH. Lifestyle and complementary therapies in multiple sclerosis guidelines: Systematic review. *Acta Neurol Scand* 2022;145:379-92.
124. Wiede F, Lu KH, Du X, Zeissig MN, Xu R, Goh PK, Xirouchaki CE, Hogarth SJ, Greatorex S, Sek K, Daly RJ, Beavis PA, Darcy PK, Tonks NK, Tiganis T. PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity. *Cancer Discov* 2022;12:752-773.
125. Xu JJ, Chalk AM, Nikolic I, Simpson KJ, Smeets MF, Walkley CR. Genome-wide screening identifies cell-cycle control as a synthetic lethal pathway with SRSF2P95H mutation. *Blood Adv* 2022;6:2092-106.

126. Ye Z, Li S, Dite GS, Nguyen TL, MacInnis RJ, Andrulis IL, Buys SS, Daly MB, John EM, Kurian AW, Genkinger JM, Chung WK, Phillips KA, Thorne H, kConFab, Winship IM, Milne RL, Dugue PA, Southey MC, Giles GG, Terry MB, Hopper JL. Weight is More Informative than Body Mass Index for Predicting Postmenopausal Breast Cancer Risk: Prospective Family Study Cohort (ProF-SC). *Cancer Prev Res* 2022;15:185-91.
127. Yeoh ZH, Roberts AW. Acute leukaemia in Australia: outcomes have improved, but there is still much to do. *Med J Aust* 2022;216:289-90.

April

1. Abo S, Parry SM, Ritchie D, Sgro G, Truong D, Denehy L, Granger CL. Exercise in allogeneic bone marrow transplantation: a qualitative representation of the patient perspective. *Support Care Cancer* 2022;30:5389-99.
2. Ahmed F, Tseng HY, Ahn A, Gunatilake D, Alavi S, Eccles M, Rizos H, Gallagher SJ, Tiffen JC, Hersey P, Emran AA. Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma. *J Invest Dermatol* 2022;142:1444-55.
3. Alese OB, Cook N, Ortega-Franco A, Ulanja MB, Tan L, Tie J. Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers. *Am Soc Clin Oncol Educ Book* 2022;42:1-20.
4. Balasubramanian A, John T, Asselin-Labat ML. Regulation of the antigen presentation machinery in cancer and its implication for immune surveillance. *Biochem Soc Trans* 2022;50:825-37.
5. Beattie BJ, Akhurst TJ, Augensen F, Humm JL. SUVfdg: A standard-uptake-value (SUV) body habitus normalizer specific to fluorodeoxyglucose (FDG) in humans. *PLoS One* 2022;17:e0266704.
6. Bogdanovic B, Solari EL, Villagran Asiares A, McIntosh L, van Marwick S, Schachoff S, Nekolla SG. PET/MR Technology: Advancement and Challenges. *Semin Nucl Med* 2022;52:340-55.
7. Brims FJ, McWilliams A, Harden SV, O'Byrne K. Lung cancer: progress with prognosis and the changing state of play. *Med J Aust* 2022;216:334-6.
8. Brown LC, Loi S. Immune checkpoint inhibition in the treatment of early stage triple negative breast cancer: 2021 update. *Breast* 2022;62:S29-S33.
9. Brown LM, Hadiyah-Zadeh S, Sadras T, Huckstep H, Sandow JJ, Bartolo RC, Kosasih HJ, Davidson NM, Schmidt B, Bjelosevic S, Johnstone R, Webb AI, Khaw SL, Oshlack A, Davis MJ, Ekert PG. SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia. *Blood Adv* 2022;6:2373-87.
10. Cole E, Huang D, Larach JT, Rajkomar A, Farmer KC, Warriar S. Robotic total pelvic exenteration with en bloc pelvic side wall clearance and internal iliac artery resection - A Video Vignette. *Colorectal Dis* 2022;24:537-538.
11. Conduit C, Mak B, Qu W, Lulio JD, Burder R, Bressel M, Cusick T, Dhillon HM, Lourenço RA, Underhill C, Torres J, Crumbaker M, Honeyball F, Linton A, Allen R, Davis ID, Clark SJ, Horvath LG, Mahon KL. GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol). *Ther Adv Med Oncol* 2022;14:17588359221092486.
12. Connolly EA, Bhadri VA, Wake J, Ingley KM, Lewin J, Bae S, Wong DD, Long AP, Pryor D, Thompson SR, Strach MC, Grimison PS, Mahar A, Bonar F, Maclean F, Hong A. Systemic treatments and outcomes in CIC-rearranged Sarcoma: A national multi-centre clinicopathological series and literature review. *Cancer Med* 2022;11:1805-16.
13. Cusack R, Bates A, Mitchell K, van Willigen Z, Denehy L, Hart N, Dushianthan A, Reading I, Chorozoglou M, Sturmev G, Davey I, Grocott M. Improving physical function of patients following intensive care unit

admission (EMPRESS): protocol of a randomised controlled feasibility trial. *BMJ Open* 2022;12:e05285.

14. Dang TH, Forkan ARM, Wickramasinghe N, Jayaraman PP, Alexander M, Burbury K, Schofield P. Investigation of Intervention Solutions to Enhance Adherence to Oral Anticancer Medicines in Adults: Overview of Reviews. *JMIR Cancer* 2022;8:e34833.
15. Dickinson M. Challenges in the development of bispecific antibodies for non-Hodgkin lymphoma. *Lancet Haematol* 2022;9:e314-15.
16. Dix-Matthews A, Palladino M, Lim S, McLeod C, Blyth CC, Yeoh DK. Rare cause of scalp swelling in an infant. *J Paediatr Child Health* 2022;58:730-731.
17. Drewett GP, Smibert OC, Holmes NE, Trubiano JA. The use of procalcitonin as an antimicrobial stewardship tool and a predictor of disease severity in coronavirus disease 2019 (COVID-19). *Infect Control Hosp Epidemiol* 2022;43:542-543.
18. Ekanayake Weeramange C, Shu D, Tang KD, Batra J, Ladwa R, Kenny L, Vasani S, Frazer IH, Dolcetti R, Ellis JJ, Sturm RA, Leo P, Punyadeera C. Analysis of human leukocyte antigen associations in human papillomavirus-positive and -negative head and neck cancer: Comparison with cervical cancer. *Cancer* 2022;128:1937-47.
19. Ellis JA, Malalasekera VS, Allan C, Choong PF, Hansford JR, Hehir R, Morello N, O'Callaghan S, Orme L, Phillipson N, Rosenthal MA, Sawyer S, Strong R, Super L, Watt A, Williams C, Woollett A, Robertson A, Lewin J. Systems-Level Change to Alleviate Barriers to Cancer Clinical Trial Access for Adolescents and Young Adults in Australia. *J Adolesc Young Adult Oncol* 2022;11:173-180.
20. Emery J, Butow P, Lai-Kwon J, Nekhlyudov L, Rynderman M, Jefford M. Management of common clinical problems experienced by survivors of cancer. *Lancet* 2022;399:1537-50.
21. Galgano SJ, Irvani A, Bodei L, El-Haddad G, Hofman MS, Kong G. Imaging of Neuroendocrine Neoplasms: Monitoring Treatment Response-AJR Expert Panel Narrative Review. *AJR Am J Roentgenol* 2022;218:767-80.
22. Gao J, Jung M, Williams RT, Hui D, Russell AJ, Naim AJ, Kamili A, Clifton M, Bongers A, Mayoh C, Ho G, Scott CL, Jessup W, Haber M, Norris MD, Henderson MJ, Australian Ovarian Cancer Study. Suppression of the ABCA1 Cholesterol Transporter Impairs the Growth and Migration of Epithelial Ovarian Cancer. *Cancers* 2022;14:1878.
23. Gaudreault M, Chang D, Hardcastle N, Jackson P, Kron T, Hanna GG, Hofman MS, Siva S. Utility of Biology-Guided Radiotherapy to De Novo Metastases Diagnosed During Staging of High-Risk Biopsy-Proven Prostate Cancer. *Front Oncol* 2022;12:854589.
24. Hussain M, Corcoran C, Sibilla C, Fizazi K, Saad F, Shore N, Sandhu S, Mateo J, Olmos D, Mehra N, Kolinsky MP, Roubaud G, Özgüroğlu M, Matsubara N, Gedye C, Choi YD, Padua C, Kohlmann A, Huisden R, Elvin JA, Kang J, Adelman CA, Allen A, Poehlein C, de Bono J. Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). *Clin Cancer Res* 2022;28:1518-30.
25. Iyengar KP, Azzopardi C, Kiernan G, Botchu R. Isolated pathologies of Tensor Fasciae Latae: Retrospective cohort analysis from a tertiary referral centre. *J Clin Orthop Trauma* 2022;29:101870.
26. Jefford M, Howell D, Li Q, Lisy K, Maher J, Alfano CM, Rynderman M, Emery J. Improved models of care for cancer survivors. *Lancet* 2022;399:1551-60.
27. Jobson D, McCormack CJ, Mar V, Tam C, Henderson MA. Impact of chronic lymphocytic leukaemia on melanoma outcomes: A retrospective case-control study. *Br J Haematol* 2022;197:320-5.
28. Jones ME, Stokes M, Warriar SK. Laparoscopic repair of coccygeal hernia with biological mesh following partial coccygectomy. *ANZ J Surg* 2022;92:912-914.

29. Katz NT, Jones J, Mansfield L, Gold M. The Impact of Health Professionals' Language on Patient Experience: A Case Study. *J Patient Exp* 2022;9:23743735221092572.
30. Kiss N, Steer B, de van der Schueren M, Loeliger J, Alizadehsani R, Edbrooke L, Deftereos I, Laing E, Khosravi A. Comparison of the prevalence of 21 GLIM phenotypic and etiologic criteria combinations and association with 30-day outcomes in people with cancer: A retrospective observational study. *Clin Nutr* 2022;41:1102-11.
31. Koulis A, Di Costanzo N, Mitchell C, Lade S, Goode D, Busuttill RA, Boussioutas A. CD10 and Das1: a biomarker study using immunohistochemistry to subtype gastric intestinal metaplasia. *BMC Gastroenterol* 2022;22:197.
32. Kulasekararaj A, Glasmacher A, Liu P, Szer J, Araten D, Rauch G, Gwaltney C, Sierra JR, Lee JW. Composite endpoint to evaluate complement inhibition therapy in patients with paroxysmal nocturnal hemoglobinuria. *Eur J Haematol* 2022;108:391-402.
33. Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. *N Engl J Med* 2022;386:1421-31.
34. Kwok MMK, Choong KWK, Virk J, Kleid S, Magarey MJR. Lateral temporal bone resections for peri-auricular cutaneous squamous cell carcinoma: prognostic indicators and radiological predictive values. *J Laryngol Otol* 2022;136:297-303.
35. Lee K, Le T, Hau E, Hanna GG, Gee H, Vinod S, Dammak S, Palma D, Ong A, Yeghiaian-Alvandi R, Buck J, Lim R. A Systematic Review Into the Radiologic Features Predicting Local Recurrence After Stereotactic Ablative Body Radiotherapy (SABR) in Patients with Non-Small Cell Lung Cancer (NSCLC). *Int J Radiat Oncol Biol Phys* 2022;113:40-59.
36. Lehmann J, Hussein M, Barry MA, Siva S, Moore A, Chu M, Díez P, Eaton DJ, Harwood J, Lonski P, Claridge Mackonis E, Meehan C, Patel R, Ray X, Shaw M, Shepherd J, Smyth G, Standen TS, Subramanian B, Greer PB, Clark CH. SEAFARER - A new concept for validating radiotherapy patient specific QA for clinical trials and clinical practice. *Radiother Oncol* 2022;171:121-128.
37. Lelliott EJ, Sheppard KE, McArthur GA. Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything? *NPJ Precis Oncol* 2022;6:26.
38. Li Z, Le Roux PY, Callahan J, Hardcastle N, Hofman MS, Siva S, Yamamoto T. Quantitative assessment of ventilation-perfusion relationships with gallium-68 positron emission tomography/computed tomography imaging in lung cancer patients. *Phys Imaging Radiat Oncol* 2022;22:8-12.
39. Maziarz RT, Zhang J, Yang H, Chai X, Yuan C, Schwarz E, Jakovac M, Martinez-Prieto M, Agarwal A, Degtyarev E, Tam C, Salles G. Indirect comparison of tisagenlecleucel and historical treatments for relapsed/refractory diffuse large B-cell lymphoma. *Blood Adv* 2022;6:2536-47.
40. McCann B, Higgins M, Kok DL, Hong W, Alipour R, Chua MST. Long-term control of melanoma adrenal metastasis treated with radiotherapy. *Melanoma Res* 2022;32:166-72.
41. McLean LS, Rischin D. In-transit cutaneous squamous cell carcinoma. *Med J Aust* 2022;216:401.
42. Muttiah C, Whittle JR, Oakman C, Lindeman GJ. PALVEN: phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer. *Future Oncol* 2022;18:1805-16.
43. Nederlof I, Hajizadeh S, Sobhani F, Raza SEA, AbdulJabbar K, Harkes R, van de Vijver MJ, Salgado R, Desmedt C, Kok M, Yuan Y, Horlings HM. Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer. *NPJ Breast Cancer* 2022;8:56.
44. Neelapu SS, Dickinson M, Munoz J, Ulrickson ML, Thieblemont C, Oluwole OO, Herrera AF, Ujjani CS, Lin Y, Riedell PA, Kekre N, de Vos S, Lui C, Milletti F, Dong J, Xu H, Chavez JC. Axicabtagene ciloleucel as

first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial. *Nat Med* 2022;28:735-42.

45. Obinata D, Funakoshi D, Takayama K, Hara M, Niranjana B, Teng L, Lawrence MG, Taylor RA, Risbridger GP, Suzuki Y, Takahashi S, Inoue S. OCT1-target neural gene PFN2 promotes tumor growth in androgen receptor-negative prostate cancer. *Sci Rep* 2022;12:6094.
46. Passaro A, Leigh N, Blackhall F, Popat S, Kerr K, Ahn MJ, Arcila ME, Arrieta O, Planchard D, de Marinis F, Dingemans AM, Dziadziuszko R, Faivre-Finn C, Feldman J, Felip E, Curigliano G, Herbst R, Jänne PA, John T, Mitsudomi T, Mok T, Normanno N, Paz-Ares L, Ramalingam S, Sequist L, Vansteenkiste J, Wistuba II, Wolf J, Wu YL, Yang SR, Yang JCH, Yatabe Y, Pentheroudakis G, Peters S. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer. *Ann Oncol* 2022;33:466-87.
47. Peters S, James PA, Fatkin D, Zentner D. Pregnancy Outcomes in Females with Dilated Cardiomyopathy-Associated Rare Genetic Variants. *Circ Genom Precis Med* 2022;15:e003540.
48. Ritter AT, Shtengel G, Xu CS, Weigel A, Hoffman DP, Freeman M, Iyer N, Alivodej N, Ackerman D, Voskoboinik I, Trapani J, Hess HF, Mellman I. ESCRT-mediated membrane repair protects tumor-derived cells against T cell attack. *Science* 2022;376:377-82.
49. Robert C, Lewis KD, Gutzmer R, Stroyakovskiy D, Gogas H, Protsenko S, Pereira RP, Eigentler T, Rutkowski P, Demidov L, Caro I, Forbes H, Shah K, Yan Y, Li H, McArthur GA, Ascierto PA. Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF^{V600} mutation-positive melanoma. *Ann Oncol* 2022;33:544-55.
50. Schrijver LH, Mooij TM, Pijpe A, Sonke GS, Mourits MJE, Andrieu N, Antoniou AC, Easton DF, Engel C, Goldgar D, John EM, Kast K, Milne RL, Olsson H, Phillips KA, Terry MB, Hopper JL, van Leeuwen FE, Rookus MA. Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits. *J Natl Cancer Inst* 2022;114:540-52.
51. Sherry NL, Gorrie CL, Kwong JC, Higgs C, Stuart RL, Marshall C, Ballard SA, Sait M, Korman TM, Slavin MA, Lee RS, Graham M, Leroi M, Worth LJ, Chan HT, Seemann T, Grayson ML, Howden BP. Multi-site implementation of whole genome sequencing for hospital infection control: A prospective genomic epidemiological analysis. *Lancet Reg Health West Pac* 2022;23:100446.
52. Simons M, Rapport F, Zurynski Y, Stoodley M, Cullis J, Davidson AS. Links between evidence-based medicine and shared decision-making in courses for doctors in training: a scoping review. *BMJ Open* 2022;12:e057335.
53. Smith Z, Barnett SA, Gorelik A, Pascoe DM, Manser RL. Strategies for the Management of Solitary Pulmonary Nodules: A Survey of Patient Preferences. *Ann Thorac Surg* 2022;113:1670-5.
54. Steffens D, Young J, Riedel B, Morton R, Denehy L, Heriot A, Koh C, Li Q, Bauman A, Sandroussi C, Ismail H, Dieng M, Ansari N, Pillinger N, O'Shannassy S, McKeown S, Cunningham D, Sheehan K, Iori G, Bartyn J, Solomon M. PREhabilitatiOn with pReoperative exercise and educaTion for patients undergoing major abdominal cancer surgery: protocol for a multicentre randomised controlled TRIAL (PRIORITY TRIAL). *BMC Cancer* 2022;22:443.
55. Thanarajasingam G, Minasian LM, Bhatnagar V, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gormley N, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Kwong YL, Little RF, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Nair A, Nastoupil L, Robertson K, Sidana S, Smedby KE, Sonneveld P, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Seymour JF, Habermann TM. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies. *Lancet Haematol* 2022;9:e374-84.
56. Tonorezos ES, Cohn RJ, Glaser AW, Lewin J, Poon E, Wakefield CE, Oeffinger KC. Long-term care for people treated for cancer during childhood and adolescence. *Lancet* 2022;399:1561-1572.

57. Wang J, Mohan H, Larach JT, Heriot A, Warriar S. Hybrid robotic and laparoscopic hand-assisted proctocolectomy with complete mesocolic excision, ileal pouch-anal anastomosis and loop ileostomy - A video vignette. *Colorectal Dis* 2022;24:548.
58. Warren M, Emery J, Krishnasamy M, O'Donnell A, Gough K. Pre-diagnostic routes to colorectal cancer in Central New Zealand: factors that lead to emergency presentation and longer diagnostic intervals at primary and secondary level care. *J Prim Health Care* 2022;14:48-56.
59. White VM, Lisy K, Ward A, Ristevski E, Clode M, Webber K, Emery J, IJerman MJ, Afshar N, Millar J, Gibbs P, Evans S, Jefford M. Disparities in quality of life, social distress and employment outcomes in Australian cancer survivors. *Support Care Cancer* 2022;30:5299-309.
60. Wohlmuth C, Djedovic V, Kjaer SK, Jensen A, Glasspool R, Roxburgh P, DeFazio A, Johnatty SE, Webb PM, Modugno F, Lambrechts D, Schildkraut JM, Berchuck A, Thomsen LCV, Bjorge L, Høgdall E, Høgdall CK, Goode EL, Winham SJ, Matsuo K, Karlan BY, Lester J, Goodman MT, Thompson PJ, Pejovic T, Riggan MJ, Lajkosz K, Tone A, May T. CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer-A Multicenter Analysis. *Cancers* 2022;14:1954.
61. Woodford R, Zhou D, Lord SJ, Marschner I, Cooper WA, Lewis CR, John T, Yang JC, Lee CK. PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer. *Future Oncol* 2022;18:1793-9.
62. Xu R, Choong PFM. Metastatic giant cell tumour of bone: a narrative review of management options and approaches. *ANZ J Surg* 2022;92:691-6.

May

1. Anderson RA, Cui W. Improving analysis of ovarian function and female fertility in cancer survivors. *Fertil Steril* 2022;117:1057-1058.
2. Anton A, Pillai S, Semira MC, Wong S, Shapiro J, Weickhardt A, Azad A, Kwan EM, Spain L, Gunjur A, Torres J, Parente P, Parnis F, Goh J, Baenziger O, Gibbs P, Tran B. Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer. *BJUI Compass* 2022;3:205-213.
3. Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Shore ND, Gomez-Veiga F, Rosbrook B, Zohren F, Yamada S, Haas GP, Stenzl A. Improved Survival with Enzalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer. *J Clin Oncol* 2022;40:1616-22.
4. Beavis PA, Derrick EB, Loi S. Challenges of Creating New Tumor-Infiltrating Lymphocyte for Combating Breast Cancer. *J Clin Oncol* 2022;40:1812-15.
5. Bland KA, Krishnasamy M, Parr EB, Mulder S, Martin P, van Loon LJC, Cormie P, Michael N, Zopf EM. "I want to get myself as fit as I can and not die just yet" - Perceptions of exercise in people with advanced cancer and cachexia: a qualitative study. *BMC Palliat Care* 2022;21:75.
6. Bolshinsky V, Ismail H, Li M, Basto J, Schier R, Hagemeyer A, Ho KM, Heriot A, Riedel B. Clinical covariates that improve surgical risk prediction and guide targeted prehabilitation: an exploratory, retrospective cohort study of major colorectal cancer surgery patients evaluated with preoperative cardiopulmonary exercise testing. *Peripher Med* 2022;11:20.
7. Campbell KL, Cormie P, Weller S, Alibhai SMH, Bolam KA, Campbell A, Cheville AL, Dalzell MA, Hart NH, Higano CS, Lane K, Mansfield S, McNeely ML, Newton RU, Quist M, Rauw J, Rosenberger F, Santa Mina D, Schmitz KH, Winters-Stone KM, Wiskemann J, Goulart J. Exercise Recommendation for People with Bone Metastases: Expert Consensus for Health Care Providers and Exercise Professionals. *JCO Oncol Pract* 2022;18:e697-e709.
8. Chan DL, Pavlakis N, Crumbaker M, Lawrence B, Barber C, Price TJ, Michael M, Oberg K. Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series. *Asia Pac J Clin Oncol* 2022;18:209-16.

9. Chen AX, Derrick EB, Beavis PA, House IG. CD4+ chimeric antigen receptor T cells in for the long journey. *Immunol Cell Biol* 2022;100:304-307.
10. Chen MZ, Tay YK, Teoh WM, Kong JC, Carne P, D'Souza B, Chandra R, Bui A, Melbourne Colorectal Collaboration. Melbourne colorectal collaboration: a multicentre review of the impact of COVID-19 on colorectal cancer in Melbourne, Australia. *ANZ J Surg* 2022;92:1110-16.
11. Choong KWK, Kwok MMK, Shen Y, Gerard JM, Teh BM. Materials used for mastoid obliteration and its complications: a systematic review. *ANZ J Surg* 2022;92:994-1006.
12. Cui W, Phillips KA, Francis PA, Anderson RA, Partridge AH, Loi S, Loibl S, Keogh L. Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials. *Breast* 2022;64:56-62.
13. Dash S, Bourke M, Parker AG, Dadswell K, Pascoe MC. Lifestyle behaviours and mental health and wellbeing of tertiary students during COVID-19 lockdown in Australia: A cross-sectional study. *Compr Psychiatry* 2022;116:152324.
14. De Gregorio M, Lee T, Krishnaprasad K, Amos G, An YK, Bastian-Jordan M, Begun J, Borok N, Brown DJM, Cheung W, Connor SJ, Gerstenmaier J, Gilbert LE, Gilmore R, Gu B, Kutaiba N, Lee A, Mahy G, Srinivasan A, Thin L, Thompson AJ, Welman CJ, Yong EXZ, De Cruz P, van Langenberg D, Sparrow MP, Ding NS. Higher Anti-tumor Necrosis Factor- α Levels Correlate with Improved Radiologic Outcomes in Crohn's Perianal Fistulas. *Clin Gastroenterol Hepatol* 2022;20:1306-14.
15. Devchand M, Nolen A, Stewardson AJ, Warrillow SJ, Garrett K, Trubiano JA. Long-term outcomes of an electronic medical record (EMR)-integrated antimicrobial stewardship (AMS) intensive care unit (ICU) ward round. *Infect Control Hosp Epidemiol* 2022;43:670-672.
16. Gaudreault M, Chang D, Hardcastle N, Jackson P, Kron T, Hofman MS, Siva S. Feasibility of biology-guided radiotherapy using PSMA-PET to boost to dominant intraprostatic tumour. *Clin Transl Radiat Oncol* 2022;35:84-89.
17. Gearing PF, Apte SS, Cohen L, Mohan H, Heriot AG, Kong JC, Waters PS. No stone left unturned: a case of malignant mimicry. *ANZ J Surg* 2022;92:1268-1270.
18. Gersekowski K, Delahunty R, Alsop K, Goode EL, Cunningham JM, Winham SJ, Pharoah P, Song H, Jordan S, Fereday S, DeFazio A, Friedlander M, Obermair A, Webb PM. Germline BRCA variants, lifestyle and ovarian cancer survival. *Gynecol Oncol* 2022;165:437-45.
19. Goel S, Bergholz JS, Zhao JJ. Targeting CDK4 and CDK6 in cancer. *Nat Rev Cancer* 2022;22:356-72.
20. Guiney N, Larach JT, Soucisse ML, Waters PS, Warriar SK, Wagner T, Heriot AG, McCormick JJ. Pre-emptive femoral-femoral crossover and subsequent resection of locally recurrent colon cancer with multiorgan involvement including the common iliac vessels. *ANZ J Surg* 2022;92:1226-1228.
21. Haeusler GM, Garnham AL, Li-Wai-Suen CS, Clark JE, Babl FE, Allaway Z, Slavin MA, Mechinaud F, Smyth GK, Phillips B, Thursky KA, Pellegrini M, Doerflinger M. Blood transcriptomics identifies immune signatures indicative of infectious complications in childhood cancer patients with febrile neutropenia. *Clin Transl Immunology* 2022;11:e1383.
22. Hayne D, Grummet J, Espinoza D, McCombie SP, Chalasani V, Ford KS, Frydenberg M, Gilling P, Gordon B, Hawks C, Konstantatos A, Martin AJ, Nixon A, O'Brien C, Patel MI, Sengupta S, Shahbaz S, Subramaniam S, Williams S, Woo HH, Stockler MR, Davis ID, Buchan N, Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). 'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501). *BJU Int* 2022;129:591-600.
23. Hyatt A, Lipson-Smith R, Gough K, Butow P, Jefford M, Hack TF, Hale S, Zucchi E, White S, Ozolins U, Schofield P. Including migrant oncology patients in research: A multisite pilot randomised controlled

trial testing consultation audio-recordings and question prompt lists. *Contemp Clin Trials Commun* 2022;28:100932.

24. Khan I, Darido C. Squamous Cell Carcinoma-A Summary of Novel Advances in Pathogenesis and Therapies. *Cancers* 2022;14:2523.
25. Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Belani A, Zhang X, Tabernero J. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. *ESMO Open* 2022;7:100477.
26. Kong BY, Carter C, Nowak AK, Hovey E, Lwin Z, Haghighi N, Gan HK, Sim HW, Ziegler DS, Barton K, Parkinson J, Leonard R, Khasraw M, Foote M. Barriers and potential solutions to international collaboration in neuro-oncology clinical trials: Challenges from the Australian perspective. *Asia Pac J Clin Oncol* 2022;18:259-66.
27. Laing E, Kiss N, Krishnasamy M, Gough K, Michael M. Exploring health professional knowledge and management of nutritional complications in neuroendocrine cancer patients: Results of an international multidisciplinary survey. *Clin Nutr ESPEN* 2022;49:466-73.
28. Lew TE, Anderson MA. Health-related quality of life for patients with chronic lymphocytic leukaemia - A critical outcome measure in the era of highly effective therapies. *Br J Haematol* 2022;197:394-6.
29. Loi JK, Alexandre YO, Senthil K, Schienstock D, Sandford S, Devi S, Christo SN, Mackay LK, Chinnery HR, Osborne PB, Downie LE, Sloan EK, Mueller SN. Corneal tissue-resident memory T cells form a unique immune compartment at the ocular surface. *Cell Rep* 2022;39:110852.
30. Lopci E, Hicks RJ, Dimitrakopoulou-Strauss A, Derclé L, Irvani A, Seban RD, Sachpekidis C, Humbert O, Gheysens O, Glaudemans A, Weber W, Wahl RL, Scott AM, Pandit-Taskar N, Aide N. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. *Eur J Nucl Med Mol Imaging* 2022;49:2323-41.
31. Mizrahi D, Murnane A, Quinn S, Crowe J, Rosenbaum S, Adams D, Atkinson M. Exercise recommendations and referral patterns of oncology professionals. *Asia Pac J Clin Oncol* 2022;18:295-302.
32. Molendijk J, Kolka CM, Cairns H, Brosda S, Mohamed A, Shah AK, Brown I, Hodson MP, Hennessy T, Liu G, Stoll T, Richards RS, Gartside M, Patel K, Clemons NJ, Phillips WA, Barbour A, Westerhuis JA, Hill MM. Elevation of fatty acid desaturase 2 in esophageal adenocarcinoma increases polyunsaturated lipids and may exacerbate bile acid-induced DNA damage. *Clin Transl Med* 2022;12:e810.
33. Muir J, McCormack C, De'Ambrosio B, Brown H, Kennedy D, Louie B, Smithers BM. Reply to: A practical guide on the use of imiquimod cream to treat lentigo maligna. *Australas J Dermatol* 2022;63:e197-8.
34. Nassiri F, Wang JZ, Au K, Barnholtz-Sloan J, Jenkinson MD, Drummond K, Zhou Y, Snyder JM, Brastianos P, Santarius T, Suppiah S, Poisson L, Gaillard F, Rosenthal M, Kaufmann T, Tsang DS, Aldape K, Zadeh G. Consensus core clinical data elements for meningiomas (v2021.1). *Neuro Oncol* 2022;24:683-93.
35. Niederwieser D, Baldomero H, Bazuaye N, Bupp C, Chaudhri N, Corbacioglu S, Elhaddad A, Frutos C, Galeano S, Hamad N, Hamidieh AA, Hashmi S, Ho A, Horowitz MM, Iida M, Jaimovich G, Karduss A, Kodera Y, Kröger N, Péffault de Latour R, Lee JW, Martínez-Rolón J, Pasquini MC, Passweg J, Paulson K, Seber A, Snowden JA, Srivastava A, Szer J, Weisdorf D, Worel N, Koh MBC, Aljurf M, Greinix H, Atsuta Y, Saber W. One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors. *Haematologica* 2022;107:1045-1053.
36. O'Brien JS, Teh J, Kelly BD, Chen K, Manning T, Furrer M, Chee J, Lawrentschuk N. Interrogating the Impassable: A Case Series and Literature Review of Unilateral SPECT-CT Groin Visualization in Men with Penile Cancer. *Front Surg* 2022;9:882011.

37. Odutola MK, van Leeuwen MT, Turner J, Bruinsma F, Seymour JF, Prince HM, Milliken ST, Trotman J, Verner E, Tiley C, Roncolato F, Underhill CR, Opat SS, Harvey M, Hertzberg M, Benke G, Giles GG, Vajdic CM. Associations between Smoking and Alcohol and Follicular Lymphoma Incidence and Survival: A Family-Based Case-Control Study in Australia. *Cancers* 2022;14:2710.
38. Ong S, Pascoe C, Kelly BD, Ballok Z, Webb D, Bolton D, Murphy D, Sengupta S, Bowden P, Lawrentschuk N. PSMA PET-CT Imaging Predicts Treatment Progression in Men with Biochemically Recurrent Prostate Cancer-A Prospective Study of Men with 3 Year Follow Up. *Cancers* 2022;14:2717.
39. O'Rourke MA, McKelvie PA, Angel CM, McNab AA. Lacrimal gland pleomorphic adenoma with extensive necrosis. *Orbit* 2022;41:378-81.
40. Palles C, West HD, Chew E, Galavotti S, Flensburg C, Grolleman JE, Jansen EAM, Curley H, Chegwidan L, Arbe-Barnes EH, Lander N, Truscott R, Pagan J, Bajel A, Sherwood K, Martin L, Thomas H, Georgiou D, Fostira F, Goldberg Y, Adams DJ, van der Biezen SAM, Christie M, Clendenning M, Thomas LE, Deltas C, Dimovski AJ, Dymerska D, Lubinski J, Mahmood K, van der Post RS, Sanders M, Weitz J, Taylor JC, Turnbull C, Vreede L, van Wezel T, Whalley C, Arnedo-Pac C, Caravagna G, Cross W, Chubb D, Frangou A, Gruber AJ, Kinnersley B, Noyvert B, Church D, Graham T, Houlston R, Lopez-Bigas N, Sottoriva A, Wedge D, Genomics England Research Consortium, CORGI Consortium, WGS500 Consortium, Jenkins MA, Kuiper RP, Roberts AW, Cheadle JP, Ligtenberg MJL, Hoogerbrugge N, Koelzer VH, Rivas AD, Winship IM, Ponte CR, Buchanan DD, Power DG, Green A, Tomlinson IPM, Sampson JR, Majewski IJ, de Voer RM. Germline MBD4 deficiency causes a multi-tumor predisposition syndrome. *Am J Hum Genet* 2022;109:953-60.
41. Parker AG, Trott E, Bourke M, Klepac Pogrmilovic B, Dadswell K, Craike M, McLean SA, Dash S, Pascoe M. Young people's attitudes towards integrating physical activity as part of mental health treatment: A cross-sectional study in youth mental health services. *Early Interv Psychiatry* 2022;16:518-526.
42. Pizzolla A, Keam SP, Vergara IA, Caramia F, Thio N, Wang M, Kocovski N, Tantalo D, Jabbari J, Au-Yeung G, Sandhu S, Gyorki DE, Weppler A, Perdicchio M, McArthur GA, Papenfuss AT, Neeson PJ. Tissue-resident memory T cells from a metastatic vaginal melanoma patient are tumor-responsive T cells and increase after anti-PD-1 treatment. *J Immunother Cancer* 2022;10:e004574.
43. Prabhakaran S, Kong JC, Williams E, Bell S, Warriar S, Simpson P, Chin M, Skinner S, Carne P. Comparison of colorectal cancer outcomes in young adults and octogenarians. *Am J Surg* 2022;223:951-956.
44. Rajabifard P, Larach JT, Mohan H, Heriot AG, Warriar SK. Application of a hybrid robotic and transanal total mesorectal excision approach to resect a bulky low rectal gastrointestinal stromal tumour. *ANZ J Surg* 2022;92:1240-1242.
45. Rogiers A, Lobon I, Spain L, Turajlic S. The Genetic Evolution of Metastasis. *Cancer Res* 2022;82:1849-57.
46. Sia J, Lim WM, Agas RA, Xie J, Burns M, Varghayee N, Chu J, Heriot A, Leong T, Ngan SY. Long-term Patterns of Failure and the Value of Blood Prognostic Markers in Anal Cancers Treated with Intensity-Modulated Radiation Therapy. *Clin Colorectal Cancer* 2022;21:e102-12.
47. Sinclair B, Cahill V, Seah J, Kitchen A, Vivash LE, Chen Z, Malpas CB, O'Shea MF, Desmond PM, Hicks RJ, Morokoff AP, King JA, Fabinyi GC, Kaye AH, Kwan P, Berkovic SF, Law M, O'Brien TJ. Machine learning approaches for imaging-based prognostication of the outcome of surgery for mesial temporal lobe epilepsy. *Epilepsia* 2022;63:1081-92.
48. Sivanathan V, Smallwood N, Strathmore A, Johnson D, Le B, Zentner D. The Palliative Approach and Terminal Heart Failure Admissions - Are We Getting it Right? *Heart Lung Circ* 2022;31:841-8.
49. Soo RA, Huat Tan E, Hayashi H, Seto T, Lin CC, Ou SHI, Kim DW, Liu G, Abbattista A, Martini JF, Hooi Wong C, Toffalorio F, Solomon BJ. Efficacy and safety of lorlatinib in Asian and non-Asian patients with ALK-positive advanced non-small cell lung cancer: Subgroup analysis of a global phase 2 trial. *Lung Cancer* 2022;169:67-76.

50. Stensland KD, Devasia T, Caram MEV, Chapman C, Zaslavsky A, Morgan TM, Hollenbeck BK, Sparks JB, Burns J, Vedapudi V, Duchesne GM, Tsodikov A, Skolarus TA. Better Understanding the Timing of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy. *JNCI Cancer Spectr* 2022;6:pkac025.
51. Sundar S, Cummins C, Kumar S, Long J, Arora V, Balega J, Broadhead T, Duncan T, Edmondson R, Fotopoulou C, Glasspool R, Kolomainen D, Leeson S, Manchanda R, McNally O, Morrison J, Mukhopadhyay A, Paul J, Tidy J, Wood N. Quality of life from cytoreductive surgery in advanced ovarian cancer: Investigating the association between disease burden and surgical complexity in the international, prospective, SOCQER-2 cohort study. *BJOG* 2022;129:1122-32.
52. Temperley H, Waters C, Larkins K, Murray C, O'Sullivan NJ, Mockler D, Humm G, Norden C, Phoenix E, Donohoe CL, Warriar S, Mohan H. The educational value of the multi-disciplinary meeting (MDM) in surgical oncology: A systematic review and thematic content analysis. *Eur J Surg Oncol* 2022;48:935-945.
53. Tew M, De Abreu Lourenco R, Gordon JR, Thursky KA, Slavin MA, Babl FA, Orme L, Bryant PA, Teh BW, Dalziel K, Haeusler GM. Cost-effectiveness of home-based care of febrile neutropenia in children with cancer. *Pediatr Blood Cancer* 2022;69:e29469.
54. Tran TH, de Boer J, Gyorki DE, Krishnasamy M. Optimising the quality of multidisciplinary team meetings: A narrative review. *Cancer Med* 2022;11:1965-71.
55. van Akkooi ACJ, Hieken TJ, Burton EM, Ariyan C, Ascierto PA, Asero S, Blank CU, Block MS, Boland GM, Caraco C, Chng S, Davidson BS, Duprat Neto JP, Faries MB, Gershenwald JE, Grunhagen DJ, Gyorki DE, Han D, Hayes AJ, van Houdt WJ, Karakousis GC, Klop WMC, Long GV, Lowe MC, Menzies AM, Olofsson Bagge R, Pennington TE, Rutkowski P, Saw RPM, Scolyer RA, Shannon KF, Sondak VK, Tawbi H, Testori AAE, Tetzlaff MT, Thompson JF, Zager JS, Zuur CL, Wargo JA, Spillane AJ, Ross MI. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). *Ann Surg Oncol* 2022;29:3694-708.
56. van Gysen K, Kneebone A, Le A, Wu K, Haworth A, Bromley R, Hraby G, O'Toole J, Booth J, Brown C, Pearse M, Sidhom M, Wiltshire K, Tang C, Eade T. Evaluating the utility of knowledge-based planning for clinical trials using the TROG 08.03 post prostatectomy radiation therapy planning data. *Phys Imaging Radiat Oncol* 2022;22:91-7.
57. Vu M, Degeling K, Thompson ER, Blombery P, Westerman D, IJerman MJ. Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review. *Eur J Haematol* 2022;108:469-85.
58. Wijewardhana UA, Apputhurai P, Jayawardana M, Meyer D. Effectiveness of the conservation areas on the Mornington Peninsula for the common resident shorebird species using citizen science data. *PLoS One* 2022;17:e0267203.
59. Williams LK, Ftanou M, Pearson EJ. Stepped-care cognitive behaviour therapy program for treating cancer-related fatigue: protocol for a feasibility study. *Pilot Feasibility Stud* 2022;8:112.
60. Xiao L, Karsa M, Ronca E, Bongers A, Kosciolk A, El-Ayoubi A, Revalde JL, Seneviratne JA, Cheung BB, Cheung LC, Kotecha RS, Newbold A, Bjelosevic S, Arndt GM, Lock RB, Johnstone RW, Gudkov AV, Gurova KV, Haber M, Norris MD, Henderson MJ, Somers K. The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression. *Front Oncol* 2022;12:863329.
61. Yeoh DK, Haeusler GM, McMullan BJ, Butters C, Bryant PA, Clark JE, Cooper CM, Gwee A, Kotecha RS, Lai T, Slavin MA, Thursky KA, Blyth CC. Antifungal use in children with acute leukaemia: state of current evidence and directions for future research. *J Antimicrob Chemother* 2022;77:1508-24.
62. Yun JS, Scardamaglia L, Tan CG, McCormack CJ. Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: a case report. *Australas J Dermatol* 2022;63:e155-8.

June

1. Allam AH, Russell SM. Establishing a multiplex imaging panel to study T cell development in the thymus in mouse. *STAR Protoc* 2022;3:101472.
2. Arnold H, Panara V, Hußmann M, Filipek-Gorniok B, Skoczylas R, Ranefall P, Gloger M, Allalou A, Hogan BM, Schulte-Merker S, Koltowska K. *mafba* and *mafbb* differentially regulate lymphatic endothelial cell migration in topographically distinct manners. *Cell Rep* 2022;39:110982.
3. Aziz D, Lee C, Chin V, Fernandez KJ, Phan Z, kConFab Investigators, AOCs Study Group, Waring P, Caldon CE. High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer. *J Pathol Clin Res* 2022;8:355-70.
4. Blombery P, Ryland GL, Fox LC, Stark Z, Wall M, Jarmolowicz A, Roesley A, Thompson ER, Grimmond SM, Panicker S, Kwok F. Methyl-CpG binding domain 4, DNA glycosylase (MBD4)-associated neoplasia syndrome associated with a homozygous missense variant in MBD4: Expansion of an emerging phenotype. *Br J Haematol* 2022;198:196-9.
5. Brennen R, Lin KY, Denehy L, Soh SE, Frawley H. Patient and clinician perspectives of pelvic floor dysfunction after gynaecological cancer. *Gynecol Oncol Rep* 2022;41:101007.
6. Caccuri F, Messali S, Zani A, Campisi G, Giovanetti M, Zanussi S, Vaccher E, Fabris S, Bugatti A, Focà E, Castelli F, Ciccozzi M, Dolcetti R, Gallo RC, Caruso A. HIV-1 mutants expressing B cell clonogenic matrix protein p17 variants are increasing their prevalence worldwide. *Proc Natl Acad Sci USA* 2022;119:e2122050119.
7. Campbell BA, Bakst RL, Milgrom SA, Seymour JF. Balancing the Therapeutic Ratio in DLBCL Requires Appropriate, Individualized Patient Selection Rather Than Broad Elimination of Radiation Therapy. *Int J Radiat Oncol Biol Phys* 2022;113:479-88.
8. Carle C, Hughes S, Freeman V, Campbell D, Egger S, Caruana M, Hui H, Yap S, Deandrea S, Onyeka TC, IJzerman MJ, Ginsburg O, Bray F, Sullivan R, Aggarwal A, Peacock SJ, Chan KKW, Hanna TP, Soerjomataram I, O'Connell DL, Canfell K, Steinberg J. The risk of contracting SARS-CoV-2 or developing COVID-19 for people with cancer: A systematic review of the early evidence. *J Cancer Policy* 2022;33:100338.
9. Casey L, Stokes M, Puckett J, Kong JC, Skinner S. Metastatic gastrointestinal stromal tumour of the descending colon: the importance of complete histological assessment prior to operative management. *ANZ J Surg* 2022;92:1530-1532.
10. Charnley M, Islam S, Bindra GK, Engwirda J, Ratcliffe J, Zhou J, Mezzenga R, Hulett MD, Han K, Berryman JT, Reynolds NP. Neurotoxic amyloidogenic peptides in the proteome of SARS-COV2: potential implications for neurological symptoms in COVID-19. *Nat Commun* 2022;13:3387.
11. Cheasley D, Fernandez ML, Köbel M, Kim H, Dawson A, Hoenisch J, Bittner M, Chiu DS, Talhouk A, Gilks CB, Jayawardana MW, Pishas KI, Mes-Masson AM, Provencher D, Nigam A, Hacker NF, Gorringer KL, Campbell IG, Carey MS. Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression. *NPJ Precis Oncol* 2022;6:47.
12. Chen K, McVey A, Kasivisvanathan V, Jenjitrant P, Azad A, Murphy DG. Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer. *Eur Urol* 2022;82:146-7.
13. Chen K, O'Brien J, McVey A, Kasivisvanathan V, Murphy DG. Re: Armando Stabile, Antony Pellegrino, Elio Mazzone, et al. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. *Eur Urol Oncol* 2022;5:1-17. *Eur Urol Oncol* 2022;5:375-6.
14. Chen L, He Z, Reis BS, Gelles JD, Chipuk JE, Ting AT, Spicer JA, Trapani JA, Furtado GC, Lira SA. IFN- γ ⁺ cytotoxic CD4⁺ T lymphocytes are involved in the pathogenesis of colitis induced by IL-23 and the food colorant Red 40. *Cell Mol Immunol* 2022;19:777-90.

15. Connolly EA, Weickhardt A, Grimison P, Asher R, Heller GZ, Lewin J, Liow E, Toner G, Tung ILY, Tran B, Hill S, Walpole E, McKenzie J, Kuchel A, Goh J, Forgeson G, Tan A, Joshi A, Wickham A, Tan H, Wang Y, Winstanley MA, Hamad N, Wong V. High-dose chemotherapy for relapsed germ cell tumours: outcomes in low-volume specialized centres. *BJU Int* 2022;130(Suppl 1):5-16.
16. Daniell JR, Dolja-Gore X, McDowell L, Udovicich C, Rowe D, Iseli TA, Wong T, Magarey MJR, Wiesenfeld D. The impact of travel distance to treatment centre on oral tongue squamous cell carcinoma survival and recurrence. *Int J Oral Maxillofac Surg* 2022;51:854-61.
17. Delahunty R, Nguyen L, Craig S, Creighton B, Ariyaratne D, Garsed DW, Christie E, Fereday S, Andrews L, Lewis A, Limb S, Pandey A, Hendley J, Traficante N, Carvajal N, Spurdle AB, Thompson B, Parsons MT, Beshay V, Volcheck M, Semple T, Lupat R, Doig K, Yu J, Chen XQ, Marsh A, Love C, Bilic S, Beilin M, Nichols CB, Greer C, Lee YC, Gerty S, Gill L, Newton E, Howard J, Williams R, Norris C, Stephens AN, Tutty E, Smyth C, O'Connell S, Jobling T, Stewart CJR, Tan A, Fox SB, Pachter N, Li J, Ellul J, Mir Arnau G, Young MA, Gordon L, Forrest L, Harris M, Livingstone K, Hill J, Chenevix-Trench G, Cohen PA, Webb PM, Friedlander M, James P, Bowtell D, Alsop K, Australian Ovarian Cancer Study, Ovarian Cancer Prognosis and Lifestyle Study, the TRACEBACK Study. TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members. *J Clin Oncol* 2022;40:2036-47.
18. Dhakal B, Shah N, Kansagra A, Kumar A, Lonial S, Garfall A, Cowan A, Poudyal BS, Costello C, Gay F, Cook G, Quach H, Einsele H, Schriber J, Hou J, Costa L, Aljurf M, Chaudhry M, Beksac M, Prince M, Mohty M, Janakiram M, Callander N, Biran N, Malhotra P, Otero PR, Moreau P, Abonour R, Iftikhar R, Silberman R, Mailankody S, Gregory T, Lin Y, Carpenter P, Hamadani M, Usmani S, Kumar S. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma. *Transplant Cell Ther* 2022;28:284-293.
19. Dhillon K, Manji J, Tapia Cespedes M, Prasad J, Kleid S, Flatman S, Nguyen K, McLean T, Magarey M. Use of telemedicine consultations in head and neck cancer: patient perceptions, acceptability and accessibility. *ANZ J Surg* 2022;92:1415-22.
20. Dixon-Douglas JR, Patel RP, Somasundram PM, McArthur GA. Triplet Therapy in Melanoma - Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies. *Curr Oncol Rep* 2022;24:1071-9.
21. Djordjevic A, Deftereos I, Carter VM, Morris S, Shannon R, Kiss N, Yeung JMC. Ability of malnutrition screening and assessment tools to identify computed tomography defined low muscle mass in colorectal cancer surgery. *Nutr Clin Pract* 2022;37:666-76.
22. Drewett GP, Encena J, Gregory J, Franklin L, Trubiano JA. Anaphylaxis in Victoria: presentations to emergency departments, with a focus on drug- and antimicrobial-related cases. *Med J Aust* 2022;216:520-4.
23. Drilon A, Chiu CH, Fan Y, Cho BC, Lu S, Ahn MJ, Krebs MG, Liu SV, John T, Otterson GA, Tan DSW, Patil T, Dziadziuszko R, Massarelli E, Seto T, Doebele RC, Pitcher B, Kurtsikidze N, Heinzmann S, Siena S. Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC. *JTO Clin Res Rep* 2022;3:100332.
24. Enjeti AK, Agarwal R, Blombery P, Chee L, Chua CC, Grigg A, Hamad N, Iland H, Lane S, Perkins A, Singhal D, Tate C, Tiong IS, Ross DM. Panel-based gene testing in myelodysplastic/myeloproliferative neoplasm overlap syndromes: Australasian Leukaemia and Lymphoma Group (ALLG) consensus statement. *Pathology* 2022;54:389-98.
25. Evangelista L, Maurer T, van der Poel H, Alongi F, Kunikowska J, Laudicella R, Fanti S, Hofman MS. [⁶⁸Ga]Ga-PSMA Versus [¹⁸F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature. *Eur Urol Oncol* 2022;5:273-82.

26. Fleming GF, Pagani O, Regan MM, Walley BA, Francis PA. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. *Ann Oncol* 2022;33:658.
27. Flood MP, Kong JC, Pham T, Waters PS, Soucisse M, Ramsay R, Wong HL, Mitchell C, Michael M, McCormick JJ, Warriar SK, Akhurst T, Heriot AG. Diagnostic performance of positron emission tomography in the staging of pseudomyxoma peritonei. *Eur J Surg Oncol* 2022;48:1606-13.
28. Fox J, Thamm C, Mitchell G, Emery J, Rhee J, Hart NH, Yates P, Jefford M, Koczwara B, Halcomb E, Steinhardt R, O'Reilly R, Chan RJ. Cancer survivorship care and general practice: A qualitative study of roles of general practice team members in Australia. *Health Soc Care Community* 2022;30:e1415-26.
29. Freeman V, Hughes S, Carle C, Campbell D, Egger S, Hui H, Yap S, Deandrea S, Caruana M, Onyeka TC, Ilzerman MJ, Ginsburg O, Bray F, Sullivan R, Aggarwal A, Peacock SJ, Chan KKW, Hanna TP, Soerjomataram I, O'Connell DL, Steinberg J, Canfell K. Are patients with cancer at higher risk of COVID-19-related death? A systematic review and critical appraisal of the early evidence. *J Cancer Policy* 2022;33:100340.
30. Gartlan KH, Jaiswal JK, Bull MR, Akhlaghi H, Sutton VR, Alexander KA, Chang K, Hill GR, Miller CK, O'Connor PD, Jose J, Trapani JA, Charman SA, Spicer JA, Jamieson SMF. Preclinical Activity and Pharmacokinetic/Pharmacodynamic Relationship for a Series of Novel Benzenesulfonamide Perforin Inhibitors. *ACS Pharmacol Transl Sci* 2022;5:429-39.
31. Gately L, Drummond K, Rosenthal M, Harrup R, Dowling A, Gogos A, Lwin Z, Collins I, Campbell D, Ahern E, Phillips C, Gan HK, Bennett I, Sieber OM, Gibbs P. Beyond standard data collection - the promise and potential of BRAIN (Brain tumour Registry Australia INnovation and translation registry). *BMC Cancer* 2022;22:604.
32. Gaudreault M, Siva S, Kron T, Hardcastle N. Assessing organ at risk position variation and its impact on delivered dose in kidney SABR. *Radiat Oncol* 2022;17:112.
33. Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt DE, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tilki D, Tombal B, Turkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. *Eur Urol* 2022;82:115-41.
34. Goh MS, Yun JS, Su JC. Management of atopic dermatitis: a narrative review. *Med J Aust* 2022;216:587-93.
35. Gordon SF, Virah Sawmy E, Duckworth E, Wolthuizen M, Clothier HJ, Chea M, Tenneti N, Blow N, BATTERY JP, de Luca J, Korman TM, Barnes S, Slade C, Maggs C, Giles ML, Teh BW, Aboltins C, Langan KM, Van Diemen A, Crawford NW. Victorian Specialist Immunisation Services (VicSIS) - bolstering adult clinics for COVID-19 vaccines. *Hum Vaccin Immunother* 2022;18:2052701.
36. Grover P, Flukes S, Jacques A, Leedman S, Lindsay A, White R, Friedland P, Gurfinkel R, Lim AM. Clinicopathological characteristics and clinical morbidity in high-risk head and neck cutaneous squamous cell carcinoma patients in Western Australia. *Intern Med J* 2022;52:944-951.
37. Haeusler GM, Lehrnbecher T, Agyeman PKA, Loves R, Castagnola E, Groll AH, van de Wetering M, Aftandilian CC, Phillips B, Chirra KM, Schneider C, Dupuis LL, Sung L. Clostridioides difficile infection in paediatric patients with cancer and haematopoietic stem cell transplant recipients. *Eur J Cancer* 2022;171:1-9.

38. Halman A, Dolzhenko E, Oshlack A. STRipy: A graphical application for enhanced genotyping of pathogenic short tandem repeats in sequencing data. *Hum Mutat* 2022;43:859-68.
39. Hau E, Clements W, Sia J. Immunotherapy, radiation oncology and radiology: An alliance into the future. *J Med Imaging Radiat Oncol* 2022;66:475-477.
40. Hoe V, Yao HH, Gough K, O'Connell HE. Long-term outcomes of polyacrylamide hydrogel treatment in women with stress urinary incontinence. *BJU Int* 2022;130(Suppl 1):22-4.
41. Holmberg CJ, Ny L, Hieken TJ, Block MS, Carr MJ, Sondak VK, Örténwall C, Katsarelias D, Dimitriou F, Menzies AM, Saw RP, Rogiers A, Straker RJ, 3rd, Karakousis G, Applewaite R, Pallan L, Han D, Vetto JT, Gyorki DE, Tie EN, Vitale MG, Ascierto PA, Dummer R, Cohen J, Hui JY, Schachter J, Asher N, Helgadottir H, Chai H, Kroon H, Coventry B, Rothermel LD, Sun J, Carlino MS, Duncan Z, Broman K, Weber J, Lee AY, Berman RS, Teras J, Ollila DW, Long GV, Zager JS, van Akkooi A, Olofsson Bagge R. The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases - A multicenter cohort study. *Eur J Cancer* 2022;169:210-22.
42. Holmes A, Clinch A, Moran J, Yoong J, Benson M, Boughey M, Philip J. Working with palliative care physicians to prepare for voluntary assisted dying legislation. *Australas Psychiatry* 2022;30:372-374.
43. Huynh TT, van Dam EM, Sreekumar S, Mpoy C, Blyth BJ, Muntz F, Harris MJ, Rogers BE. Copper-67-Labeled Bombesin Peptide for Targeted Radionuclide Therapy of Prostate Cancer. *Pharmaceuticals* 2022;15:728.
44. Hyatt A, Shelly A, Cox R, Humphries E, Lock G, Varlow M. How can we improve information for people affected by cancer? A national survey exploring gaps in current information provision, and challenges with accessing cancer information online. *Patient Educ Couns* 2022;105:2763-70.
45. Iravani A, Parihar AS, Akhurst T, Hicks RJ. Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms. *Cancer Imaging* 2022;22:25.
46. James PA, Fortuno C, Li N, Lim BWX, Campbell IG, Spurdle AB. Estimating the proportion of pathogenic variants from breast cancer case-control data: Application to calibration of ACMG/AMP variant classification criteria. *Hum Mutat* 2022;43:882-8.
47. Jiang J, Cohen L, Mohan H, Apte SS, Warriar SK. Advanced application of transanal total mesorectal excision in the frozen pelvis: a novel application in a challenging Hartmann's reversal. *ANZ J Surg* 2022;92:1549-1550.
48. Kimura S, Montefiori L, Iacobucci I, Zhao Y, Gao Q, Paietta EM, Haferlach C, Laird AD, Mead PE, Gu Z, Stock W, Litzow M, Rowe JM, Luger SM, Hunger SP, Ryland GL, Schmidt B, Ekert PG, Oshlack A, Grimmond SM, Rehn J, Breen J, Yeung D, White DL, Aldoss I, Jabbour EJ, Pui CH, Meggendorfer M, Walter W, Kern W, Haferlach T, Brady S, Zhang J, Roberts KG, Blombery P, Mullighan CG. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia. *Blood* 2022;139:3519-31.
49. Kliman D, Tran S, Kennedy G, Curley C, McLean A, Gottlieb D, Kwan J, Ritchie D, Chee L, Spencer A, Purtill D, Bardy P, Larsen S, Chien N, Perera T, Greenwood M, Hamad N, Moore J. The improvement in overall survival from unrelated donor transplantation in Australia and New Zealand is driven by a reduction in non-relapse mortality: A study from the ABMTRR. *Bone Marrow Transplant* 2022;57:982-9.
50. Koneshamoorthy A, Hulse D, Yuen Chong C, Krishnamurthy B, Ananda S, Hamblin PS. Massive hypertriglyceridemia associated with paclitaxel; a case report. *Gynecol Oncol Rep* 2022;42:101030.
51. Kothari G. Role of radiomics in predicting immunotherapy response. *J Med Imaging Radiat Oncol* 2022;66:575-91.
52. Ladefoged Kopp Schmidt M, Ostergren P, Cormie P, Sonksen J, Midtgaard J. Delivering Physical Activity Recommendations in Daily Clinical Cancer Care: An Observational Interview Study in Prostate Cancer Out-Patient Clinics Using an Empirical Ethics of Care Approach. *Qual Health Res* 2022;32:1086-98.

53. Laing E, Gough K, Krishnasamy M, Michael M, Kiss N. Prevalence of malnutrition and nutrition-related complications in patients with gastroenteropancreatic neuroendocrine tumours. *J Neuroendocrinol* 2022;34:e13116.
54. Lawrentschuk N. Sensible government decisions on funding for imaging can change practice and deliver better care for men with prostate cancer. *BJU Int* 2022;130(Suppl 1):4.
55. Lawson M, Berk K, Badawy M, Qi Y, Kuganesan A, Metcalfe P. Comparison of organ and effective dose estimations from different Monte Carlo simulation-based software methods in infant CT and comparison with direct phantom measurements. *J Appl Clin Med Phys* 2022;23:e13625.
56. Lee AHH, Oo J, Cabalag CS, Link E, Duong CP. Increased risk of diaphragmatic herniation following esophagectomy with a minimally invasive abdominal approach. *Dis Esophagus* 2022;35:doab066.
57. Lee ST, Emmett LM, Pattison DA, Hofman MS, Bailey DL, Latter MJ, Francis RJ, Scott AM. The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective. *J Nucl Med* 2022;63:819-22.
58. Lew TE, Seymour JF. Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination. *J Hematol Oncol* 2022;15:75.
59. Lewis AC, Pope VS, Tea MN, Li M, Nwosu GO, Nguyen TM, Wallington-Beddoe CT, Moretti PAB, Anderson D, Creek DJ, Costabile M, Ali SR, Thompson-Peach CAL, Dredge BK, Bert AG, Goodall GJ, Ekert PG, Brown AL, D'Andrea R, Robinson N, Pitman MR, Thomas D, Ross DM, Gliddon BL, Powell JA, Pitson SM. Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia. *Blood* 2022;139:3737-51.
60. Lowther N, Louwe R, Yuen J, Hardcastle N, Yeo A, Jameson M, Medical Image and Registration Special Interest Group (MIRSIG) of the ACPSEM. MIRSIG position paper: the use of image registration and fusion algorithms in radiotherapy. *Phys Eng Sci Med* 2022;45:421-8.
61. Maharaj AD, Evans SM, Ioannou LJ, Croagh D, Earnest A, Holland JF, Pilgrim CHC, Neale RE, Goldstein D, Kench JG, Merrett ND, White K, Burmeister EA, Evans PM, Hayes TM, Houli N, Knowles B, Leong T, Nikfarjam M, Philip J, Quinn M, Shapiro J, Smith MD, Spillane JB, Wong R, Zalcborg JR. The association between quality care and outcomes for a real-world population of Australian patients diagnosed with pancreatic cancer. *HPB* 2022;24:950-962.
62. Mason E. Variability exposes hidden buffering in the network specifying intestinal cell fate. *Nat Rev Genet* 2022;23:392-3.
63. Miles LF, Pac Soo V, Braat S, Bade-Boon J, Heritier S, Klein AA, Myles PS, Richards T, Symons J, Burbury KL, Story DA. Associations between non-anaemic iron deficiency and outcomes following elective cardiac surgery (IDOCs): a prospective cohort study. *Lancet Haematol* 2022;9:e514-22.
64. Mileshkin L, Bochtler T, Gatta G, Kurzrock R, Beringer A, Müller-Ohldach M, Surinach A, Perret C, Thomas M, Gondos A, Krämer A. Cancer-of-Unknown-Primary-Origin: A SEER-Medicare Study of Patterns of Care and Outcomes among Elderly Patients in Clinical Practice. *Cancers* 2022;14:2905.
65. Monohan K, Purvis R, Sexton A, Kentwell M, Thet M, Stafford L, Forrest L. Assessing the acceptability, feasibility, and usefulness of a psychosocial screening tool to patients and clinicians in a clinical genetics service in Australia. *J Genet Couns* 2022;31:653-662.
66. Mundell NL, Owen PJ, Dalla Via J, Macpherson H, Daly R, Livingston PM, Rantalainen T, Foulkes S, Millar J, Murphy DG, Fraser S. Effects of a multicomponent resistance-based exercise program with protein, vitamin D and calcium supplementation on cognition in men with prostate cancer treated with ADT: secondary analysis of a 12-month randomised controlled trial. *BMJ Open* 2022;12:e060189.
67. Murphy AN, Kearns C. Gastrointestinal Stromal Tumors and their Appearance in Patients with Neurofibromatosis Type 1. *Radiographics* 2022;42:E111-12.

68. Niaz A, Truong J, Manoleras A, Fox LC, Blombery P, Vasireddy RS, Pickett HA, Curtin JA, Barbaro PM, Rodgers J, Roy J, Riley LG, Holien JK, Cohen SB, Bryan TM. Functional interaction between compound heterozygous TERT mutations causes severe telomere biology disorder. *Blood Adv* 2022;6:3779-91.
69. Noë G, Cardin A, Lasocki A. Part 1: Imaging findings of common immune checkpoint inhibitor-related adverse effects. *J Med Imaging Radiat Oncol* 2022;66:495-501.
70. Noë G, Cardin A, Lasocki A. Part 2: Imaging findings of uncommon but important immune checkpoint inhibitor-related adverse effects. *J Med Imaging Radiat Oncol* 2022;66:502-507.
71. O'Brien JS, Teh J, Chen K, Kelly BD, Chee J, Lawrentschuk N. Dynamic Sentinel Lymph Node Biopsy for Penile Cancer: Accuracy is in the Technique. *Urology* 2022;164:e308.
72. O'Grady HK, Edbrooke L, Farley C, Berney S, Denehy L, Puthuchery Z, Kho ME. The sit-to-stand test as a patient-centered functional outcome for critical care research: a pooled analysis of five international rehabilitation studies. *Crit Care* 2022;26:175.
73. Ong WL, Thangasamy I, Murphy D, Pritchard E, Evans S, Millar J, Chalasani V, Rashid P, Winter M, Vela I, Pryor D, Mark S, Lawrentschuk N. Large variation in conservative management of low-risk prostate cancer in Australia and New Zealand. *BJU Int* 2022;130(Suppl 1):17-19.
63. Parakh S, Davies A, Westcott K, Roos D, Abou-Hamden A, Ahern E, Lau PKH, Cheruvu S, Pranavan G, Pullar A, Lynam J, Gzell C, Whittle JR, Cain S, Inglis PL, Harrup R, Anazodo A, Hovey E, Cher L, Gan HK. Adult medulloblastoma in an Australian population. *J Clin Neurosci* 2022;102:65-70.
74. Peacock A, Dehle F, Mesa Zapata OA, Prince HM, Gennari F, Taylor C. Cost-Effectiveness of Extracorporeal Photopheresis for the Treatment of Patients with Erythrodermic (Stage T₄, M₀) Cutaneous T-Cell Lymphoma in the Australian Setting. *Value Health* 2022;25:965-974.
75. Petrara MR, Shalaby S, Ruffoni E, Tadorelli M, Carmona F, Giunco S, Del Bianco P, Piselli P, Serraino D, Cillo U, Dolcetti R, Burra P, De Rossi A. Immune Activation, Exhaustion and Senescence Profiles as Possible Predictors of Cancer in Liver Transplanted Patients. *Front Oncol* 2022;12:899170.
64. Phillips KA, Friedlander ML. Risk of Peritoneal Cancer after Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable? *J Clin Oncol* 2022;40:1850-2.
65. Phillips T, Chan H, Tam CS, Tedeschi A, Johnston P, Oh SY, Opat S, Eom HS, Allewelt H, Stern JC, Tan Z, Novotny W, Huang J, Trotman J. Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma. *Blood Adv* 2022;6:3472-9.
66. Poh AR, Love CG, Chisanga D, Steer JH, Baloyan D, Chopin M, Nutt S, Rautela J, Huntington ND, Etemadi N, O'Brien M, O'Keefe R, Ellies LG, Macri C, Mintern JD, Whitehead L, Gangadhara G, Boon L, Chand AL, Lowell CA, Shi W, Pixley FJ, Ernst M. Therapeutic inhibition of the SRC-kinase HCK facilitates T cell tumor infiltration and improves response to immunotherapy. *Sci Adv* 2022;8:eabl7882.
67. Prasit KK, Ferrer-Font L, Burn OK, Anderson RJ, Compton BJ, Schmidt AJ, Mayer JU, Chen CJ, Dasyam N, Ritchie DS, Godfrey DI, Mattarollo SR, Dundar PR, Painter GF, Hermans IF. Intratumoural administration of an NKT cell agonist with CpG promotes NKT cell infiltration associated with an enhanced antitumour response and abscopal effect. *Oncoimmunology* 2022;11:2081009.
68. Ramanathan V, Balawardane J, Dilip Kumara AH, Sarasanandarajah S. Current status and future prospects of radiation oncology in Sri Lanka. *Phys Med* 2022;100:6-11.
69. Rees MJ, Panigrahi A, Harrison SJ, Spencer A, Khong T, Gibbs S, Hocking J, Grigg A, Zantomio D. The impact of G-CSF alone vs G-CSF and cyclophosphamide mobilisation on autograft immune cell content in multiple myeloma. *Bone Marrow Transplant* 2022;57:1001-03.
70. Riddell K, Bignell L, Bourne D, Boyd L, Crowe S, Cucanic S, Flynn M, Gillan K, Heinjus D, Mathieson J, Nankervis K, Reed F, Townsend L, Twomey B, Weir-Phyland J, Bagot K. The context, contribution and consequences of addressing the COVID-19 pandemic: A qualitative exploration of executive nurses' perspectives. *J Adv Nurs* 2022;78:2214-31.

71. Salgado R, Loi S. What's in a Name? That Which We Call Immune Cells by Any Other Name Would All Smell as Sweet. *Clin Cancer Res* 2022;28:2728-9.
72. Salmon JM, Todorovski I, Stanley KL, Bruedigam C, Kearney CJ, Martelotto LG, Rossello F, Semple T, Arnau GM, Zethoven M, Bots M, Bjelosevic S, Cluse LA, Fraser PJ, Litalien V, Vidacs E, McArthur K, Matthews AY, Gressier E, de Weerd NA, Lichte J, Kelly MJ, Hogg SJ, Hertzog PJ, Kats LM, Vervoort SJ, De Carvalho DD, Scheu S, Bedoui S, Kile BT, Lane SW, Perkins AC, Wei AH, Dominguez PM, Johnstone RW. Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML. *Cancer Discov* 2022;12:1560-79.
73. Segal R, Mezzavia PM, Krieser RB, Sampurno S, Taylor M, Ramsay R, Kluger M, Lee K, Loh FL, Tatoulis J, O'Keefe M, Chen Y, Sindoni T, Ng I. Warm humidified CO2 insufflation improves pericardial integrity for cardiac surgery: a randomized control study. *J Cardiovasc Surg* 2022;63:369-75.
76. Shipton MJ, Kinsella PM, Davis T, Azzato F, Taiaroa G, Szer J, Routledge D, Smibert O. Infective hyperammonaemic encephalopathy after allogeneic stem cell transplant. *Bone Marrow Transplant* 2022;57:1028-1030.
74. Sia J, Neeson PJ, Haynes NM. Basic cancer immunology for radiation oncologists. *J Med Imaging Radiat Oncol* 2022;66:508-18.
75. Siew CCH, Apte SS, Baia M, Gyorki DE, Ford S, van Houdt WJ. Retroperitoneal and Mesenteric Liposarcomas. *Surg Oncol Clin N Am* 2022;31:399-417.
76. Simond AM, Bui T, Zuo D, Sanguin-Gendreau V, Rao T, Phillips WA, Cardiff RD, Muller WJ. Physiological expression of PI3K H1047R mutation reveals its anti-metastatic potential in ErbB2-driven breast cancer. *Oncogene* 2022;41:3445-51.
77. So WKW, Chan DNS, Law BMH, Choi KC, Krishnasamy M, Chan CWH. Effect of a family-based multimedia intervention on the uptake of faecal immunohistochemical test among South Asian older adults: A cluster-randomised controlled trial. *Int J Nurs Stud* 2022;132:104254.
78. Stolz RG, Dowling MR, Lin BB, Mason K, Muhi S. Strongyloides hyperinfection: a preventable complication of immunosuppression. *Med J Aust* 2022;216:561-2.
79. Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson S, Kuss BJ, Moreno C, Szafer-Glusman E, Russell K, Zhou C, Ninomoto J, Dean JP, Wierda WG, Ghia P. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. *Blood* 2022;139:3278-89.
80. Tang H, Besson A, Deftereos I, Mahon B, Cho J, Faragher I, Gough K, Yeung J. The health-related quality of life changes following surgery in patients with colorectal cancer: a longitudinal study. *ANZ J Surg* 2022;92:1461-5.
81. Terbuch A, Posch F, Bauernhofer T, Jost PJ, Partl R, Stranzl-Lawatsch H, Baciarello G, Fizazi K, Giannatempo P, Verzoni E, Sweeney C, Ravi P, Tran B, Basso U, White J, Vincenzi B, Oing C, Cutuli HJ, Dieckmann KP, Gamulin M, Chovanec M, Fankhauser CD, Heidenreich A, Mohamad O, Thibault C, Fischer S, Gillissen S, International Germ Cell Cancer Collaborative Group. Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. *Int J Radiat Oncol Biol Phys* 2022;113:825-32.
82. Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, Wong R, Shapiro J, Lee M, Harris S, Khattak A, Burge M, Harris M, Lynam J, Nott L, Day F, Hayes T, McLachlan SA, Lee B, Ptak J, Silliman N, Dobbyn L, Popoli M, Hruban R, Lennon AM, Papadopoulos N, Kinzler KW, Vogelstein B, Tomasetti C, Gibbs P. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. *N Engl J Med* 2022;386:2261-72.
83. Trigos AS, Pasam A, Banks P, Wallace R, Guo C, Keam S, Thorne H, kConFab, Mitchell C, Lade S, Clouston D, Hakansson A, Liu Y, Blyth B, Murphy D, Lawrentschuk N, Bolton D, Moon D, Darcy P, Haupt Y, Williams SG, Castro E, Olmos D, Goode D, Neeson P, Sandhu S. Tumor immune microenvironment of

primary prostate cancer with and without germline mutations in homologous recombination repair genes. *J Immunother Cancer* 2022;10:e003744.

84. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke Onyeonunam N, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Pablo Sade J, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zepatero A, Gillissen S, Omlin A. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. *Eur Urol* 2022;82:6-11.
85. Wong J, Gruber E, Maher B, Waltham M, Sabouri-Thompson Z, Jong I, Luong Q, Levy S, Kumar B, Brasacchio D, Jia W, So J, Skinner H, Lewis A, Hogg SJ, Vervoort S, DiCorleto C, Uhe M, Gamgee J, Opat S, Gregory GP, Polekhina G, Reynolds J, Hawkes EA, Kailainathan G, Gasiorowski R, Kats LM, Shortt J. Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma. *Leukemia* 2022;36:1654-65.
86. Yuen KC, Tran B, Anton A, Hamidi H, Costello AJ, Corcoran NM, Lawrentschuk N, Rainey N, Semira MCG, Gibbs P, Mariathasan S, Sandhu S, Kadel EE 3rd. Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens. *Prostate* 2022;82:993-1002.
87. Zhu H, Chan KT, Huang X, Cerra C, Blake S, Trigos AS, Anderson D, Creek DJ, De Souza DP, Wang X, Fu C, Jana M, Sanij E, Pearson RB, Kang J. Cystathionine- β -synthase is essential for AKT-induced senescence and suppresses the development of gastric cancers with PI3K/AKT activation. *eLife* 2022;11:e71929.

July

1. Achard V, Jaccard M, Vanhoutte F, Siva S, Heikkilä R, Dirix P, Liefhooghe N, Otte FX, Gomez-Iturriaga A, Berghen C, Shelan M, Conde-Moreno A, López Campos F, Papachristofilou A, Guckenberger M, Meersschout S, Putora PM, Zwahlen D, Couñago F, Scorsetti M, Eito C, Barrado M, Zepatero A, Muto P, Van De Voorde L, Lamanna G, Koutsouvelis N, Dipasquale G, Ost P, Zilli T. Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial. *Radiother Oncol* 2022;172:1-9.
2. Ali M, Gaudreault M, Siva S. SABR for Synchronous Bilateral Primary Renal Cell Carcinoma: A Case Report. *Adv Radiat Oncol* 2022;7:100991.
3. Barmanray RD, Cheuk N, Furlanos S, Greenberg PB, Colman PG, Worth LJ. In-hospital hyperglycemia but not diabetes mellitus alone is associated with increased in-hospital mortality in community-acquired pneumonia (CAP): a systematic review and meta-analysis of observational studies prior to COVID-19. *BMJ Open Diabetes Res Care* 2022;10:e002880.
4. Bhave P, Ahmed T, Lo SN, Shoushtari A, Zaremba A, Versluis JM, Mangana J, Weichenthal M, Si L, Lesimple T, Robert C, Trojanello C, Wicky A, Heywood R, Tran L, Batty K, Dimitriou F, Stansfeld A, Allayous C, Schwarze JK, Mooradian MJ, Klein O, Mehmi I, Roberts-Thomson R, Maurichi A, Yeoh HL, Khattak A, Zimmer L, Blank CU, Ramelyte E, Kähler KC, Roy S, Ascierto PA, Michielin O, Lorigan PC, Johnson DB, Plummer R, Lebbe C, Neyns B, Sullivan R, Hamid O, Santinami M, McArthur GA, Haydon AM, Long GV, Menzies AM, Carlino MS. Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma. *J Immunother Cancer* 2022;10:e004668.
5. Burtneß B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Ge J,

- Swaby RF, Gumuscu B, Harrington K. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. *J Clin Oncol* 2022;40:2321-32.
6. Chi LH, Cross RSN, Redvers RP, Davis M, Hediye-Zadeh S, Mathivanan S, Samuel M, Lucas EC, Mouchemore K, Gregory PA, Johnstone CN, Anderson RL. MicroRNA-21 is immunosuppressive and pro-metastatic via separate mechanisms. *Oncogenesis* 2022;11:38.
 7. Chua CC, Hammond D, Kent A, Tiong IS, Konopleva MY, Pollyea DA, DiNardo CD, Wei AH. Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. *Blood Adv* 2022;6:3879-83.
 8. Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P, KEYNOTE-355 Investigators. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. *N Engl J Med* 2022;387:217-26.
 9. de Jong VMT, Wang Y, Ter Hoeve ND, Opdam M, Stathonikos N, Józwiak K, Hauptmann M, Cornelissen S, Vreuls W, Rosenberg EH, Koop EA, Varga Z, van Deurzen CHM, Mooyaart AL, Córdoba A, Groen EJ, Bart J, Willems SM, Zolota V, Wesseling J, Sapino A, Chmielik E, Ryska A, Broeks A, Voogd AC, Loi S, Michiels S, Sonke GS, van der Wall E, Siesling S, van Diest PJ, Schmidt MK, Kok M, Dackus G, Salgado R, Linn SC. Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. *J Clin Oncol* 2022;40:2361-74.
 10. de Mendoza A, Nguyen TV, Ford E, Poppe D, Buckberry S, Pflueger J, Grimmer MR, Stolzenburg S, Bogdanovic O, Oshlack A, Farnham PJ, Blancafort P, Lister R. Large-scale manipulation of promoter DNA methylation reveals context-specific transcriptional responses and stability. *Genome Biol* 2022;23:163.
 11. Douglas A, Thursky K, Spelman T, Szer J, Bajel A, Harrison S, Tio SY, Bupha-Intr O, Tew M, Worth L, Teh B, Chee L, Ng A, Carney D, Khot A, Haeusler G, Yong M, Trubiano J, Chen S, Hicks R, Ritchie D, Slavin M. [¹⁸F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial. *Lancet Haematol* 2022;9:e573-84.
 12. Duan J, Tan F, Bi N, Chen C, Chen KN, Cheng Y, Chu Q, Ge D, Hu J, Huang Y, Jiang T, Long H, Lu Y, Shi M, Wang J, Wang Q, Yang F, Yang N, Yao Y, Ying J, Zhou C, Zhou Q, Zhou Q, Bongiolatti S, Brunelli A, Fiorelli A, Gobbi E, Gridelli C, John T, Kim JJ, Lin SH, Metro G, Minervini F, Novoa NM, Owen DH, Rodriguez M, Sakanoue I, Scarci M, Suda K, Tabbò F, Tam TCC, Tsuchida M, Uchino J, Voltolini L, Wang J, Gao S. Expert consensus on perioperative treatment for non-small cell lung cancer. *Transl Lung Cancer Res* 2022;11:1247-1267.
 13. Forrest LE, Forbes Shepherd R, Tutty E, Pearce A, Campbell I, Devereux L, Trainer AH, James PA, Young MA. The Clinical and Psychosocial Outcomes for Women Who Received Unexpected Clinically Actionable Germline Information Identified through Research: An Exploratory Sequential Mixed-Methods Comparative Study. *J Pers Med* 2022;12:1112.
 14. Gerratana L, Pierga JY, Reuben JM, Davis AA, Wehbe FH, Dirix L, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, Bonotto M, Fernandez de Lascoiti A, De Mattos-Arruda L, Ignatiadis M, Sandri MT, Generali D, De Angelis C, Dawson SJ, Janni W, Carañana V, Riethdorf S, Solomayer EF, Puglisi F, Giuliano M, Pantel K, Bidard FC, Cristofanilli M. Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. *Oncologist* 2022;27:e561-e570.
 15. Glewis S, Alexander M, Khabib MNH, Brennan A, Lazarakis S, Martin J, Tie J, Lingaratnam S, Michael M. A systematic review and meta-analysis of toxicity and treatment outcomes with pharmacogenetic-guided dosing compared to standard of care BSA-based fluoropyrimidine dosing. *Br J Cancer* 2022;127:126-136.

16. Grogan A, Loveday B, Michael M, Wong HL, Gibbs P, Thomson B, Lee B, Ko HS. Real-world staging computed tomography scanning technique and important reporting discrepancies in pancreatic ductal adenocarcinoma. *ANZ J Surg* 2022;92:1789-1796.
17. Hogg SJ, Motorna O, Kearney CJ, Derrick EB, House IG, Todorovski I, Kelly MJ, Zethoven M, Bromberg KD, Lai A, Beavis PA, Shortt J, Johnstone RW, Vervoort SJ. Distinct modulation of IFN γ -induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer. *Clin Epigenetics* 2022;14:96.
18. Hughes RE, Elliott RJR, Li X, Munro AF, Makda A, Carter RN, Morton NM, Fujihara K, Clemons NJ, Fitzgerald R, O'Neill JR, Hupp T, Carragher NO. Multiparametric High-Content Cell Painting Identifies Copper Ionophores as Selective Modulators of Esophageal Cancer Phenotypes. *ACS Chem Biol* 2022;17:1876-89.
19. Humm G, Mohan H, Fleming C, Harries R, Wood C, Dawas K, Stoyanov D, Lovat LB. The impact of virtual reality simulation training on operative performance in laparoscopic cholecystectomy: meta-analysis of randomized clinical trials. *BJS Open* 2022;6:zrac086.
20. Key S, Chia C, Hasan Z, Sundaresan P, Dwivedi RC, Riffat F. Systematic review of prognostic factors in carcinoma ex pleomorphic adenoma. *Oral Oncol* 2022;133:106052.
21. Kothari G, Woon B, Patrick CJ, Korte J, Wee L, Hanna GG, Kron T, Hardcastle N, Siva S. The impact of inter-observer variation in delineation on robustness of radiomics features in non-small cell lung cancer. *Sci Rep* 2022;12:12822.
22. Lasocki A, Sia J, Stuckey SL. Improving the diagnosis of radiation necrosis after stereotactic radiosurgery to intracranial metastases with conventional MRI features: a case series. *Cancer Imaging* 2022;22:33.
23. Lelliott EJ, Ramsbottom KM, Dowling MR, Shembrey C, Noori T, Kearney CJ, Michie J, Parish IA, Jordan MA, Baxter AG, Young ND, Brennan AJ, Oliaro J. NKG7 Enhances CD8+ T Cell Synapse Efficiency to Limit Inflammation. *Front Immunol* 2022;13:931630.
24. Li C, Ferro A, Mhatre SK, Lu D, Lawrance M, Li X, Li S, Allen S, Desai J, Fakhri M, Cecchini M, Pedersen KS, Kim TY, Reyes-Rivera I, Segal NH, Lenain C. Hybrid-control arm construction using historical trial data for an early-phase, randomized controlled trial in metastatic colorectal cancer. *Commun Med* 2022;2:90.
25. Liu DS, Newbold R, Stevens S, Wong E, Fong J, Mori K, Wong DJ, Gill AS, Lee S, Jamel W, Crowe A, Howard T, Jain A, Beh PS, Slevin M, Fleming N, Bennet S, Chung C, VERITAS collaborative. Early Versus Postoperative Chemical Thromboprophylaxis Is Associated with Increased Bleeding Risk Following Abdominal Visceral Resections: a Multicenter Cohort Study. *J Gastrointest Surg* 2022;26:1495-1502.
26. Lockie EB, Knowles B, Gill PK, Thomson B, Loveday BPT. Comparison of risk adjusted excess post-operative pancreatic fistula rates after pancreaticoduodenectomy using cumulative sum analysis. *ANZ J Surg* 2022;92:1784-1788.
27. McLean LS, Morris TA, Gramza A, Liu S, Khan SA, Colevas AD, Pearce T, Rischin D. A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin. *Invest New Drugs* 2022;40:782-8.
28. Mondschein R, Bolton D, Clouston D, Dowty J, Kavanagh L, Murphy D, Scott P, Taylor RA, Thorne H. Novel Germline Mutations in a Cohort of Men with Familial Prostate Cancer. *Cancers* 2022;14:3623.
29. Munoz I, Beavis PA. PARP11 interfer(on)es with CAR T cell efficacy. *Nat Cancer* 2022;3:790-792.
30. Nagla A, Le B, White C, V Kiburg K, Philip J. Attitudes of Palliative Care Practitioners Towards Enrolling Patients in Clinical Trials. *J Palliat Care* 2022;37:447-455.
31. Nilsson M, Olafsdottir H, Alexandersson von Döbeln G, Villegas F, Gagliardi G, Hellström M, Wang QL, Johansson H, Gebiski V, Hedberg J, Klevebro F, Markar S, Smyth E, Lagergren P, Al-Haidari G, Rekstad

- LC, Aahlin EK, Wallner B, Edholm D, Johansson J, Szabo E, Reynolds JV, Pramesh CS, Mummudi N, Joshi A, Ferri L, Wong RK, O'Callaghan C, Lukovic J, Chan KK, Leong T, Barbour A, Smithers M, Li Y, Kang X, Kong FM, Chao YK, Crosby T, Bruns C, van Laarhoven H, van Berge Henegouwen M, van Hillegersberg R, Rosati R, Piessen G, de Manzoni G, Lordick F. Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial. *Front Oncol* 2022;12:917961.
32. O'Malley DM, Bariani GM, Cassier PA, Marabelle A, Hansen AR, De Jesus Acosta A, Miller WH Jr, Safra T, Italiano A, Mileshkin L, Amonkar M, Yao L, Jin F, Norwood K, Maio M. Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study. *Gynecol Oncol* 2022;166:245-53.
 33. Overmars I, Au-Yeung G, Nolan TM, Steer AC. mRNA vaccines: a transformative technology with applications beyond COVID-19. *Med J Aust* 2022;217:71-5.
 34. Philip J, Wawryk O, Pasanen L, Wong A, Schwetlik S, Collins A. Telehealth in outpatient delivery of palliative care: a prospective survey evaluation by patients and clinicians. *Intern Med J* 2022;52:1144-1153.
 35. Prang KH, Karanatsios B, Verbunt E, Wong HL, Yeung J, Kelaher M, Gibbs P. Clinical registries data quality attributes to support registry-based randomised controlled trials: A scoping review. *Contemp Clin Trials* 2022;119:106843.
 36. Rosario R, Cui W, Anderson RA. Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies. *Reprod Fertil* 2022;3:R147-62.
 37. Schmidt B, Brown LM, Ryland GL, Lonsdale A, Kosasih HJ, Ludlow LE, Majewski IJ, Blombery P, Ekert PG, Davidson NM, Oshlack A. ALLSorts: an RNA-Seq subtype classifier for B-cell acute lymphoblastic leukemia. *Blood Adv* 2022;6:4093-7.
 38. See AW, Bowden P, Wells G, Appu S, Lawrentschuk N, Lioudakis P, Pandeli C, Aarons Y, Smyth LML, McKenzie DP. Dose-escalated radiotherapy to 82 Gy for prostate cancer following insertion of a perirectal hydrogel spacer: 3-year outcomes from a phase II trial. *Radiat Oncol* 2022;17:131.
 39. Shah MV, Chhetri R, Dholakia R, Kok CH, Gangat N, Alkhateeb HB, Al-Kali A, Patnaik MM, Baranwal A, Greipp PT, He R, Begna KH, Tiong IS, Wei AH, Hiwase D. Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms. *Am J Hematol* 2022;97:1013-22.
 40. Shapira-Frommer R, Mileshkin L, Manzyuk L, Penel N, Burge M, Piha-Paul SA, Girda E, Lopez Martin JA, van Dongen MGJ, Italiano A, Xu L, Jin F, Norwood K, Ott PA. Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study. *Gynecol Oncol* 2022;166:211-8.
 41. Sharma D, Denmat SH, Matzke NJ, Hannan K, Hannan RD, O'Sullivan JM, Ganley ARD. A new method for determining ribosomal DNA copy number shows differences between *Saccharomyces cerevisiae* populations. *Genomics* 2022;114:110430.
 42. Shemesh B, Opie J, Tsiamis E, Ayton D, Satasivam P, Wilton P, Gough K, Lewis K, O'Brien C, Shub M, Pomery A, Mac Manus C, Millar J, Evans S. Codesigning a patient support portal with health professionals and men with prostate cancer: An action research study. *Health Expect* 2022;25:1319-31.
 43. Sivakumaran T, Krasovitsky M, Freimund A, Lee YC, Webber K, So J, Norris C, Friedlander M, Mileshkin L, Au-Yeung G. Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients. *Int J Gynecol Cancer* 2022;32:906-912.
 44. Smith IS, Wallace R, Wellecke C, Bind MA, Weihs KL, Bei B, Wiley JF. Assessing an Internet-Delivered, Emotion-Focused Intervention Compared with a Healthy Lifestyle Active Control Intervention in Improving Mental Health in Cancer Survivors: Protocol for a Randomized Controlled Trial. *JMIR Res Protoc* 2022;11:e36658.

45. So J, Lewis AC, Smith LK, Stanley K, Franich R, Yoannidis D, Pijpers L, Dominguez P, Hogg SJ, Vervoort SJ, Brown FC, Johnstone RW, McDonald G, Ulanet DB, Murtie J, Gruber E, Kats LM. Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemia. *EMBO Mol Med* 2022;14:e15203.
46. Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, Šimkovič M, Shadman M, Österborg A, Laurenti L, Walker P, Opat S, Chan H, Ciepluch H, Greil R, Tani M, Trněný M, Brander DM, Flinn IW, Grosicki S, Verner E, Tedeschi A, Li J, Tian T, Zhou L, Marimpietri C, Paik JC, Cohen A, Huang J, Robak T, Hillmen P. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. *Lancet Oncol* 2022;23:1031-43.
47. Tam CS, Gregory GP, Ku M, Fleming S, Handunnetti SM, Lee D, Walker P, Perkins A, Lew TE, Sirdesai S, Chua CC, Gilbertson M, Lasica M, Anderson MA, Renwick W, Grigg A, Patil S, Opat S, Friebe A, Cooke R, De Boer J, Spencer A, Ritchie D, Agarwal R, Blombery P. Recommendation for TP53 mutation testing in newly diagnosed mantle cell lymphoma: a statement from working groups sponsored by the Victorian Comprehensive Cancer Centre. *Intern Med J* 2022;52:1286-1287.
48. Teh BW. The long and short of antibiotic management for neutropenic fever in patients with haematological malignancy. *Lancet Haematol* 2022;9:e548-9.
49. Thambiraj J, Kirshbaum MN, Liu XL, Waheed N, Valery PC. "You feel different in your body": Experiences of fatigue among children undergoing radiotherapy for cancer treatment. *J Pediatr Nurs* 2022;67:7-14.
50. Tokarsky EJ, Crow JC, Guenther LM, Sherman J, Taslim C, Alexe G, Pishas KI, Rask G, Justis BS, Kasumova A, Stegmaier K, Lessnick SL, Theisen ER. Mitochondrial Dysfunction Is a Driver of SP-2509 Drug Resistance in Ewing Sarcoma. *Mol Cancer Res* 2022;20:1035-46.
51. Valentine JC, Hall L, Verspoor KM, Gillespie E, Worth LJ. Use of a Victorian statewide surveillance programme to evaluate the burden of healthcare-associated *Staphylococcus aureus* bacteraemia and *Clostridioides difficile* infection in patients with cancer. *Intern Med J* 2022;52:1215-1224.
52. Vaughan E, Ftanou M, Lewin J, Murnane A, Berger I, Wiley JF, Hickey M, Bullen D, Jefford M, Goldin J, Stonehouse J, Thompson K. AYA 'Can-Sleep' programme: protocol for a stepped-care, cognitive behavioural therapy-based approach to the management of sleep difficulties in adolescents and young adults with cancer. *Pilot Feasibility Stud* 2022;8:159.
53. Warriar SK, Williams E, Prabhakaran S, Farmer KC, Kong JC. Surgical quality in colorectal anastomosis: the time is overdue in the assessment of anastomotic integrity. *ANZ J Surg* 2022;92:1598-1599.
54. Wei AH, Seymour JF. Enhancing our chances of picking a winner in higher-risk myelodysplastic syndromes. *Br J Haematol* 2022;198:415-8.
55. Worel N, Aljurf M, Anthias C, Buser AS, Cody M, Fechter M, Galeano S, Greinix HT, Kisch AM, Koh MBC, Mengling T, Nicoloso G, Niederwieser D, Pulsipher MA, Seber A, Shaw BE, Stefanski HE, Switzer GE, Szer J, van Walraven SM, Yang H, Halter JP. Suitability of haematopoietic cell donors: updated consensus recommendations from the WBMT standing committee on donor issues. *Lancet Haematol* 2022;9:e605-14.
56. Wu A, Fahey MT, Cui D, El-Behesy B, Story DA. An evaluation of the outcome metric 'days alive and at home' in older patients after hip fracture surgery. *Anaesthesia* 2022;77:901-9.
57. Yeung TM, Apte SS, Behrenbruch CC, Warriar SK, Heriot AG. Fluorescent imaging in colorectal surgery: an essential component of care? *ANZ J Surg* 2022;92:1600-1601.

August

1. Akhurst T, Gönen M, Baser RE, Schwartz LH, Tuorto S, Brody LA, Covey A, Brown KT, Larson SM, Fong Y. Prospective evaluation of ¹⁸F-FDG positron emission tomography in the preoperative staging of patients with hepatic colorectal metastases. *Hepatobiliary Surg Nutr* 2022;11:539-554.
2. Averbuch D, De Greef J, Dureault A, Wendel L, Tridello G, Lebeaux D, Mikulska M, Gil L, Knelange N, Zuckerman T, Roussel X, Robin C, Xhaard A, Aljurf M, Beguin Y, Le Bourgeois A, Botella-Garcia C, Khanna N, Van Praet J, Kroger N, Blijlevens N, Ducastelle Lepretre S, Ho A, Roos-Weil D, Yeshurun M, Lortholary O, Fontanet A, de la Camara R, Coussement J, Maertens J, Styczynski J, European Study Group for Nocardia in Hematopoietic Cell T. Nocardia Infections in Hematopoietic Cell Transplant Recipients: A Multicenter International Retrospective Study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation. *Clin Infect Dis* 2022;75:88-97.
3. Azad AA, Tran B, Davis ID, Parente P, Evans M, Wong S, Brown S, Evans S, Millar J, Murphy DG, Papa N. Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer. *Intern Med J* 2022;52:1339-46.
4. Barry AS, Helou J, Bezjak A, Wong R, Dawson LA, Ringash J, Fazelzad R, Liu Z, Olson R, Palma D, Ost P, Siva S, Phillips R, Adhikari NKJ. Health related quality of life outcomes following stereotactic body radiotherapy in patients with oligo-metastatic disease: A systematic review and individual patient data meta-analysis. *Radiother Oncol* 2022;173:163-169.
5. Beaumont S, Angel CM, Dawson SJ. Denosumab and invasive cervical root resorption: a case report. *Aust Dent J* 2022;67:183-9.
6. Bolton D, Hong A, Papa N, Perera M, Kelly B, Duncan C, Clouston D, Lawrentschuk N. Cribriform pattern disease over-represented in pelvic lymph node metastases identified on ⁶⁸GA PSMA-PET/CT. *BJUI Compass* 2022;3:371-6.
7. Bonney A, Malouf R, Marchal C, Manners D, Fong KM, Marshall HM, Irving LB, Manser R. Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality. *Cochrane Database Syst Rev* 2022;8:CD013829.
8. Bucknell NW, Belderbos J, Palma DA, Iyengar P, Samson P, Chua K, Gomez D, McDonald F, Louie AV, Faivre-Finn C, Hanna GG, Siva S, International Association for the Study of Lung Cancer Advanced Radiation Technology Committee. Avoiding Toxicity with Lung Radiation Therapy: An IASLC Perspective. *J Thorac Oncol* 2022;17:961-73.
9. Cabalag CS, Yates M, Corrales MB, Yeh P, Wong SQ, Zhang BZ, Fujihara KM, Chong L, Hii MW, Dawson SJ, Phillips WA, Duong CP, Clemons NJ. Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma. *Ann Surg* 2022;276:e120-6.
10. Chen K, Ong S, Lawrentschuk N. Biomarkers Accurately Inform Treatment Decisions in Localised Prostate Cancer. *Eur Urol Focus* 2022;8:643-5.
11. Choy KT, Lam K, Kong JC. Exercise and colorectal cancer survival: an updated systematic review and meta-analysis. *Int J Colorectal Dis* 2022;37:1751-8.
12. Chua BH, Link EK, Kunkler IH, Whelan TJ, Westenberg AH, Gruber G, Bryant G, Ahern V, Purohit K, Graham PH, Akra M, McArdle O, O'Brien P, Harvey JA, Kirkove C, Maduro JH, Campbell ID, Delaney GP, Martin JD, Vu TTT, Muanza TM, Neal A, Olivetto IA. Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study. *Lancet* 2022;400:431-40.
13. Clarke EM, Rahme J, Larach T, Rajkomar A, Jain A, Hiscock R, Warriar S, Smart P. Robotic versus laparoscopic right hemicolectomy: a retrospective cohort study of the Binational Colorectal Cancer Database. *J Robot Surg* 2022;16:927-933.
14. Copaescu AM, James F, Vogrin S, Rose M, Chua K, Holmes NE, Turner NA, Stone C, Phillips E, Trubiano J. Use of a penicillin allergy clinical decision rule to enable direct oral penicillin provocation: an

international multicentre randomised control trial in an adult population (PALACE): study protocol. *BMJ Open* 2022;12:e063784.

15. Crake RLI, Burgess ER, Wiggins GAR, Magon NJ, Das AB, Vissers MCM, Morrin HR, Royds JA, Slatter TL, Robinson BA, Phillips E, Dachs GU. Ascorbate content of clinical glioma tissues is related to tumour grade and to global levels of 5-hydroxymethyl cytosine. *Sci Rep* 2022;12:14845.
16. Cremona M, Vandenberg CJ, Farrelly AM, Madden SF, Morgan C, Kalachand R, McAlpine JN, Toomey S, Huntsman DG, Grogan L, Breathnach O, Morris P, Carey MS, Scott CL, Hennessy BT. BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors. *Br J Cancer* 2022;127:488-99.
17. Cristofanilli M, Rugo HS, Im SA, Slamon DJ, Harbeck N, Bondarenko I, Masuda N, Colleoni M, DeMichele A, Loi S, Iwata H, O'Leary B, Andre F, Loibl S, Bananis E, Liu Y, Huang X, Kim S, Lechuga Freaan MJ, Turner NC. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. *Clin Cancer Res* 2022;28:3433-42.
18. Cucanic O, Farnsworth RH, Stacker SA. The cellular and molecular mediators of metastasis to the lung. *Growth Factors* 2022;40:119-52.
19. Czosnek L, Zopf EM, Cormie P, Rosenbaum S, Richards J, Rankin NM. Developing an implementation research logic model: using a multiple case study design to establish a worked exemplar. *Implement Sci Commun* 2022;3:90.
20. de Latour RP, Szer J, Weitz IC, Röth A, Höchsmann B, Panse J, Usuki K, Griffin M, Kiladjian JJ, de Castro CM, Nishimori H, Ajayi T, Al-Adhami M, Deschatelets P, Francois C, Grossi F, Risitano AM, Hillmen P. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial. *Lancet Haematol* 2022;9:e648-59.
21. Dolzhenko E, Weisburd B, Ibañez K, Rajan-Babu IS, Anyansi C, Bennett MF, Billingsley K, Carroll A, Clamons S, Danzi MC, Deshpande V, Ding J, Fazal S, Halman A, Jadhav B, Qiu Y, Richmond PA, Saunders CT, Scheffler K, van Vugt J, Zwamborn R, Chong SS, Friedman JM, Tucci A, Rehm HL, Eberle MA. REViewer: haplotype-resolved visualization of read alignments in and around tandem repeats. *Genome Med* 2022;14:84.
22. Dowling MR, Dickinson M. Post CAR-T cytopenia: poorly understood and clinically challenging. *Leuk Lymphoma* 2022;63:1774-6.
23. Eroglu Z, Broman KK, Thompson JF, Nijhuis A, Hieken TJ, Kottschade L, Farma JM, Hotz M, Deneve J, Fleming M, Bartlett EK, Sharma A, Dossett L, Hughes T, Gyorki DE, Downs J, Karakousis G, Song Y, Lee A, Berman RS, van Akkooi A, Stahlie E, Han D, Vetto J, Beasley G, Farrow NE, Hui JYC, Moncrieff M, Nobes J, Baecher K, Perez M, Lowe M, Ollila DW, Collichio FA, Bagge RO, Mattsson J, Kroon HM, Chai H, Teras J, Sun J, Carr MJ, Tandon A, Babacan NA, Kim Y, Naqvi M, Zager J, Khushalani NI. Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection. *J Immunother Cancer* 2022;10:e004417.
24. Fogarty T, Tacey M, McCorkell G, Kok D, Hornby C, Milne RL, Millar J, Foroudi F, Ong WL. Patterns of the use of advanced radiation therapy techniques for the management of bone metastases and the associated factors in Victoria. *J Med Imaging Radiat Oncol* 2022;66:678-87.
25. Gates P, Krishnasamy M, Wilson C, Hawkes EA, Doré V, Perchyonok Y, Rowe CC, Walker AK, Vardy JL, de Ruyter MB, Cushion T, Dhillon HM, Gough K. Cancer-related cognitive impairment in patients with newly diagnosed aggressive lymphoma undergoing standard chemotherapy: a longitudinal feasibility study. *Support Care Cancer* 2022;30:7731-43.
26. Grootes I, Keeman R, Blows FM, Milne RL, Giles GG, Swerdlow AJ, Fasching PA, Abubakar M, Andrulis IL, Anton-Culver H, Beckmann MW, Blomqvist C, Bojesen SE, Bolla MK, Bonanni B, Briceno I, Burwinkel B, Camp NJ, Castelao JE, Choi JY, Clarke CL, Couch FJ, Cox A, Cross SS, Czene K, Devilee P, Dörk T,

Dunning AM, Dwek M, Easton DF, Eccles DM, Eriksson M, Ernst K, Evans DG, Figueroa JD, Fink V, Floris G, Fox S, Gabrielson M, Gago-Dominguez M, García-Sáenz JA, González-Neira A, Haeberle L, Haiman CA, Hall P, Hamann U, Harkness EF, Hartman M, Hein A, Hoening MJ, Hou MF, Howell SJ, Ito H, Jakubowska A, Janni W, John EM, Jung A, Kang D, Kristensen VN, Kwong A, Lambrechts D, Li J, Lubiński J, Manoochehri M, Margolin S, Matsuo K, Taib NAM, Mulligan AM, Nevanlinna H, Newman WG, Offit K, Osorio A, Park SK, Park-Simon TW, Patel AV, Presneau N, Pylkäs K, Rack B, Radice P, Rennert G, Romero A, Saloustros E, Sawyer EJ, Schneeweiss A, Schochter F, Schoemaker MJ, Shen CY, Shibli R, Sinn P, Tapper WJ, Tawfiq E, Teo SH, Teras LR, Torres D, Vachon CM, van Deurzen CHM, Wendt C, Williams JA, Winqvist R, Elwood M, Schmidt MK, García-Closas M, Pharoah PDP. Incorporating progesterone receptor expression into the PREDICT breast prognostic model. *Eur J Cancer* 2022;173:178-93.

27. Gruber E, So J, Lewis AC, Franich R, Cole R, Martelotto LG, Rogers AJ, Vidacs E, Fraser P, Stanley K, Jones L, Trigos A, Thio N, Li J, Nicolay B, Daigle S, Tron AE, Hyer ML, Shortt J, Johnstone RW, Kats LM. Inhibition of mutant IDH1 promotes cycling of acute myeloid leukemia stem cells. *Cell Rep* 2022;40:111182.
28. Hall VG, Humar A, Kumar D. Utility of Cytomegalovirus Cell-Mediated Immunity Assays in Solid Organ Transplantation. *J Clin Microbiol* 2022;60:e0171621.
29. Higgins MJ, Alipour R, Pope K, Ung KA, Kok DL, Chua MS. QUAD SHOT Radiotherapy and Doublet Immunotherapy in the Management of Anal Mucosal Melanoma: A Case Series of Efficacy and Toxicity of a Novel Treatment Approach and a Review of the Literature. *Clin Colorectal Cancer* 2022;21:e179-86.
30. Holmes Z, Courtney A, Hiong A. Haemophagocytic lymphohistiocytosis as a complication of combination anti-PD-1 and anti-CTLA-4 checkpoint inhibitor immunotherapy for metastatic melanoma, and the outcome of rechallenge with single-agent anti-PD-1 immunotherapy. *BMJ Case Rep* 2022;15:e251052.
31. Hong DS, Gopal AK, Shoushtari AN, Patel SP, He AR, Doi T, Ramalingam SS, Patnaik A, Sandhu S, Chen Y, Davis CB, Fisher TS, Huang B, Fly KD, Ribas A. Utomilumab in Patients with Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer. *Front Immunol* 2022 Aug 2;13:897991.
32. Islam Roney MMS, Lanagan MC, Sheng Y, Gough MM, Snell C, Nguyen NT, Lawler K, Liu C, Lam AK, Kijanka GS. Isotypic analysis of anti-p53 serum autoantibodies and p53 protein tissue phenotypes in colorectal cancer. *Hum Pathol* 2022;128:1-10.
33. Jaeger U, Tam CS, Borchmann P, McGuirk JP, Johansen M, Waller EK, Jaglowski S, Andreadis C, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Salles G, Schuster SJ, He F, Maziarz RT, Mayer S, Makita S, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Goto H, Colicino S, Agarwal A, Lobetti-Bodoni C, Bishop MR. Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma. *Blood Adv* 2022;6:4816-20.
34. James F, Goh MSY, Mouhtouris E, Vogrin S, Chua KYL, Holmes NE, Awad A, Copaescu AM, De Luca JF, Zubrinich C, Gin D, Cleland H, Douglas A, Kern JS, Katelaris CH, Thien F, Barnes S, Yun J, Tong W, Smith WB, Carr A, Anderson T, Legg A, Bourke J, Mackay LK, Aung AK, Phillips EJ, Trubiano J. Study protocol: Australasian Registry of Severe Cutaneous Adverse Reactions (AUS-SCAR). *BMJ Open* 2022;12:e055906.
35. Jangholi A, Müller Bark J, Kenny L, Vasani S, Rao S, Dolcetti R, Punyadeera C. Exosomes at the crossroad between therapeutic targets and therapy resistance in head and neck squamous cell carcinoma. *Biochim Biophys Acta Rev Cancer* 2022;1877:188784.
36. Jiang W, Clancy LE, Avdic S, Sutrave G, Street J, Simms R, McGuire HM, Patrick E, Chan AS, McCaughan G, Myers N, Micklethwaite KP, Antonenas V, Selim AG, Ritchie D, Bateman CM, Shaw PJ, Blyth E, Gottlieb DJ. Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant. *Blood Adv* 2022;6:4949-66.

37. Jobson D, Roffey B, Arnold C, Azzi A, Button-Sloan A, Dawson T, Fernandez-Penas P, Fishburn P, Gyorki DE, Hiscutt EL, Jakrot V, Lilleyman A, Lochhead A, Long GV, Mailer S, Mann G, McCormack CJ, Muir J, Pratt GF, Scolyer RA, Shackelton M, Shumack S, Soyer HP, Tan CG, Webb A, Zalberg J, Morton R, Mar V. Development of melanoma clinical quality indicators for the Australian melanoma clinical outcomes registry (MelCOR): A modified Delphi study. *Australas J Dermatol* 2022;63:344-51.
38. Kang TM, Hardcastle N, Singh AK, Slotman BJ, Videtic GMM, Stephans KL, Couñago F, Louie AV, Guckenberger M, Harden SV, Plumridge NM, Siva S. Practical considerations of single-fraction stereotactic ablative radiotherapy to the lung. *Lung Cancer* 2022;170:185-193.
39. Kim TW, Burris HA, de Miguel Luken MJ, Pishvaian MJ, Bang YJ, Gordon M, Awada A, Camidge DR, Hodi FS, McArthur GA, Miller WH, Cervantes A, Chow LQ, Lesokhin AM, Rutten A, Sznol M, Rishipathak D, Chen SC, Stefanich E, Pourmohamad T, Anderson M, Kim J, Huseni M, Rhee I, Siu LL. First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. *Clin Cancer Res* 2022;28:3452-63.
40. Kron T, Bressel M, Lonski P, Hill C, Mercieca-Bebber R, Ahern V, Lehman M, Johnson C, Latty D, Ward R, Miller D, Banjade D, Morriss D, De Abreu Lourenco R, Woodcock J, Montgomery R, Lehmann J, Chua BH. TROG 14.04: Multicentre Study of Feasibility and Impact on Anxiety of DIBH in Breast Cancer Patients. *Clin Oncol* 2022;34:e410-19.
41. Lakhani A, Jamel W, Riddiough GE, Cabalag CS, Stevens S, Liu DS. Prophylactic negative pressure wound dressings reduces wound complications following emergency laparotomies: A systematic review and meta-analysis. *Surgery* 2022;172:949-54.
42. Lamberti MJ, Montico B, Ravo M, Nigro A, Giurato G, Iorio R, Tarallo R, Weisz A, Stellato C, Steffan A, Dolcetti R, Casolaro V, Faè DA, Dal Col J. Integration of miRNA:mRNA Co-Expression Revealed Crucial Mechanisms Modulated in Immunogenic Cancer Cell Death. *Biomedicines* 2022;10:1896.
43. Lamkin DM, Chen S, Bradshaw KP, Xu S, Faull KF, Sloan EK, Cole SW. Low-dose exposure to PBDE disrupts genomic integrity and innate immunity in mammary tissue. *Front Genet* 2022;13:904607.
44. Lasocki A, McArthur GA. Correlation of MRI signal characteristics of intracranial melanoma metastases with BRAF mutation status. *Melanoma Res* 2022;32:373-8.
45. Lau KK, Steinke K, Reis S, Cherukuri SP, Cejna M. Current trends in image-guided chest interventions. *Respirology* 2022;27:581-599.
46. Lee JJ, Burbury K, Underhill C, Harris S, Shackleton K, McBurnie J, McPhee N, Osmond F, Wilkins K, Baden P, Krishnasamy M. Exploring Australian regional cancer patients' experiences of clinical trial participation via telehealth. *J Telemed Telecare* 2022;28:508-516.
47. Li S, Hoefnagel SJM, Read M, Meijer S, van Berge Henegouwen MI, Gisbertz SS, Bonora E, Liu DSH, Phillips WA, Calpe S, Correia ACP, Sancho-Serra MDC, Mattioli S, Krishnadath KK, Members of the Esophageal Adenocarcinoma Study Group Europe (EACSGE). Selective targeting BMP2 and 4 in SMAD4 negative esophageal adenocarcinoma inhibits tumor growth and aggressiveness in preclinical models. *Cell Oncol* 2022;45:639-658.
48. Lindeman GJ, Fernando TM, Bowen R, Jerzak KJ, Song X, Decker T, Boyle F, McCune S, Armstrong A, Shannon C, Bertelli G, Chang CW, Desai R, Gupta K, Wilson TR, Flechais A, Bardia A. VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results. *Clin Cancer Res* 2022;28:3256-67.
49. Lindsay J, Krantz EM, Morris J, Sweet A, Tverdek F, Joshi A, Yeh R, Hill JA, Greenwood M, Chen SC, Kong DCM, Slavin M, Pergam SA, Liu C. Voriconazole in Hematopoietic Stem Cell Transplantation and Cellular Therapies: Real-World Usage and Therapeutic Level Attainment at a Major Transplantation Center. *Transplant Cell Ther* 2022;28:511.e1-511.e10.
50. Maccora J, Garland SN, Ftanou M, Day D, White M, Lopez VA, Mortimer D, Diggins J, Phillips AJK, Wallace R, Alexander M, Boyle F, Stafford L, Francis PA, Bei B, Wiley JF. The sleep, cancer and rest (SleepCaRe) trial: Rationale and design of a randomized, controlled trial of cognitive behavioral and

bright light therapy for insomnia and fatigue in women with breast cancer receiving chemotherapy. *Contemp Clin Trials* 2022;120:106877.

51. Martin FC, Conduit C, Loveland KL, Thomas B, Lewin J, Tran B. Genetics of testicular cancer: a review. *Curr Opin Urol* 2022;32:481-7.
52. McMullan BJ, Valentine JC, Hall L, Thursky K. Disease and economic burden of infections in hospitalised children in New South Wales, Australia. *Aust Health Rev* 2022;46:471-477.
53. McNamara N, Saunders E, Varghese S, Zheng R, Simpson K, Varma DM, Johnson MM, Hasan Zahid MS, Bachelder EM, Ainslie KM, No JH, Koh D, Shum D, Das N, Patra B, Roy J, Talukdar A, Ganguly D, McConville M, Baell J. Hit-to-lead optimization of novel phenyl imidazole carboxamides that are active against *Leishmania donovani*. *Eur J Med Chem* 2022;240:114577.
54. McQuilten Z, Wellard C, Moore E, Augustson B, Bergin K, Blacklock H, Harrison S, Ho PJ, King T, Quach H, Mollee P, Rosengarten B, Walker P, Wood E, Spencer A. Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). *Br J Haematol* 2022;198:830-7.
55. Mejía-Hernández JO, Raghu D, Caramia F, Clemons N, Fujihara K, Riseborough T, Teunisse A, Jochemsen AG, Abrahmsén L, Blandino G, Russo A, Gamell C, Fox SB, Mitchell C, Takano EA, Byrne D, Miranda PJ, Saleh R, Thorne H, Sandhu S, Williams SG, Keam SP, Haupt Y, Haupt S. Targeting MDM4 as a Novel Therapeutic Approach in Prostate Cancer Independent of p53 Status. *Cancers* 2022;14:3947.
56. Molica S, Tam C, Polliack A. Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia. *Hematol Oncol* 2022;40:313-19.
57. Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. *Blood* 2022;140:419-37.
58. Oo HP, Pasricha SR, Thompson B, Winship I, Scardamaglia L. Rivaroxaban in the treatment of TEK-related venous malformation. *Australas J Dermatol* 2022;63:e255-8.
59. Owen D, Siva S, Salama JK, Robinson C, Kruser TJ, Giuliani M. If at First You Don't Succeed-Stereotactic Body Radiation Therapy for Recurrent Non-Small Cell Lung Cancer. *Int J Radiat Oncol Biol Phys* 2022;114:5-9.
60. Palmer CD, Rappaport AR, Davis MJ, Hart MG, Scallan CD, Hong SJ, Gitlin L, Kraemer LD, Kounlavouth S, Yang A, Smith L, Schenk D, Skoberne M, Taquechel K, Marrali M, Jaroslavsky JR, Nganje CN, Maloney E, Zhou R, Navarro-Gomez D, Greene AC, Grotenbreg G, Greer R, Blair W, Cao MD, Chan S, Bae K, Spira AI, Roychowdhury S, Carbone DP, Henick BS, Drake CG, Solomon BJ, Ahn DH, Mahipal A, Maron SB, Johnson B, Rousseau R, Yelensky R, Liao CY, Catenacci DVT, Allen A, Ferguson AR, Jooss K. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. *Nat Med* 2022;28:1619-1629.
61. Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD, Montagut C, Normanno N, Pantel K, Pentheroudakis G, Popat S, Reis-Filho JS, Tie J, Seoane J, Tarazona N, Yoshino T, Turner NC. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. *Ann Oncol* 2022;33:750-768.
62. Pirie K, Traer E, Finniss D, Myles PS, Riedel B. Current approaches to acute postoperative pain management after major abdominal surgery: a narrative review and future directions. *Br J Anaesth* 2022;129:378-93.

63. Quek LE, van Geldermalsen M, Guan YF, Wahi K, Mayoh C, Balaban S, Pang A, Wang Q, Cowley MJ, Brown KK, Turner N, Hoy AJ, Holst J. Glutamine addiction promotes glucose oxidation in triple-negative breast cancer. *Oncogene* 2022;41:4066-78.
64. Ramanathan V, Balawardane J, Dilip Kumara AH, Sarasanandarajah S. Current status and future prospects of radiation oncology in Sri Lanka. *Phys Med* 2022;100:6-11.
65. Ramsay RG, Flood M. New insights into the unique nature of colorectal cancer peritoneal metastases- rethinking HIPEC. *Br J Cancer* 2022;127:377-8.
66. Rathmell WK, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ, Louie AV, Milowsky MI, Molina AM, Rose TL, Siva S, Zaorsky NG, Zhang T, Qamar R, Kungel TM, Lewis B, Singer EA. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. *J Clin Oncol* 2022;40:2957-95.
67. Reck M, Mok TSK, Mansfield A, De Boer R, Losonczy G, Sugawara S, Dziadziuszko R, Krzakowski M, Smolin A, Hochmair M, Garassino MC, de Castro Junior G, Bischoff H, Lam S, Cardona A, Morris S, Liu SV. Brief Report: Exploratory Analysis of Maintenance Therapy in Patients with Extensive-Stage SCLC Treated First Line with Atezolizumab plus Carboplatin and Etoposide. *J Thorac Oncol* 2022;17:1122-9.
68. Riedel B, Dubowitz J, Yeung J, Jhanji S, Kheterpal S, Avidan MS. On the horns of a dilemma: choosing total intravenous anaesthesia or volatile anaesthesia. *Br J Anaesth* 2022;129:284-9.
69. Rinott Mizrahi G, Williams I, Azad A, Lawrentschuk N. Genetics of neuroendocrine prostate cancer: recent progress in genetic understanding is translating into therapeutic opportunities. *Curr Opin Urol* 2022;32:462-5.
70. Rischin D, Mehanna H, Young RJ, Bressel M, Dunn J, Corry J, Soni P, Fulton-Lieuw T, Iqbal G, Kenny L, Porceddu S, Wratten C, Robinson M, Solomon BJ, Trans-Tasman Radiation Oncology Group, De-ESCALaTE HPV Trial Group. Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103⁺ immune cell abundance in patients treated on TROG 12.01 and De-ESCALaTE randomized trials. *Ann Oncol* 2022;33:804-13.
71. Santucci J, Tacey M, Thomson B, Michael M, Wong R, Shapiro J, Jennens R, Clarke K, Pattison S, Burge M, Zielinski R, Nikfarjam M, Ananda S, Lipton L, Gibbs P, Lee B. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry. *Eur J Cancer* 2022;174:102-12.
72. Savas P, Lo LL, Luen SJ, Blackley EF, Callahan J, Moodie K, van Geelen CT, Ko YA, Weng CF, Wein L, Silva MJ, Bujak AZ, Yeung MM, Ftouni S, Hicks RJ, Francis PA, Lee CK, Dawson SJ, Loi S. Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study. *Cancer Discov* 2022;12:2058-73.
73. Schmitt AM, Spain L, Larkin J. Hitting the sweet spot: optimal use of corticosteroids for immune checkpoint inhibitor side-effects. *Lancet Oncol* 2022;23:1123-4.
74. Seymour JF, Kipps TJ, Eichhorst BF, D'Rozario J, Owen CJ, Assouline S, Lamanna N, Robak T, de la Serna J, Jaeger U, Cartron G, Montillo M, Mellink C, Chyla B, Panchal A, Lu T, Wu JQ, Jiang Y, Lefebure M, Boyer M, Kater AP. Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. *Blood* 2022;140:839-50.
75. Smith S, Brand M, Harden S, Briggs L, Leigh L, Brims F, Brooke M, Brunelli VN, Chia C, Dawkins P, Lawrenson R, Duffy M, Evans S, Leong T, Marshall H, Patel D, Pavlakis N, Philip J, Rankin N, Singhal N, Stone E, Tay R, Vinod S, Windsor M, Wright GM, Leong D, Zalberg J, Stirling RG. Development of an Australia and New Zealand Lung Cancer Clinical Quality Registry: a protocol paper. *BMJ Open* 2022;12:e060907.
76. Souza-Fonseca-Guimaraes F, Rossi GR, Dagley LF, Foroutan M, McCulloch TR, Yousef J, Park HY, Gunter JH, Beavis PA, Lin CY, Hediye-Zadeh S, Camilleri T, Davis MJ, Huntington ND. TGF β and CIS Inhibition

Overcomes NK-cell Suppression to Restore Antitumor Immunity. *Cancer Immunol Res* 2022;10:1047-54.

77. Stacchiotti S, Maria Frezza A, Demetri GD, Blay JY, Bajpai J, Baldi GG, Baldini EH, Benjamin RS, Bonvalot S, Bovée JVMG, Callegaro D, Casali PG, D'Angelo SP, Davis EJ, Dei Tos AP, Demicco EG, Desai J, Dileo P, Eriksson M, Gelderblom H, George S, Gladdy RA, Gounder MM, Gupta AA, Haas R, Hayes A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleiner ES, Le Cesne A, Maestro R, Martin Broto J, Maki RG, Miah AB, Palmerini E, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Strauss SJ, Tap WD, Thomas DM, Trama A, Trent JC, van der Graaf WTA, van Houdt WJ, von Mehren M, Wilky BA, Fletcher CDM, Gronchi A, Miceli R, Wagner AJ. Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. *Cancer Treat Rev* 2022;110:102455.
78. Stewart GD, Klatter T, Cosmai L, Bex A, Lamb BW, Moch H, Sala E, Siva S, Porta C, Gallieni M. The multispecialty approach to the management of localised kidney cancer. *Lancet* 2022;400:523-34.
79. Tam CS, Ho PJ, Purtill D, Blyth E, Butler J, Dickinson M, Harrison S. Fitness criteria for Australian patients referred for chimeric antigen receptor T-cell therapy. *Intern Med J* 2022;52:1454-1456.
80. Tang JS, Varatharajah K, Hansa A, Choong PF. Extraskeletal myxoid chondrosarcoma: A rare but important differential of a retroperitoneal mass. *J Med Imaging Radiat Oncol* 2022;66:647-9.
81. Thompson D, Choo N, Bolton DM, Lawrentschuk N, Risbridger GP, Lawrence MG, Taylor RA. New approaches to targeting epigenetic regulation in prostate cancer. *Curr Opin Urol* 2022;32:472-80.
82. Thompson MC, Harrup RA, Coombs CC, Roeker LE, Pu JJ, Choi MY, Barr PM, Allan JN, Simkovic M, Leslie L, Rhodes J, Chong EA, Kamdar M, Skarbnik A, Lansigan F, McCall B, Saja K, Dyer MJS, Walter HS, Lefebure M, Thadani-Mulero M, Boyer M, Biondo J, Sail K, Manzoor BS, Furman R, Bantilan KS, Goy A, Feldman T, Labella D, Schuster SJ, Park J, Palomba L, Zelenetz A, Eyre TA, Kater AP, Seymour JF, Mato AR. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. *Blood Adv* 2022;6:4553-7.
83. To YH, Shapiro J, Wong R, Thomson B, Nagrial A, Mendis S, Gibbs P, Shapiro J, Lee B. Treatment and outcomes of unresectable and metastatic pancreatic cancer treated in public and private Australian hospitals. *Asia Pac J Clin Oncol* 2022;18:448-455.
84. Tran MJ, Jefford M, Smith B, Lynch F, Dhillion HM, Shaw J, McDowell L, White A, Halloran C, Wiesenfeld D, Ftanou M. Study protocol for the evaluation of Fear-Less: a stepped-care program for fear of cancer recurrence in survivors with early-stage disease. *Pilot Feasibility Stud* 2022;8:177.
85. van Dijk E, van Werkhoven E, Asher R, Mooi JK, Espinoza D, van Essen HF, van Tinteren H, van Grieken NCT, Punt CJA, Tebbutt NC, Ylstra B. Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX. *Int J Cancer* 2022;151:1166-74.
86. Waterland JL, Ismail H, Granger CL, Patrick C, Denehy L, Riedel B. Prehabilitation in high-risk patients scheduled for major abdominal cancer surgery: a feasibility study. *Perioper Med* 2022;11:32.
87. Winship AL, Alesi LR, Sant S, Stringer JM, Cantavenera A, Hegarty T, Requesens CL, Liew SH, Sarma U, Griffiths MJ, Zerafa N, Fox SB, Brown E, Caramia F, Zareie P, La Gruta NL, Phillips KA, Strasser A, Loi S, Hutt KJ. Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice. *Nat Cancer* 2022;3:1-13.
88. Wong AK, Philip J, Wawryk O, Sabe MG, Yoong J, Everitt R, Mendis R, Chua J, Pisasale M, Le B. A Multi-Centre COVID-19 Study Examining Symptoms and Medication Use in the Final Week of Life. *J Pain Symptom Manage* 2022;64:e139-47.
89. Xu W, Yang S, Tam CS, Seymour JF, Zhou K, Opat S, Qiu L, Sun M, Wang T, Trotman J, Pan L, Gao S, Zhou J, Zhou D, Zhu J, Song Y, Hu J, Feng R, Huang H, Su D, Shi M, Li J. Zanubrutinib Monotherapy for

Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pooled Analysis of Three Studies. *Adv Ther* 2022;39:4250-65.

90. Yeoh DK, Blyth CC, Kotecha RS. Blinatumomab as bridging therapy in paediatric B-cell acute lymphoblastic leukaemia complicated by invasive fungal disease. *Br J Haematol* 2022;198:887-92.
91. Zhu Z, Turner NC, Loi S, André F, Martin M, Diéras V, Gelmon KA, Harbeck N, Zhang C, Cao JQ, Yan Z, Lu DR, Wei P, VanArsdale TL, Rejto PA, Huang X, Rugo HS, Loibl S, Cristofanilli M, Finn RS, Liu Y. Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib. *NPJ Precis Oncol* 2022;6:56.

September

1. Acs B, Leung SCY, Kidwell KM, Arun I, Augulis R, Badve SS, Bai Y, Bane AL, Bartlett JMS, Bayani J, Bigras G, Blank A, Buikema H, Chang MC, Dietz RL, Dodson A, Fineberg S, Focke CM, Gao D, Gown AM, Gutierrez C, Hartman J, Kos Z, Lænkholm AV, Laurinavicius A, Levenson RM, Mahboubi-Ardakani R, Mastropasqua MG, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Quintayo MA, Rau TT, Reinhard S, Robertson S, Salgado R, Sugie T, van der Vegt B, Viale G, Zabaglo LA, Hayes DF, Dowsett M, Nielsen TO, Rimm DL. Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. *Mod Pathol* 2022;35:1362-9.
2. Adams V, Katz NT, Philip JAM, Gold M. Desire to Die Statements in the Era of Voluntary Assisted Dying: An Audit of Patients Known to a Victorian Consultation-Liaison Palliative Care Service. *Am J Hosp Palliat Care* 2022;39:1203-9.
3. Airth A, Whittle JR, Dimou J. How has the COVID-19 pandemic impacted clinical care and research in Neuro-Oncology? *J Clin Neurosci* 2022;105:91-102.
4. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso-Ramos CE, Cortes JE, Dal Cin P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, Gokbuget N, Gotlib J, Hellstrom-Lindberg E, Hobbs GS, Hoffman R, Jabbour EJ, Kiladjian JJ, Larson RA, Le Beau MM, Loh ML, Lowenberg B, Macintyre E, Malcovati L, Mullighan CG, Niemeyer C, Odenike OM, Ogawa S, Orfao A, Papaemmanuil E, Passamonti F, Porkka K, Pui CH, Radich JP, Reiter A, Rozman M, Rudelius M, Savona MR, Schiffer CA, Schmitt-Graeff A, Shimamura A, Sierra J, Stock WA, Stone RM, Tallman MS, Thiele J, Tien HF, Tzankov A, Vannucchi AM, Vyas P, Wei AH, Weinberg OK, Wierzbowska A, Cazzola M, Dohner H, Tefferi A. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. *Blood* 2022;140:1200-28.
5. Arez M, Eckersley-Maslin M, Klobučar T, von Gilsa Lopes J, Krueger F, Mupo A, Raposo AC, Oxley D, Mancino S, Gendrel AV, Bernardes de Jesus B, da Rocha ST. Imprinting fidelity in mouse iPSCs depends on sex of donor cell and medium formulation. *Nat Commun* 2022;13:5432.
6. Arnolda R, Howlett K, Chan T, Raleigh J, Hatzimihalis A, Bell A, Fellowes A, Sandhu S, McArthur GA, Fox SB, Dawson SJ, Hewitt C, Jones K, Wong SQ. Clinical validation and implementation of droplet digital PCR for the detection of BRAF mutations from cell-free DNA. *Pathology* 2022;54:772-8.
7. Baez-Navarro X, Salgado R, Denkert C, Lennerz JK, Penault-Llorca F, Viale G, Bartlett JMS, van Deurzen CHM. Selecting patients with HER2-low breast cancer: Getting out of the tangle. *Eur J Cancer* 2022;175:187-92.
8. Becker-Cohen M, Szer J, Arbel N, Frydman D, Dinur T, Istiti M, Revel-Vilk S, Zimran A. Rapid velaglucerase alfa infusion for Gaucher disease: 5-year data. *Intern Med J* 2022;52:1645-6.
9. Bhandari A, Marwah R, Smith J, Nguyen D, Bhatti A, Lim CP, Lasocki A. Machine learning imaging applications in the differentiation of true tumour progression from treatment-related effects in brain tumours: A systematic review and meta-analysis. *J Med Imaging Radiat Oncol* 2022;66:781-97.
10. Blombery P, Cheah CY. Predicting the future in MCL with MRD. *Blood* 2022;140:1332-3.

11. Bondeson DP, Mullin-Bernstein Z, Oliver S, Skipper TA, Atack TC, Bick N, Ching M, Guirguis AA, Kwon J, Langan C, Millson D, Paoella BR, Tran K, Wie SJ, Vazquez F, Tothova Z, Golub TR, Sellers WR, Ianari A. Systematic profiling of conditional degron tag technologies for target validation studies. *Nat Commun* 2022;13:5495.
12. Bound NT, Vandenberg CJ, Kartikasari AER, Plebanski M, Scott CL. Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system. *Front Genet* 2022;13:886170.
13. Brown K, Kupfer T, Harris B, Penso S, Khor R, Moseshvili E. Not all 3D-printed bolus is created equal: Variation between 3D-printed polylactic acid (PLA) bolus samples sourced from external manufacturers. *J Med Radiat Sci* 2022;69:348-56.
14. Burton A, Beveridge S, Hardcastle N, Lye J, Sanagou M, Franich R. Adoption of respiratory motion management in radiation therapy. *Phys Imaging Radiat Oncol* 2022;24:21-9.
15. Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S, Dogan A, Feldman AL, Fend F, Friedberg JW, Gaulard P, Ghia P, Horwitz SM, King RL, Salles G, San-Miguel J, Seymour JF, Treon SP, Vose JM, Zucca E, Advani R, Ansell S, Au WY, Barrionuevo C, Bergsagel L, Chan WC, Cohen JJ, d'Amore F, Davies A, Falini B, Ghobrial IM, Goodlad JR, Gribben JG, Hsi ED, Kahl BS, Kim WS, Kumar S, LaCasce AS, Laurent C, Lenz G, Leonard JP, Link MP, Lopez-Guillermo A, Mateos MV, Macintyre E, Melnick AM, Morschhauser F, Nakamura S, Narbaitz M, Pavlovsky A, Pileri SA, Piris M, Pro B, Rajkumar V, Rosen ST, Sander B, Sehn L, Shipp MA, Smith SM, Staudt LM, Thieblemont C, Tousseyn T, Wilson WH, Yoshino T, Zinzani PL, Dreyling M, Scott DW, Winter JN, Zelenetz AD. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. *Blood* 2022;140:1229-53.
16. Canny D, Larach JT, Mohan H, Warriar SK, McCormick JJ, Heriot AG, Waters PS. Resection of an abdominal wall rectal cancer recurrence with posterior component separation and transverse abdominis release following image-guided botulinum toxin A injection. *ANZ J Surg* 2022;92:2328-30.
17. Casey M, Tu C, Harrison SJ, Nakamura K. Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA. *Blood Adv* 2022;6:5165-70.
18. Chong CY, Jalali A, Wong HL, Loft M, Wong R, Lee M, Gately L, Hong W, Shapiro J, Kosmider S, Tie J, Ananda S, Yeung JM, Ma B, Burge M, Jennens R, Tran B, Lee B, Lim L, Dean A, Nott L, Gibbs P. Impact of the evolution in RAS mutation analysis in Australian patients with metastatic colorectal cancer. *Asia Pac J Clin Oncol* 2022;18:e363-8.
19. Cliff ERS, Dickinson M. Treatment of Mantle-Cell Lymphoma. *N Engl J Med* 2022;387:1146-7.
20. Collins A, McLachlan SA, Pasanen L, Wawryk O, Philip J. Perceptions of telehealth in real-world oncological care: An exploration of matched patient- and clinician-reported acceptability data from an Australian cancer centre. *Cancer Med* 2022;11:3342-51.
21. Davies A, Foo M, Gan CL, Kourambas J, Redgrave N, Donnellan S, Appu S, Williams S, Coleman A, Segelov E, Bradley J, Soo G, Ramdave S, Kwan EM, Azad AA. ⁶⁸Ga-prostate-specific membrane antigen (PSMA) PET/CT as a clinical decision-making tool in biochemically recurrent prostate cancer. *Asia Pac J Clin Oncol* 2022;18:e204-10.
22. Dax V, Ftanou M, Tran B, Lewin J, Wallace R, Seidler Z, Wiley JF. The impact of testicular cancer and its treatment on masculinity: A systematic review. *Psychooncology* 2022;31:1459-73.
23. Dimitriou F, Namikawa K, Reijers ILM, Buchbinder EI, Soon JA, Zaremba A, Teterycz P, Mooradian MJ, Armstrong E, Nakamura Y, Vitale MG, Tran LE, Bai X, Allayous C, Provent-Roy S, Indini A, Bhave P, Farid M, Kahler KC, Mehmi I, Atkinson V, Klein O, Stonesifer CJ, Zaman F, Haydon A, Carvajal RD, Hamid O, Dummer R, Hauschild A, Carlino MS, Mandala M, Robert C, Lebbe C, Guo J, Johnson DB, Ascierto PA, Shoushtari AN, Sullivan RJ, Cybulska-Stopa B, Rutkowski P, Zimmer L, Sandhu S, Blank CU, Lo SN, Menzies AM, Long GV. Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. *Ann Oncol* 2022;33:968-80.

24. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Rollig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang J, Wierzbowska A, Lowenberg B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. *Blood* 2022;140:1345-77.
25. Duffy MF, Tonkin-Hill GQ, Trianty L, Noviyanti R, Nguyen HHT, Rambhatla JS, McConville MJ, Rogerson SJ, Brown GV, Price RN, Anstey NM, Day KP, Papenfuss AT. Relationship of circulating Plasmodium falciparum lifecycle stage to circulating parasitemia and total parasite biomass. *Nat Commun* 2022;13:5557.
26. Fereydooni S, Lorenz KA, Ganesh A, Satija A, Spruijt O, Bhatnagar S, Gamboa RC, Singh N, Giannitrapani KF. Empowering families to take on a palliative caregiver role for patients with cancer in India: Persistent challenges and promising strategies. *PLoS One* 2022;17:e0274770.
27. Ferguson MT, Fernando JR, McManus S, Richardson I, Nicholson J, Storey DA, Ismail H, Riedel B. Perioperative medicine in Australia and New Zealand: A cross-sectional survey. *Anaesth Intensive Care* 2022;50:403-6.
28. Flood MP, Kong JCH, Wilson K, Mohan H, Waters PS, McCormick JJ, Warriar SK, Tie J, Ramsay R, Michael M, Heriot AG. The Impact of Neoadjuvant Chemotherapy on the Surgical Management of Colorectal Peritoneal Metastases: A Systematic Review and Meta-Analysis. *Ann Surg Oncol* 2022;29:6619-31.
29. Flood MP, Narasimhan V, Waters PS, Kong JC, Ramsay R, Michael M, Tie J, McCormick JJ, Warriar SK, Heriot AG. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases in an elderly population: outcomes from a single centre. *ANZ J Surg* 2022;92:2192-8.
30. Flood MP, Ramsay R, Michael M, Heriot AG. ASO Author Reflections: Neoadjuvant Systemic Chemotherapy in Isolated Resectable Colorectal Peritoneal Metastases: Ready for Standard of Care? *Ann Surg Oncol* 2022;29:6632-3.
31. Flynn J, Larach JT, Kong JCH, Waters PS, McCormick JJ, Warriar SK, Heriot A. Patient-Related Functional Outcomes After Robotic-Assisted Rectal Surgery Compared With a Laparoscopic Approach: A Systematic Review and Meta-analysis. *Dis Colon Rectum* 2022;65:1191-204.
32. Fox SB, Webster F, Chen CJ, Chua B, Collins L, Foschini MP, Mann GB, Millar E, Pinder SE, Rakha E, Shaaban A, Tan BY, Tse G, Watson P, Tan PH. Dataset for pathology reporting of ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions: recommendations from the International Collaboration on Cancer Reporting (ICCR). *Histopathology* 2022;81:467-76.
33. Fujihara KM, Zhang BZ, Jackson TD, Ogunkola MO, Nijagal B, Milne JV, Sallman DA, Ang CS, Nikolic I, Kearney CJ, Hogg SJ, Cabalag CS, Sutton VR, Watt S, Fujihara AT, Trapani JA, Simpson KJ, Stojanovski D, Leimkühler S, Haupt S, Phillips WA, Clemons NJ. Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction. *Sci Adv* 2022;8:eabm9427.
34. Gaudreault M, Yeo A, Kron T, Hanna GG, Siva S, Hardcastle N. Treatment Time Optimization in Single Fraction Stereotactic Ablative Radiation Therapy: A 10-Year Institutional Experience. *Adv Radiat Oncol* 2022;7:100829.
35. Gearing PF, Larach JT, Mohan H, Cohen L, Heriot AG, Warriar SK. Utilization of a transanal approach to facilitate beyond total mesorectal excision dissection including en bloc subcortical high sacrectomy for locally recurrent rectal cancer. *ANZ J Surg* 2022;92:2368-70.
36. Gough K, Bergin RJ, Drosdowsky A, Aranda S, Mileskin L, Jackson M, Kinnane N, Bernshaw D, Juraskova I, White K, Mohamed M, Schofield P. Women with gynaecological cancer awaiting radiotherapy: Self-reported wellbeing, general psychological distress, symptom distress, sexual function, and supportive care needs. *Gynecol Oncol* 2022;167:42-50.

37. Guccione L, Fisher K, Mileshkin L, Tothill R, Bowtell D, Quinn S, DeFazio A, Karapetis CS, Wilcken N, Singh M, Steer C, Gao B, Warren M, Collins IM, Karanth N, Bryant C, Schofield P. Uncertainty and the unmet informational needs of patients with cancer of unknown primary (CUP): a cross-sectional multi-site study. *Support Care Cancer* 2022;30:8217-29.
38. Haskali MB, Roselt PD, O'Brien TJ, Hutton CA, Ali I, Vivash L, Jupp B. Effective Preparation of [¹⁸F]Flumazenil Using Copper-Mediated Late-Stage Radiofluorination of a Stannyl Precursor. *Molecules* 2022;27:5931.
39. Hawson J, Kalman J, Goldblatt J, Anderson RD, Watts T, Hardcastle N, Siva S, Kumar S, Lee G. From minimally to maximally invasive; VT ablation in the setting of mechanical aortic and mitral valves. *J Cardiovasc Electrophysiol* 2022;33:2116-20.
40. Hui L, De Catte L, Beard S, Maksimovic J, Vora NL, Oshlack A, Walker SP, Hannan NJ. RNA-Seq of amniotic fluid cell-free RNA: a discovery phase study of the pathophysiology of congenital cytomegalovirus infection. *Am J Obstet Gynecol* 2022;227:634.e1-634.e12.
41. Jones ME, Mohan HM, Larach JT, Apte S, Heriot AG, Warriar SK. Transanal total mesorectal excision and robotic ultra-low anterior resection with en bloc left seminal vesicle excision: a video vignette. *Colorectal Dis* 2022;24:1015.
42. Kang YJ, Caruana M, McLoughlin K, Killen J, Simms K, Taylor N, Frayling IM, Coupe VMH, Boussioutas A, Trainer AH, Ward RL, Macrae F, Canfell K. The predicted effect and cost-effectiveness of tailoring colonoscopic surveillance according to mismatch repair gene in patients with Lynch syndrome. *Genet Med* 2022;24:1831-46.
43. Kannan A, Clouston D, Frydenberg M, Ilic D, Karim MN, Evans SM, Toivanen R, Risbridger GP, Taylor RA. Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta-analysis. *BJU Int* 2022;130:420-33.
44. Key S, Chia C, Nixon G, Paddle P. Cost-minimisation analysis of polysomnography and pulse oximetry in a risk stratification protocol for paediatric adenotonsillectomy. *ANZ J Surg* 2022;92:2292-8.
45. Kok DL, Dushyanthen S, Peters G, Sapkaroski D, Barrett M, Sim J, Eriksen JG. Virtual reality and augmented reality in radiation oncology education - A review and expert commentary. *Tech Innov Patient Support Radiat Oncol* 2022;24:25-31.
46. Kostos L, Murphy DG. Treatment options for metastatic hormone-sensitive prostate cancer. *Lancet Oncol* 2022;23:1234-5.
47. Lim E, Boyle F, Okera M, Loi S, Goksu SS, van Hal G, Chapman SC, Gable JC, Chen Y, Price GL, Hossain AM, Gainford MC, Ezquerro MB. An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer. *Breast Cancer Res Treat* 2022;195:275-87.
48. Liow E, Howard N, Jung CH, Pope B, Campbell BK, Nguyen A, Kerger M, Ruddle JB, Anton A, Thomas B, Chu K, Dundee P, Peters JS, Costello AJ, Ryan AS, Hovens CM, Tran B, Corcoran NM. Phase 2 Study of Neoadjuvant FGFR Inhibition and Androgen Deprivation Therapy Prior to Prostatectomy. *Clin Genitourin Cancer* 2022;20:452-8.
49. Lockstone J, Denehy L, Truong D, Whish-Wilson GA, Boden I, Abo S, Parry SM. Prophylactic Postoperative Noninvasive Ventilation in Adults Undergoing Upper Abdominal Surgery: A Systematic Review and Meta-Analysis. *Crit Care Med* 2022;50:1522-32.
50. Lokuhetty N, Larach JT, Rajkomar AKS, Mohan H, Waters PS, Heriot AG, Warriar SK. Robotic pelvic side-wall dissection and en-bloc excision for locally advanced and recurrent rectal cancer: outcomes on feasibility and safety. *ANZ J Surg* 2022;92:2185-91.
51. Long E, Babl FE, Phillips N, Craig S, Zhang M, Kochar A, McCaskill M, Borland ML, Slavin MA, Phillips R, Lourenco RA, Michinaud F, Thursky KA, Haeusler G, Australian PICNICC Study Group, PREDICT Network.

Prevalence and predictors of poor outcome in children with febrile neutropaenia presenting to the emergency department. *Emerg Med Australas* 2022;34:786-93.

52. Ma J, Zhang Y, Gu S, An X, Wang Z, Ge C, Wang C, Zhang F, Wang Y, Xu Y, Gou S, Thaler F, Payer C, Štern D, Henderson EGA, McSweeney DM, Green A, Jackson P, McIntosh L, Nguyen QC, Qayyum A, Conze PH, Huang Z, Zhou Z, Fan DP, Xiong H, Dong G, Zhu Q, He J, Yang X. Fast and Low-GPU-memory abdomen CT organ segmentation: The FLARE challenge. *Med Image Anal* 2022;82:102616.
53. Marra G, Laguna MP, Walz J, Pavlovich CP, Bianco F, Gregg J, Lebastchi AH, Lepor H, Macek P, Rais-Bahrami S, Robertson C, Rukstalis D, Salomon G, Ukimura O, Abreu AL, Barbe Y, Cathelineau X, Gandaglia G, George AK, Gomez Rivas J, Gupta RT, Lawrentschuk N, Kasivisvanathan V, Lomas D, Malavaud B, Margolis D, Matsuoka Y, Mehralivand S, Moschini M, Oderda M, Orabi H, Rastinehad AR, Remzi M, Schulman A, Shin T, Shiraishi T, Sidana A, Shoji S, Stabile A, Valerio M, Tammisetti VS, Phin Tan W, W VDB, Villers A, Willemse PP, J DLR, Polascik T, Sanchez-Salas R, Focal Therapy S. Molecular biomarkers in the context of focal therapy for prostate cancer: recommendations of a Delphi Consensus from the Focal Therapy Society. *Minerva Urol Nephrol* 2022;74:581-9.
54. Mejía-Hernández JO, Keam SP, Saleh R, Muntz F, Fox SB, Byrne D, Kogan A, Pang L, Huynh J, Litchfield C, Caramia F, Lozano G, He H, You JM, Sandhu S, Williams SG, Haupt Y, Haupt S. Modelling aggressive prostate cancers of young men in immune-competent mice, driven by isogenic Trp53 alterations and Pten loss. *Cell Death Dis* 2022;13:777.
55. Michael M, Thursfield V, Te Marvelde L, Kong G, Hicks RJ. Incidence, prevalence, and survival trends for neuroendocrine neoplasms in Victoria, Australia, from 1982 to 2019: Based on site, grade, and region. *Asia Pac J Clin Oncol* 2022;18:e306-17.
56. Miles LF, Burbury KL, Richards T, IDOCS authors. Factors to consider when assessing the IDOCS study - Authors' reply. *Lancet Haematol* 2022;9:e639-40.
57. Mina DS, Tandon P, Kow AWC, Chan A, Edbrooke L, Raptis DA, Spiro M, Selzner N, Denehy L, ERAS4OLT.org Working Group. The role of acute in-patient rehabilitation on short-term outcomes after liver transplantation: A systematic review of the literature and expert panel recommendations. *Clin Transplant* 2022;36:e14706.
58. Møller P, Seppälä T, Dowty JG, Haupt S, Dominguez-Valentin M, Sunde L, Bernstein I, Engel C, Aretz S, Nielsen M, Capella G, Evans DG, Burn J, Holinski-Feder E, Bertario L, Bonanni B, Lindblom A, Levi Z, Macrae F, Winship I, Plazzer JP, Sijmons R, Laghi L, Valle AD, Heinimann K, Half E, Lopez-Koestner F, Alvarez-Valenzuela K, Scott RJ, Katz L, Laish I, Vainer E, Vaccaro CA, Carraro DM, Gluck N, Abu-Freha N, Stakelum A, Kennelly R, Winter D, Rossi BM, Greenblatt M, Bohorquez M, Sheth H, Tibiletti MG, Lino-Silva LS, Horisberger K, Portenkirchner C, Nascimento I, Rossi NT, da Silva LA, Thomas H, Zaránd A, Mecklin JP, Pylvänäinen K, Renkonen-Sinisalo L, Lepisto A, Peltomäki P, Therkildsen C, Lindberg LJ, Thorlacius-Ussing O, von Knebel Doeberitz M, Loeffler M, Rahner N, Steinke-Lange V, Schmiegel W, Vangala D, Perne C, Hüneburg R, de Vargas AF, Latchford A, Gerdes AM, Backman AS, Guillén-Ponce C, Snyder C, Lautrup CK, Amor D, Palmero E, Stoffel E, Duijkers F, Hall MJ, Hampel H, Williams H, Okkels H, Lubiński J, Reece J, Ngeow J, Guillem JG, Arnold J, Wadt K, Monahan K, Senter L, Rasmussen LJ, van Hest LP, Ricciardiello L, Kohonen-Corish MRJ, Ligtenberg MJL, Southey M, Aronson M, Zahary MN, Samadder NJ, Poplawski N, Hoogerbrugge N, Morrison PJ, James P, Lee G, Chen-Shtoyerman R, Ankathil R, Pai R, Ward R, Parry S, Dębniak T, John T, van Overeem Hansen T, Caldés T, Yamaguchi T, Barca-Tierno V, Garre P, Cavestro GM, Weitz J, Redler S, Büttner R, Heuveline V, Hopper JL, Win AK, Lindor N, Gallinger S, Le Marchand L, Newcomb PA, Figueiredo J, Buchanan DD, Thibodeau SN, Ten Broeke SW, Hovig E, Nakken S, Pineda M, Dueñas N, Brunet J, Green K, Lalloo F, Newton K, Crosbie EJ, Mints M, Tjandra D, Neffa F, Esperon P, Kariv R, Rosner G, Pavicic WH, Kalfayan P, Torrezan GT, Bassaneze T, Martin C, Moslein G, Ahadova A, Kloor M, Sampson JR, Jenkins MA. Colorectal cancer incidences in Lynch syndrome: a comparison of results from the prospective lynch syndrome database and the international mismatch repair consortium. *Hered Cancer Clin Pract* 2022;20:36.
59. Mondschein R, Taylor R, Thorne H, Bolton D. Novel germline mutations for active surveillance and imaging strategies in prostate cancer. *Curr Opin Urol* 2022;32:456-61.

60. Mui M, Kong JCH, Ramsay R, Michael M, Heriot AG. Total neoadjuvant therapy (TNT) in rectal cancer: to or not to give? *ANZ J Surg* 2022;92:1978-9.
61. Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank CU, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel JC, Ugurel S, Zimmer L, Banks P, Spain L, Soon JA, Enokida T, Tahara M, Kähler KC, Seggewiss-Bernhardt R, Harvey C, Long GV, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French LE, Knauss S, Heinzerling LM. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study. *Eur J Cancer* 2022;175:224-35.
62. Multicenter Selective Lymphadenectomy Trials Study Group, Crystal JS, Thompson JF, Hyngstrom J, Caraco C, Zager JS, Jahkola T, Bowles TL, Pennacchioli E, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, van Akkooi A, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Neves RI, Rossi CR, Kane JM, 3rd, Trocha S, Wright F, Byrd DR, Matter M, Hsueh EC, MacKenzie-Ross A, Kelley M, Terheyden P, Huston TL, Wayne JD, Neuman H, Smithers BM, Ariyan CE, Desai D, Gershenwald JE, Schneebaum S, Gesierich A, Jacobs LK, Lewis JM, McMasters KM, O'Donoghue C, van der Westhuizen A, Sardi A, Barth R, Barone R, McKinnon JG, Slingluff CL, Farma JM, Schultz E, Scheri RP, Vidal-Sicart S, Molina M, Testori AAE, Foshag LJ, Van Kreuningem L, Wang HJ, Sim MS, Scolyer RA, Elashoff DE, Cochran AJ, Faries MB. Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial. *JAMA Surg* 2022;157:835-42.
63. Ngo P, Goldsbury DE, Karikios D, Yap S, Yap ML, Egger S, O'Connell DL, Ball D, Fong KM, Pavlakis N, Rankin NM, Vinod S, Canfell K, Weber MF. Lung cancer treatment patterns and factors relating to systemic therapy use in Australia. *Asia Pac J Clin Oncol* 2022;18:e235-46.
64. Odutola MK, van Leeuwen MT, Turner J, Bruinsma F, Seymour JF, Prince HM, Milliken ST, Hertzberg M, Trotman J, Opat SS, Lindeman R, Roncolato F, Verner E, Harvey M, Tiley C, Underhill CR, Benke G, Giles GG, Vajdic CM. Associations between early-life growth pattern and body size and follicular lymphoma risk and survival: a family-based case-control study. *Cancer Epidemiol* 2022;80:102241.
65. O'Haire S, Degeling K, Franchini F, Tran B, Luen SJ, Gaff C, Smith K, Fox S, Desai J, Ijzerman M. Comparing Survival Outcomes for Advanced Cancer Patients Who Received Complex Genomic Profiling Using a Synthetic Control Arm. *Target Oncol* 2022;17:539-48.
66. Ong WL, Finn N, Te Marvelde L, Hornby C, Milne RL, Hanna GG, Pitson G, Elsaleh H, Millar JL, Foroudi F. Disparities in radiation therapy utilization for cancer patients in Victoria. *J Med Imaging Radiat Oncol* 2022;66:830-9.
67. Prabhakaran S, Carne P, Kong JCH. The role of MRI scans in selective lateral pelvic lymph node dissection. *ANZ J Surg* 2022;92:1980-1.
68. Pryde K, Brusco N, O'Callaghan C, Baird A, Moore R, White J, Bull C, Lee AL, Michael N. Caregiver delivered massage therapy options in inpatient palliative care: A mixed methods exploratory study. *Complement Ther Clin Pract* 2022;49:101663.
69. Pudsey LMM, Biasi G, Ralston A, Rosenfeld A, Poder J. Detection of rotational errors in single-isocenter multiple-target radiosurgery: Is a routine off-axis Winston-Lutz test necessary? *J Appl Clin Med Phys* 2022;23:e13665.
70. Rickard JA, Burr ML, Williams B, Murugasu A, Fellowes A, John T, Christie M. SMARCB1/INI1-deficient primary lung carcinoma with hepatic metastasis. *Pathology* 2022;54:817-20.
71. Sharma G, Shah M, Ahluwalia P, Dasgupta P, Challacombe BJ, Bhandari M, Ahlawat R, Rawal S, Buffi NM, Sivaraman A, Porter JR, Rogers C, Mottrie A, Abaza R, Rha KH, Moon D, Yuvaraja TB, Parekh DJ, Capitanio U, Maes KK, Porpiglia F, Turkeri L, Gautam G. Comparison of perioperative outcomes following transperitoneal versus retroperitoneal robot-assisted partial nephrectomy: a propensity-matched analysis of VCQI database. *World J Urol* 2022;40:2283-91.

72. Simpson-Page E, Coogan P, Kron T, Lowther N, Murray R, Noble C, Smith I, Wilks R, Crowe SB. Webinar and survey on quality management principles within the Australian and New Zealand ACPSEM Workforce. *Phys Eng Sci Med* 2022;45:679-85.
73. Singh N, Giannitrapani KF, Satija A, Ganesh A, Gamboa R, Fereydooni S, Hennings T, Chandrashekar S, Spruijt O, Bhatnagar S, Lorenz KA. Considerations for Fostering Palliative Care Awareness in Developing Contexts: Strategies From Locally Initiated Projects in India. *J Pain Symptom Manage* 2022;64:370-6.
74. Smith AL, Watts CG, Henderson M, Long GV, Rapport F, Saw RPM, Scolyer RA, Spillane AJ, Thompson JF, Cust AE. Factors influencing acceptance, adoption and adherence to sentinel node biopsy recommendations in the Australian Melanoma Management Guidelines: a qualitative study using an implementation science framework. *Implement Sci Commun* 2022;3:103.
75. Steinfort DP, Siva S, Rangamuwa K, Lee P, Fielding D, Nguyen P, Jennings BR, Yo S, Hardcastle N, Kothari G, Crombag L, Annema J, Yasufuku K, Ost DE, Irving LB. Systematic endoscopic staging of mediastinum to determine impact on radiotherapy for locally advanced lung cancer (SEISMIC): protocol for a prospective single arm multicentre interventional study. *BMC Pulm Med* 2022;22:364.
76. Trappetti V, Potez M, Fernandez-Palomo C, Volarevic V, Shintani N, Pelliccioli P, Ernst A, Haberthür D, Fazzari JM, Krisch M, Laissue JA, Anderson RL, Martin OA, Djonov VG. Microbeam Radiation Therapy Controls Local Growth of Radioresistant Melanoma and Treats Out-of-Field Locoregional Metastasis. *Int J Radiat Oncol Biol Phys* 2022;114:478-93.
77. Tsui C, Kretschmer L, Rapelius S, Gabriel SS, Chisanga D, Knopper K, Utzschneider DT, Nussing S, Liao Y, Mason T, Torres SV, Wilcox SA, Kanev K, Jarosch S, Leube J, Nutt SL, Zehn D, Parish IA, Kastenmuller W, Shi W, Buchholz VR, Kallies A. MYB orchestrates T cell exhaustion and response to checkpoint inhibition. *Nature* 2022;609:354-60.
78. Tung I, Moldovan C, Wong V, De Boer R, Yeo B, Malik L, Greenberg S, Anton A, Nott L, Barnett F, Collins IM, Lombard J, Nottage M, Sahu A, Torres J, Gibbs P, Lok SW. Real-World Outcomes in Patients With Brain Metastases Secondary to HER2-Positive Breast Cancer: An Australian Multi-centre Registry-based Study. *Clin Breast Cancer* 2022;22:e764-72.
79. Vasina EN, Kong N, Greer P, Baeza Ortega J, Kron T, Ludbrook JJ, Thwaites D, Lehmann J. First clinical experience with real-time portal imaging-based breath-hold monitoring in tangential breast radiotherapy. *Phys Imaging Radiat Oncol* 2022;24:1-6.
80. Vermij L, Leon-Castillo A, Singh N, Powell ME, Edmondson RJ, Genestie C, Khaw P, Pyman J, McLachlin CM, Ghatage P, de Boer SM, Nijman HW, Smit V, Crosbie EJ, Leary A, Creutzberg CL, Horeweg N, Bosse T, TransPORTEC consortium. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial. *Mod Pathol* 2022;35:1475-83.
81. Wall I, Boulat V, Shah A, Blenman KRM, Wu Y, Alberts E, Calado DP, Salgado R, Grigoriadis A. Leveraging the Dynamic Immune Environment Triad in Patients with Breast Cancer: Tumour, Lymph Node, and Peripheral Blood. *Cancers* 2022;14:4505.
82. Wander SA, O'Brien N, Litchfield LM, O'Dea D, Morato Guimaraes C, Slamon DJ, Goel S. Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib. *Oncologist* 2022;27:811-21.
83. Ward J, Gill S, Armstrong K, Fogarty T, Tan D, Scott A, Yahya A, Dhaliwal SS, Jacques A, Tang C. Randomised controlled trial on the effect of simethicone bowel preparation on rectal variability during image-guided radiation therapy for prostate cancer (SPoRT study). *J Med Imaging Radiat Oncol* 2022;66:866-73.
84. White C, Scott RJ, Paul C, Ziolkowski A, Mossman D, Fox SB, Michael M, Ackland S. Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping. *Clin Pharmacol Ther* 2022;112:791-802.

85. Wight J, Hamad N, Campbell BA, Ku M, Lee K, Rose H, Armytage T, Latimer M, Lee HP, Lee ST, Dickinson M, Khor R, Verner E. Diffuse large B-cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance. *Intern Med J* 2022;52:1609-23.
86. Wong AK, Somogyi AA, Rubio J, Philip J. The Role of Pharmacogenomics in Opioid Prescribing. *Curr Treat Options Oncol* 2022;23:1353-69.
87. Wright C, Matthews K. An intentional approach to the development and implementation of meaningful assessment in advanced radiation therapy practice curricula. *Tech Innov Patient Support Radiat Oncol* 2022;24:13-18.
88. Xu J, Larach JT, Mohan H, Heriot AG, Warriar S. Retroperitoneal lymph node dissection as salvage surgery in metachronous nodal recurrence in colorectal cancer. *ANZ J Surg* 2022;92:2356-8.
89. Yeung TM, Apte SS, Behrenbruch CC, Heriot AG. Clostridioides difficile infection following ileostomy reversal - can we clean up our act? *ANZ J Surg* 2022;92:1982-3.
90. Zattoni F, Marra G, Kasivisvanathan V, Grummet J, Nandurkar R, Ploussard G, Olivier J, Chiu PK, Valerio M, Gontero P, Guo H, Zhuang J, Barletta F, Leni R, Frydenberg M, Moon D, Hanegbi U, Landaumailto A, Snow R, Apfelbeck M, Kretschmer A, van den Bergh R, Novara G, Briganti A, Dal Moro F, Gandaglia G. The Detection of Prostate Cancer with Magnetic Resonance Imaging-Targeted Prostate Biopsies is Superior with the Transperineal vs the Transrectal Approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-Institutional Study. *J Urol* 2022;208:830-7.
91. Zhong Y, Zhao H, Lee TY, Yu T, Liu MF, Ji J. Experiences of COVID-19 patients in a Fangcang shelter hospital in China during the first wave of the COVID-19 pandemic: a qualitative descriptive study. *BMJ Open* 2022;12:e065799.

October

1. Agarwal N, Azad A, Shore ND, Carles J, Fay AP, Dunshee C, Karsh LI, Paccagnella ML, Santo ND, Elmeliegy M, Lin X, Czibere A, Fizazi K. Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer. *Future Oncol* 2022;18:2979-86.
2. Ali SR, Humphreys KJ, Simpson KJ, McKinnon RA, Meech R, Michael MZ. Functional high-throughput screen identifies microRNAs that promote butyrate-induced death in colorectal cancer cells. *Mol Ther Nucleic Acids* 2022;30:30-47.
3. Anil N, Smallwood N, Dunn S. Opioids in advanced lung malignancy: a clinical audit of opioid prescription, patient education and safeguarding. *Intern Med J* 2022;52:1698-706.
4. Apte SS, Cohen LC, Larach JT, Mohan HM, Snow HA, Wagner T, McCormick JJ, Warriar SK, Gyorki DE, Waters PS, Heriot AG. Major vascular reconstruction in colorectal adenocarcinoma and retroperitoneal sarcoma: A retrospective study of safety and margins in a tertiary referral centre. *Surg Oncol* 2022;45:101871.
5. Barr PM, Tedeschi A, Wierda WG, Allan JN, Ghia P, Vallisa D, Jacobs R, O'Brien S, Grigg AP, Walker P, Zhou C, Ninomoto J, Krigsfeld G, Tam CS. Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts. *Clin Cancer Res* 2022;28:4385-91.
6. Bennett R, Thompson E, Tam C. SOHO State of the Art Updates and Next Questions | Mechanisms of Resistance to BCL2 Inhibitor Therapy in Chronic Lymphocytic Leukemia and Potential Future Therapeutic Directions. *Clin Lymphoma Myeloma Leuk* 2022;22:795-804.
7. Blombery P, Thompson ER, Lew TE, Tiong IS, Bennett R, Cheah CY, Lewis KL, Handunnetti SM, Tang CPS, Roberts A, Seymour JF, Tam CS. Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance. *Blood Adv* 2022;6:5589-92.

8. Britto DD, He J, Misa JP, Chen W, Kakadia PM, Grimm L, Herbert CD, Crosier KE, Crosier PS, Bohlander SK, Hogan BM, Hall CJ, Torres-Vázquez J, Astin JW. Plexin D1 negatively regulates zebrafish lymphatic development. *Development* 2022;149:dev200560.
9. Chan JM, Clendenning M, Joseland S, Georgeson P, Mahmood K, Walker R, Como J, Joo JE, Preston S, Hutchinson RA, Pope BJ, Metz A, Beard C, Purvis R, Arnold J, Vijay V, Konycheva G, Atkinson N, Parry S, Jenkins MA, Macrae FA, Rosty C, Winship IM, Buchanan DD. Rare germline variants in the AXIN2 gene in families with colonic polyposis and colorectal cancer. *Fam Cancer* 2022;21:399-413.
10. Chan KL, Gomez J, Cardinez C, Kumari N, Sparbier CE, Lam EYN, Yeung MM, Garcia S, Kuzich JA, Ong DM, Brown FC, Chan YC, Vassiliadis D, Wainwright EN, Motazedian A, Gillespie A, Fennell KA, Lai J, House IG, Macpherson L, Ang CS, Dawson SJ, Beavis PA, Wei AH, Burr ML, Dawson MA. Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses. *Cancer Cell* 2022;40:1190-206.e9.
11. Chang D, Blanchard P, Siva S. The Deep Blue of Prostate Cancer Metastasis Evolution: The LEVIATHAN Pooled Analysis. *Eur Urol* 2022;82:499-500.
12. Conduit C, Guo C, Smith AB, Rincones O, Baenziger O, Thomas B, Goad J, Lenaghan D, Lawrentschuk N, Wong LM, Corcoran NM, Ross M, Gibbs P, O'Haire S, Anton A, Liow E, Lewin J, Tran B. Role for a Web-Based Intervention to Alleviate Distress in People With Newly Diagnosed Testicular Cancer: Mixed Methods Study. *JMIR Cancer* 2022;8:e39725.
13. Conduit C, Koh TT, Hofman MS, Toner GC, Goad J, Lawrentschuk N, Tai KH, Lewin JH, Tran B. Two decades of FDG-PET/CT in seminoma: exploring its role in diagnosis, surveillance and follow-up. *Cancer Imaging* 2022;22:58.
14. Copaescu AM, Ben-Shoshan M, Trubiano JA. Tools to improve the diagnosis and management of T-cell mediated adverse drug reactions. *Front Med* 2022;9:923991.
15. Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, Decaestecker K, Kiess AP, Lumen N, Phillips R, De Bruycker A, Mishra M, Rana Z, Molitoris J, Lambert B, Delrue L, Wang H, Lowe K, Verbeke S, Van Dorpe J, Bultijnck R, Villeirs G, De Man K, Ameye F, Song DY, DeWeese T, Paller CJ, Feng FY, Wyatt A, Pienta KJ, Diehn M, Bentzen SM, Joniau S, Vanhaverbeke F, De Meerleer G, Antonarakis ES, Lotan TL, Berlin A, Siva S, Ost P, Tran PT. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials. *J Clin Oncol* 2022;40:3377-82.
16. Delisle M, Gyorki D, Bonvalot S, Nessim C. Landmark Series: A Review of Landmark Studies in the Treatment of Primary Localized Retroperitoneal Sarcoma. *Ann Surg Oncol* 2022;29:7297-311.
17. Denehy L, Edbrooke L. The Role of Exercise Before Cancer Treatment. *Semin Oncol Nurs* 2022;38:151330.
18. Drosdowsky A, Gough K. The Charlson Comorbidity Index: problems with use in epidemiological research. *J Clin Epidemiol* 2022;148:174-7.
19. Fanti S, Briganti A, Emmett L, Fizazi K, Gillessen S, Goffin K, Hadaschik BA, Herrmann K, Kunikowska J, Maurer T, MacLennan S, Mottet N, Murphy DG, Oprea-Lager DE, O'Sullivan JM, Oyen WJG, Rouviere O, Sartor O, Stenzl A, Van Poppel H, Walz J, Witjes W, Bjartell A. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [¹⁷⁷Lu]Lu-PSMA Radioligand Therapy. *Eur Urol Oncol* 2022;5:530-6.
20. Flood MP, Jain A, Mitchell C, Hewitt C, Ramsay R, Michael M, Heriot AG, Tie J. The impact of molecular and mismatch repair status on the survival outcomes of surgically treated patients with colorectal peritoneal metastases. *Eur J Surg Oncol* 2022;48:2218-25.
21. Flood MP, Kong JCH, Heriot AG. Reply to Comments on "The Impact of Neoadjuvant Chemotherapy on the Surgical Management of Colorectal Peritoneal Metastases: A Systematic Review and Meta-analysis". *Ann Surg Oncol* 2022;29:7935-6.

22. Frenel JS, Kim JW, Aryal N, Asher R, Berton D, Vidal L, Pautier P, Ledermann JA, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Colombo N, Park-Simon TW, Tamura K, Sonke GS, Freimund AE, Lee CK, Pujade-Lauraine E. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. *Ann Oncol* 2022;33:1021-8.
23. Gazinska P, Milton C, Iacovacci J, Ward J, Buus R, Alaguthurai T, Graham R, Akarca A, Lips E, Naidoo K, Wesseling J, Marafioti T, Cheang M, Gillett C, Wu Y, Khan A, Melcher A, Salgado R, Dowsett M, Tutt A, Roxanis I, Haider S, Irshad S. Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers. *Clin Cancer Res* 2022;28:4494-508.
24. Glicksman RM, Palma DA, Deek MP, Tsai CJ, Chmura S, Siva S, Ost P, Tran PT, Berlin A. Stereotactic Body Radiation Therapy for Oligometastasis: GUst Do It? *Int J Radiat Oncol Biol Phys* 2022;114:561-70.
25. Godbee K, Guccione L, Palmer VJ, Gunn J, Lautenschlager N, Francis JJ. Dementia Risk Reduction in Primary Care: A Scoping Review of Clinical Guidelines Using a Behavioral Specificity Framework. *J Alzheimers Dis* 2022;89:789-802.
26. Gross ND, Miller DM, Khushalani NI, Divi V, Ruiz ES, Lipson EJ, Meier F, Su YB, Swiecicki PL, Atlas J, Geiger JL, Hauschild A, Choe JH, Hughes BGM, Schadendorf D, Patel VA, Homsí J, Taube JM, Lim AM, Ferrarotto R, Kaufman HL, Seebach F, Lowy I, Yoo SY, Mathias M, Fenech K, Han H, Fury MG, Rischin D. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma. *N Engl J Med* 2022;387:1557-68.
27. Hakkaart C, Pearson JF, Marquart L, Dennis J, Wiggins GAR, Barnes DR, Robinson BA, Mace PD, Aittomäki K, Andrulis IL, Arun BK, Azzollini J, Balmaña J, Barkardottir RB, Belhadj S, Berger L, Blok MJ, Boonen SE, Borde J, Bradbury AR, Brunet J, Buys SS, Caligo MA, Campbell I, Chung WK, Claes KBM, Collonge-Rame MA, Cook J, Cosgrove C, Couch FJ, Daly MB, Dandiker S, Davidson R, de la Hoya M, de Putter R, Delnatte C, Dhawan M, Diez O, Ding YC, Domchek SM, Donaldson A, Eason J, Easton DF, Ehrencrona H, Engel C, Evans DG, Faust U, Feliubadaló L, Fostira F, Friedman E, Frone M, Frost D, Garber J, Gayther SA, Gehrig A, Gesta P, Godwin AK, Goldgar DE, Greene MH, Hahnen E, Hake CR, Hamann U, Hansen TVO, Hauke J, Hentschel J, Herold N, Honisch E, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Izquierdo A, Jakubowska A, James PA, Janavicius R, John EM, Joseph V, Karlan BY, Kemp Z, Kirk J, Konstantopoulou I, Koudijs M, Kwong A, Laitman Y, Laloo F, Lasset C, Lautrup C, Lazaro C, Legrand C, Leslie G, Lesueur F, Mai PL, Manoukian S, Mari V, Martens JWM, McGuffog L, Mebirouk N, Meindl A, Miller A, Montagna M, Moserle L, Mouret-Fourme E, Musgrave H, Nambot S, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nguyen-Dumont T, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Osorio A, Ott CE, Park SK, Parsons MT, Pedersen IS, Peixoto A, Perez-Segura P, Peterlongo P, Pocza T, Radice P, Ramser J, Rantala J, Rodriguez GC, Rønlund K, Rosenberg EH, Rossing M, Schmutzler RK, Shah PD, Sharif S, Sharma P, Side LE, Simard J, Singer CF, Snape K, Steinemann D, Stoppa-Lyonnet D, Sutter C, Tan YY, Teixeira MR, Teo SH, Thomassen M, Thull DL, Tischkowitz M, Toland AE, Trainer AH, Tripathi V, Tung N, van Engelen K, van Rensburg EJ, Vega A, Viel A, Walker L, Weitzel JN, Wevers MR, Chenevix-Trench G, Spurdle AB, Antoniou AC, Walker LC. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers. *Commun Biol* 2022;5:1061.
28. Hapgood G, Latimer M, Lee ST, Kuss B, Lade S, Tobin JWD, Purtill D, Campbell BA, Prince HM, Hawkes EA, Shortt J, Radeski D. Diagnosis, management and follow up of peripheral T-cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance. *Intern Med J* 2022;52:1806-17.
29. Hartmann JA, Nelson B, Amminger GP, Spark J, Yuen HP, Kerr MJ, Polari A, Wallis N, Blasioli J, Dixon L, Carter C, Loewy R, Niendam TA, Shumway M, McGorry PD. Baseline data of a sequential multiple assignment randomized trial (STEP study). *Early Interv Psychiatry* 2022;16:1130-42.
30. Kansal A, Quinlan C, Stark Z, Kerr PG, Mallett AJ, Lakshmanan C, Best S, Jayasinghe K. Theory Designed Strategies to Support Implementation of Genomics in Nephrology. *Genes* 2022;13:1919.

31. Katz NT, Le BH, Berger I, Lewin J, Thompson K, Pitt H, Philip J. A Descriptive Cohort Study of Adolescent and Young Adult Decedents Known to an Australian Comprehensive Cancer Center. *J Adolesc Young Adult Oncol* 2022;11:535-9.
32. Kostos L, Murphy DG, Azad AA. Double or Triple Trouble in Metastatic Hormone-sensitive Prostate Cancer? *Eur Urol Oncol* 2022;5:503-4.
33. Lapidus AH, Anderson MA, Harrison SJ, Dickinson M, Kalincik T, Lasocki A. Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy. *Leuk Lymphoma* 2022;63:2364-74.
34. Larkins K, Loveday B. Affecting positive social change in surgical culture: can it be achieved through apprenticeship? *ANZ J Surg* 2022;92:2414-16.
35. Larkins K, Mohan H, Apte SS, Chen V, Rajkomar A, Larach JT, Smart P, Heriot A, Warriar S. A systematic review and meta-analysis of robotic resections for diverticular disease. *Colorectal Dis* 2022;24:1105-16.
36. Lau KK, Troupis JM, Parsons D. Transformative radiology: Chest imaging is being re-defined. *Respirology* 2022;27:815-17.
37. Leal JL, Hoang W, Xue J, Dunne B, John T, Harden S. What's Current and What's New in Mesothelioma? *Clin Oncol* 2022;34:771-80.
38. Lindsay J, Greenwood M, Othman J, Chen SC, Kong DCM, Pergam SA, Liu C, Slavin MA. Treatment failure cost analysis of Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation. *Leuk Lymphoma* 2022;63:2254-6.
39. Lonski P, Kron T. Impact through versatility: Patterns of *in vivo* dosimetry utilization with TLD across a large multi-site radiotherapy department. *Front Oncol* 2022;12:918178.
40. Luk IY, Jenkins LJ, Schoffer KL, Ng I, Tse JWT, Mouradov D, Kaczmarczyk S, Nightingale R, Burrows AD, Anderson RL, Arango D, Dopeso H, Croft L, Richardson MF, Sieber OM, Liao Y, Mooi JK, Vukelic N, Reehorst CM, Afshar-Sterle S, Whitehall VLJ, Fennell L, Abud HE, Tebbutt NC, Phillips WA, Williams DS, Shi W, Mielke LA, Ernst M, Dhillon AS, Clemons NJ, Mariadason JM. Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progression. *Cell Death Differ* 2022;29:2288-302.
41. Madani I, Sahgal A, Erler D, Stish BJ, Olivier KR, Park SS, Eppinga WSC, Seravalli E, Redmond KJ, Cao Y, Siva S, Chang D, Nguyen TK, O'Neil M, Guckenberger M. Stereotactic Body Radiation Therapy for Metastases in Long Bones. *Int J Radiat Oncol Biol Phys* 2022;114:738-46.
42. Manfredi C, Fernandez-Pascual E, Arcaniolo D, Emberton M, Sanchez-Salas R, Artigas Guix C, Bianco F, Cathcart P, Murphy DG, Counago F, Martinez-Ballesteros C, Verze P, Martinez-Salamanca JI. The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Magnetic Resonance Imaging in Primary and Recurrent Prostate Cancer: A Systematic Review of the Literature. *Eur Urol Focus* 2022;8:942-57.
43. Margalit DN, Salz T, Venchiarutti R, Milley K, McNamara M, Chima S, Wong J, Druce P, Nekhlyudov L. Interventions for head and neck cancer survivors: Systematic review. *Head Neck* 2022;44:2579-99.
44. Mehdiabadi NR, Boon Sim C, Phipson B, Kalathur RKR, Sun Y, Vivien CJ, Ter Huurne M, Piers AT, Hudson JE, Oshlack A, Weintraub RG, Konstantinov IE, Palpant NJ, Elliott DA, Porrello ER. Defining the Fetal Gene Program at Single-Cell Resolution in Pediatric Dilated Cardiomyopathy. *Circulation* 2022;146:1105-8.
45. Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken NCT, Vogel A, Smyth EC; ESMO Guidelines Committee. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol* 2022;33:992-1004.
46. Ong WL, Byrne A, Chelvarajah R, Chong C, Gallo J, Kain M, Khong J, O'Reilly E, Udovicich C, Weeransinghe C, Zhong Hu TC, Bece A. Survey of brachytherapy training experience among radiation

oncology trainees and fellows in the Royal Australian and New Zealand College of Radiologists (RANZCR). *J Med Imaging Radiat Oncol* 2022;66:980-92.

47. Philip J, Collins A, Warwyk O, Sundararajan V, Le B. Is the use of palliative care services increasing? A comparison of current versus historical palliative care access using health service datasets for patients with cancer. *Palliat Med* 2022;36:1426-31.
48. Phipson B, Sim CB, Porrello ER, Hewitt AW, Powell J, Oshlack A. propeller: testing for differences in cell type proportions in single cell data. *Bioinformatics* 2022;38:4720-6.
49. Pinard CJ, Lagree A, Lu FI, Klein J, Oblak ML, Salgado R, Cardenas JCP, Brunetti B, Muscatello LV, Sarli G, Foschini MP, Hardas A, Castillo SP, AbdulJabbar K, Yuan Y, Moore DA, Tran WT. Comparative Evaluation of Tumor-Infiltrating Lymphocytes in Companion Animals: Immuno-Oncology as a Relevant Translational Model for Cancer Therapy. *Cancers* 2022;14:5008.
50. Pomykala KL, Herrmann K, Padhani AR, Hofman MS, Lalumera E, Fanti S. Role of Prostate-Specific Membrane Antigen PET in Metastatic Prostate Cancer: We Have the Answers. *J Nucl Med* 2022;63:1480-1.
51. Prabahan A, Koldej R, Chee L, Szer J, Ritchie D. Non-relapse cytopenias following allogeneic stem cell transplantation, a case based review. *Bone Marrow Transplant* 2022;57:1489-99.
52. Quah PS, Sutton V, Whitlock E, Figgett WA, Andrews DM, Fairfax KA, Mackay F. The effects of B-cell-activating factor on the population size, maturation and function of murine natural killer cells. *Immunol Cell Biol* 2022;100:761-76.
53. Renehan S, Tencic M, Jackson K, Krishnasamy M. Improving preparation for scalp cooling: Learning from women undergoing chemotherapy for early-stage breast cancer-The COOL study. *J Clin Nurs* 2022;31:3222-34.
54. Robella M, Hubner M, Sgarbura O, Reymond M, Khomiakov V, di Giorgio A, Bhatt A, Bakrin N, Willaert W, Alyami M, Teixeira H, Kaprin A, Ferracci F, De Meeus G, Berchiolla P, Vaira M; ISSPP PIPAC study group. Feasibility and safety of PIPAC combined with additional surgical procedures: PLUS study. *Eur J Surg Oncol* 2022;48:2212-7.
55. Robinson MJ, Dowling MR, Pitt C, O'Donnell K, Webster RH, Hill DL, Ding Z, Dvorscek AR, Brodie EJ, Hodgkin PD, Quast I, Tarlinton DM. Long-lived plasma cells accumulate in the bone marrow at a constant rate from early in an immune response. *Sci Immunol* 2022;7:eabm8389.
56. Rusconi C, Cheah CY, Eyre TA, Tucker D, Klener P, Gine E, Crucitti L, Muzi C, Iadecola S, Infante G, Bernard S, Auer RL, Pagani C, Duglosz-Danecka M, Mocikova H, van Meerten T, Cencini E, Marin-Niebla A, Williams ME, Angelillo P, Nicoli P, Arcari A, Morello L, Mannina D, Vitagliano O, Sartori R, Chiappella A, Sciarra R, Stefani PM, Dreyling M, Seymour JF, Visco C. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse. *Blood* 2022;140:1907-16.
57. Sampurno S, Chittleborough T, Dean M, Flood M, Carpinteri S, Roth S, Millen RM, Cain H, Kong JCH, MacKay J, Warriar SK, McCormick J, Hiller JG, Heriot AG, Ramsay RG, Lynch AC. Effect of Surgical Humidification on Inflammation and Peritoneal Trauma in Colorectal Cancer Surgery: A Randomized Controlled Trial. *Ann Surg Oncol* 2022;29:7911-20.
58. Satija A, Lorenz KA, Spruijt O, Ganesh A, Singh N, Connell NB, Gamboa RC, Fereydooni S, Chandrashekar S, Hennings T, Giannitrapani KF, Bhatnagar S. *Quality Improvement in Itself Changes Your Thinking*: Lessons From Disseminating Quality Improvement Methods Through a Multisite International Collaborative Palliative Care Project in India. *JCO Glob Oncol* 2022;8:e2200147.
59. Schneider T, Fernandez-Palomo C, Bertho A, Fazzari J, Iturri L, Martin OA, Trappetti V, Djonov V, Prezado Y. Combining FLASH and spatially fractionated radiation therapy: The best of both worlds. *Radiother Oncol* 2022;175:169-77.
60. Shanthikumar S, Colenutt S, Cole T, Conyers R, Rozen T, Harrison J, Robinson P, Haeusler GM. Clinical Utility of Bronchoalveolar Lavage in Pediatric Oncology Patients. *Pediatr Infect Dis J* 2022;41:899-903.

61. Sharma G, Shah M, Ahluwalia P, Dasgupta P, Challacombe BJ, Bhandari M, Ahlawat R, Rawal S, Buffi NM, Sivaraman A, Porter JR, Rogers C, Mottrie A, Abaza R, Rha KH, Moon D, Yuvaraja TB, Parekh DJ, Capitanio U, Maes KK, Porpiglia F, Turkeri L, Gautam G. Perioperative outcomes following robot-assisted partial nephrectomy in elderly patients. *World J Urol* 2022;40:2789-98.
62. Smith JL, Menzies AM, Cohen JV, Mut-Lloret M, Ozgun A, Spain L, Park J, Quach HT, Pallan L, McQuade J, Feng S, Sandhu S, Atkinson V, Tsai K, Long GV, Larkin J, Eroglu Z, Johnson DB, Sullivan R, Herkes GK, Henderson A, Carlino MS. Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series. *Melanoma Res* 2022;32:451-9.
63. Solomon BJ, Bauer TM, Ou SHI, Liu G, Hayashi H, Bearz A, Penkov K, Wu YL, Arrieta O, Jassem J, Calella AM, Peltz G, Polli A, Thurm H, Mok T. Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study. *J Clin Oncol* 2022;40:3593-602.
64. Talarmain L, Clarke MA, Shorthouse D, Cabrera-Cosme L, Kent DG, Fisher J, Hall BA. HOXA9 has the hallmarks of a biological switch with implications in blood cancers. *Nat Commun* 2022;13:5829.
65. Tapia M, Manji J, Dhillon K, Kleid S, Flatman S, Prasad J, Cardin A, Fua T, Rischin D, Dixon B, Magarey MJR. The negative predictive value of FDG PET/CT staging in early oropharyngeal squamous cell carcinoma and implications to transoral robotic surgery patient selection. *Oral Oncol* 2022;135:106213.
66. Tay KH, Slavin MA, Thursky KA, Coussement J, Worth LJ, Teh BW, Khot A, Tam CS, Yong MK. Cytomegalovirus DNAemia and disease: current-era epidemiology, clinical characteristics and outcomes in cancer patients other than allogeneic haemopoietic transplantation. *Intern Med J* 2022;52:1759-67.
67. Tseng WW, Swallow CJ, Strauss DC, Bonvalot S, Rutkowski P, Ford SJ, Gonzalez RJ, Gladly RA, Gyorki DE, Fairweather M, Lee KW, Albertsmeier M, van Houdt WJ, Fau M, Nessim C, Grignani G, Cardona K, Quagliuolo V, Grignol V, Farma JM, Pennacchioli E, Fiore M, Hayes A, Tzanis D, Skoczylas J, Almond ML, Mullinax JE, Johnston W, Snow H, Haas RL, Callegaro D, Smith MJ, Bouhadiba T, Desai A, Voss R, Sanfilippo R, Jones RL, Baldini EH, Wagner AJ, Catton CN, Stacchiotti S, Thway K, Roland CL, Raut CP, Gronchi A, Transatlantic Australasian Retroperitoneal Sarcoma Working G. Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. *Ann Surg Oncol* 2022;29:7335-48.
68. Udovicich C, Callahan J, Bressel M, Ong WL, Perera M, Tran B, Azad A, Haran S, Moon D, Chander S, Shaw M, Eapen R, Goad J, Lawrentschuk N, Murphy DG, Hofman M, Siva S. Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma. *Eur Urol Open Sci* 2022;44:60-8.
69. van Delft FA, Schuurbijs M, Muller M, Burgers SA, van Rossum HH, IJzerman MJ, Koffijberg H, van den Heuvel MM. Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer. *Heliyon* 2022;8:e10932.
70. Walker H, Esbenschade AJ, Dale S, Bhatia K, Zhao Z, Babl FE, Conyers R, Haeusler GM. Non-neutropenic fever in children with cancer: Management, outcomes and clinical decision rule validation. *Pediatr Blood Cancer* 2022;69:e29931.
71. Weitgasser L, Barton R, Ricketts S, Murray SS, Matros E, Morrison EJ. Donor Side Preference in Maxillary Reconstruction With the Free Fibula Flap. *J Craniofac Surg* 2022;33:2178-80.
72. Williams IS, McVey A, Perera S, O'Brien JS, Kostos L, Chen K, Siva S, Azad AA, Murphy DG, Kasivisvanathan V, Lawrentschuk N, Frydenberg M. Modern paradigms for prostate cancer detection and management. *Med J Aust* 2022;217:424-33.
73. Williams ISC, Perera S, Murphy DG, Corcoran NM, Bolton DM, Lawrentschuk N. Active surveillance versus enzalutamide for low-risk prostate cancer - was it really a trial we needed? *BJU Int* 2022;130:580-1.

74. Wong V, de Boer R, Dunn C, Anton A, Malik L, Greenberg S, Yeo B, Nott L, Collins IM, Torres J, Barnett F, Nottage M, Gibbs P, Lok SW. Uptake of bone-modifying agents in patients with HER2+ metastatic breast cancer with bone metastases - prospective data from a multi-site Australian registry. *Intern Med J* 2022;52:1707-16.
75. Zethoven M, Martelotto L, Pattison A, Bowen B, Balachander S, Flynn A, Rossello FJ, Hogg A, Miller JA, Frysak Z, Grimmond S, Fishbein L, Tischler AS, Gill AJ, Hicks RJ, Dahia PLM, Clifton-Bligh R, Pacak K, Tothill RW. Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment. *Nat Commun* 2022;13:6262.

November

1. Ahn MJ, Mendoza MJL, Pavlakis N, Kato T, Soo RA, Kim DW, Liam CK, Hsia TC, Lee CK, Reungwetwattana T, Geater S, Chan OSH, Prasongsook N, Solomon BJ, Nguyen TTH, Kozuki T, Yang JC, Wu YL, Mok TSK, Tan DS, Yatabe Y. Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations. *Clin Lung Cancer* 2022;23:670-85.
2. Alhamdani Z, Ong S, Lawrentschuk N, Woon D. A Unique Urine Isolating Drape Technique for on Table Pyeloscopy Post Radical Cystectomy for a Suspected Upper Tract Lesion With an Obliterated Ureteric Orifice. *Urology* 2022;170:e6-e7.
3. Ali M, Mooi J, Lawrentschuk N, McKay RR, Hannan R, Lo SS, Hall WA, Siva S. The Role of Stereotactic Ablative Body Radiotherapy in Renal Cell Carcinoma. *Eur Urol* 2022;82:613-22.
4. Allard N, Miller A, Morgan M, Chakraborty S. Post-COVID-19 syndrome/condition or long COVID: Persistent illness after acute SARS CoV-2 infection. *Aust J Gen Pract* 2022;51:952-7.
5. Azad AA, Kostos L, Agarwal N. KIT as a therapeutic target in neuroendocrine prostate cancer. *Cancer Cell* 2022;40:1266-8.
6. Bae S, Brnabic A, Crowe P, Carey-Smith R, Andelkovic V, Singhal N, Stalley P, Yip D, Desai J. Managing patients with advanced soft tissue sarcoma: Evolving landscape from an Australian perspective. *Asia Pac J Clin Oncol* 2022;18:605-13.
7. Baldwin LA, Bartonicek N, Yang J, Wu SZ, Deng N, Roden DL, Chan CL, Al-Eryani G, Zanker DJ, Parker BS, Swarbrick A, Junankar S. DNA barcoding reveals ongoing immunoediting of clonal cancer populations during metastatic progression and immunotherapy response. *Nat Commun* 2022;13:6539.
8. Brandl A, Lunden D, Lorenzon L, Schrage Y, Caballero C, Holmberg CJ, Santrac N, Vasileva-Slaveva M, Montagna G, Sgarbura O, Sayyed R, Ben-Yaacov A, Herrera Kok JH, Suppan I, Mohan H, Kovacs T, D'Ugo D, Sandrucci S, Ceelen W, Academy ER. Standards in surgical training in advanced pelvic malignancy across Europe and beyond - A Snapshot analysis. *Eur J Surg Oncol* 2022;48:2338-45.
9. Burg ML, Sholkapper T, Kohli P, Kaneko M, Maria Autran A, Teoh J, Murphy DG, Samplasky M, Psutka SP, Loeb S, Ribal MJ, Cacciamani GE. Gender Disparities Among Editorial Boards of International Urology Journals. *Eur Urol Focus* 2022;8:1840-6.
10. Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, Francis RJ, Zhang AY, Scott AM, Lee ST, Azad AA, McJannett MM, Stockler MR, Williams SG, Davis ID, Hofman MS, TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [¹⁷⁷Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. *Lancet Oncol* 2022;23:1389-97.
11. Casey L, Larach JT, Waters PS, Kong JC, McCormick JJ, Heriot AG, Warriar SK. Application of minimally invasive approaches to pelvic exenteration for locally advanced and locally recurrent pelvic malignancy - A narrative review of outcomes in an evolving field. *Eur J Surg Oncol* 2022;48:2330-7.

12. Chazan G, Anton A, Wong S, Shapiro J, Weickhardt A, Azad A, Kwan EM, Spain L, Gunjur A, Torres J, Parente P, Parnis F, Goh J, Gibbs P, Tran B. Beyond cabazitaxel: Late line treatments in metastatic castration resistant prostate cancer: A retrospective multicentre analysis. *Asia Pac J Clin Oncol* 2022;18:642-9.
13. Chidley P, Shanker M, Phillips C, Haghghi N, Pinkham MB, Whittle JR, Sia J. Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: an institutional experience and meta-analysis of literature. *J Neurooncol* 2022;160:361-74.
14. Chiong E, Murphy DG, Buchan NC, Chua MLK, Hakim L, Hamid AR, Hong SK, Horvath LG, Kanesvaran R, Khochikar M, Letran J, Lojanapiwat B, Malek R, Ng ACF, Vinh NT, Pang ST, Poon DMC, Ong TA, Saad M, Schubach K, Shiroki R, Turkeri L, Williams S, Wong A, Ye D, ANZUP Cancer Trials Group, Davis ID. Managing advanced prostate cancer in the Asia Pacific region: "Real-world" application of Advanced Prostate Cancer Consensus Conference 2019 statements. *Asia Pac J Clin Oncol* 2022;18:686-95.
15. Choy KT, Lee DJ, Prabhakaran S, Warriar S, Heriot A, Kong JC. The complication profile of low Hartmann's in rectal cancer: a systematic review and meta-analysis. *ANZ J Surg* 2022;92:2829-39.
16. Daver NG, Maiti A, Kadia TM, Vyas P, Majeti R, Wei AH, Garcia-Manero G, Craddock C, Sallman DA, Kantarjian HM. TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions. *Cancer Discov* 2022;12:2516-29.
17. Devlin MJ, Miller R, Laforets F, Kotantaki P, Garsed DW, Kristeleit R, Bowtell DD, McDermott J, Maniati E, Balkwill FR. The Tumor Microenvironment of Clear-Cell Ovarian Cancer. *Cancer Immunol Res* 2022;10:1326-39.
18. DeVries AA, Dennis J, Tyrer JP, Peng PC, Coetzee SG, Reyes AL, Plummer JT, Davis BD, Chen SS, Dezem FS, Aben KKH, Anton-Culver H, Antonenkova NN, Beckmann MW, Beeghly-Fadiel A, Berchuck A, Bogdanova NV, Bogdanova-Markov N, Brenton JD, Butzow R, Campbell I, Chang-Claude J, Chenevix-Trench G, Cook LS, DeFazio A, Doherty JA, Dork T, Eccles DM, Eliassen AH, Fasching PA, Fortner RT, Giles GG, Goode EL, Goodman MT, Gronwald J, Opal Study Group, AOCS Group, Hakansson N, Hildebrandt MAT, Huff C, Huntsman DG, Jensen A, Kar S, Karlan BY, Khusnutdinova EK, Kiemeny LA, Kjaer SK, Kupryjanczyk J, Labrie M, Lambrechts D, Le ND, Lubinski J, May T, Menon U, Milne RL, Modugno F, Monteiro AN, Moysich KB, Odunsi K, Olsson H, Pearce CL, Pejovic T, Ramus SJ, Riboli E, Riggan MJ, Romieu I, Sandler DP, Schildkraut JM, Setiawan VW, Sieh W, Song H, Sutphen R, Terry KL, Thompson PJ, Titus L, Tworoger SS, Van Nieuwenhuysen E, Edwards DV, Webb PM, Wentzensen N, Whittemore AS, Wolk A, Wu AH, Ziogas A, Freedman ML, Lawrenson K, Pharoah PDP, Easton DF, Gayther SA, Jones MR. Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci. *J Natl Cancer Inst* 2022;114:1533-44.
19. Dillon R, Maycock S, Jackson A, Fox S, Freeman S, Craddock C, Thomas C, Homer E, Leahy J, Mamwell A, Potter N, Russell N, Wei A, Ommen HB, Hemmaway C, Knapper S, Billingham L. Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial. *BMC Cancer* 2022;22:1174.
20. Douglas A, Thursky K, Slavin M. New approaches to management of fever and neutropenia in high-risk patients. *Curr Opin Infect Dis* 2022;35:500-16.
21. Elliott J, Ahlawat S, Prince HM, Kennedy G, Wells J, Huang G, Collins J, Bardy P, Van Der Weyden C, Ritchie D, Khot A. Long-term outcomes for allogeneic bone marrow transplantation in Sezary syndrome and mycosis fungoides. *Bone Marrow Transplant* 2022;57:1724-6.
22. Emmett L, Papa N, Buteau J, Ho B, Liu V, Roberts M, Thompson J, Moon D, Sheehan-Dare G, Alghazo O, Agrawal S, Murphy D, Stricker P, Hope TA, Hofman MS. The PRIMARY Score: Using Intraprostatic ⁶⁸Ga-PSMA PET/CT Patterns to Optimize Prostate Cancer Diagnosis. *J Nucl Med* 2022;63:1644-50.

23. Fernando D, Larach JT, Flood MP, Warriar SK, McCormick JJ, Heriot AG, Waters PS. Cytoreductive surgery and concomitant hyperthermic thoracoabdominal chemotherapy for pseudomyxoma peritonei with abdominal and pleural involvement. *ANZ J Surg* 2022;92:3072-4.
24. Garcia K, Gingras AC, Harvey KF, Tanas MR. TAZ/YAP fusion proteins: mechanistic insights and therapeutic opportunities. *Trends Cancer* 2022;8:1033-45.
25. Geyer CE Jr, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, Rastogi P, Cui K, Arahmani A, Aktan G, Armstrong AC, Arnedos M, Balmana J, Bergh J, Bliss J, Delalogue S, Domchek SM, Eisen A, Elsafy F, Fein LE, Fielding A, Ford JM, Friedman S, Gelmon KA, Gianni L, Gnant M, Hollingsworth SJ, Im SA, Jager A, Johannsson O, Lakhani SR, Janni W, Linderholm B, Liu TW, Loman N, Korde L, Loibl S, Lucas PC, Marme F, Martinez de Duenas E, McConnell R, Phillips KA, Piccart M, Rossi G, Schmutzler R, Senkus E, Shao Z, Sharma P, Singer CF, Spanic T, Stickeler E, Toi M, Traina TA, Viale G, Zoppoli G, Park YH, Yerushalmi R, Yang H, Pang D, Jung KH, Mailliez A, Fan Z, Tennevet I, Zhang J, Nagy T, Sonke GS, Sun Q, Parton M, Colleoni MA, Schmidt M, Brufsky AM, Razaq W, Kaufman B, Cameron D, Campbell C, Tutt ANJ, OlympiA Clinical Trial Steering Committee and Investigators. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. *Ann Oncol* 2022;33:1250-68.
26. Gillespie E, Faul C, Worth LJ. "Hands off hand hygiene training": Implementation of a COVID safe auditor training program. *Am J Infect Control* 2022;50:1271-3.
27. Glewis S, Alexander M, Lingaratnam S, Lee B, Campbell I, Krishnasamy M, IJerman M, Fagery M, Harris S, Georgiou C, Underhill C, Warren M, Campbell R, Martin J, Tie J, Michael M. Pharmacogenomics guided dosing for fluoropyrimidine and irinotecan chemotherapies for patients with cancer (PACIFIC-PGx): study protocol of a multicentre clinical trial. *Acta Oncol* 2022;61:1136-9.
28. Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J, ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol* 2022;33:1217-38.
29. Hall VG, Solera JT, Al-Alahmadi G, Marinelli T, Cardinal H, Poirier C, Huard G, Prasad GVR, De Serres SA, Isaac D, Mainra R, Lamarche C, Sapir-Pichhadze R, Gilmour S, Humar A, Kumar D. Gravit  de la COVID-19 chez les receveurs d'une transplantation d'organe plein au Canada, 2020–2021:  tude de cohorte prospective multicentrique. *CMAJ* 2022;194:E1578-E86. French.
30. Hamilton DG, Page MJ, Finch S, Everitt S, Fidler F. How often do cancer researchers make their data and code available and what factors are associated with sharing? *BMC Med* 2022;20:438.
31. Hannan KM, Soo P, Wong MS, Lee JK, Hein N, Poh P, Wysoke KD, Williams TD, Montellese C, Smith LK, Al-Obaidi SJ, N nuez-Villac s L, Pavy M, He JS, Parsons KM, Loring KE, Morrison T, Diesch J, Burgio G, Ferreira R, Feng ZP, Gould CM, Madhamshettiwar PB, Flygare J, Gonda TJ, Simpson KJ, Kutay U, Pearson RB, Engel C, Watkins NJ, Hannan RD, George AJ. Nuclear stabilization of p53 requires a functional nucleolar surveillance pathway. *Cell Rep* 2022;41:111571.
32. Hegi-Johnson F, Rudd SE, Wichmann C, Akhurst T, Roselt P, Trinh J, John T, Devereux L, Donnelly PS, Hicks R, Scott AM, Steinfort D, Fox S, Blyth B, Parakh S, Hanna GG, Callahan J, Burbury K, MacManus M. ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with (⁸⁹Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol. *BMJ Open* 2022;12:e056708.
33. Higgins MJ, Harrop S, Lade S, Prince HM, McCormack C, Campbell BA. Unifocal cutaneous blastic plasmacytoid dendritic cell neoplasm with a favorable response following high-dose radiotherapy alone. *Leuk Lymphoma* 2022;63:3004-7.
34. Ho GY, Kyran EL, Bedo J, Wakefield MJ, Ennis DP, Mirza HB, Vandenberg CJ, Lieschke E, Farrell A, Hadla A, Lim R, Dall G, Vince JE, Chua NK, Kondrashova O, Upstill-Goddard R, Bailey UM, Dowson S, Roxburgh P, Glasspool RM, Bryson G, Biankin AV, Scottish Genomes Partnership, Cooke SL, Ratnayake G, McNally O, Traficante N, Australian Ovarian Cancer Study, DeFazio A, Weroha SJ, Bowtell DD, McNeish IA,

Papenfuss AT, Scott CL, Barker HE. Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin. *Cancer Res* 2022;82:4457-73.

35. Hong AM, Lo H, Lawless A, Zhou D, Bae S, Phillips M, Maclean F, Desai J, Mar J, Lazarakis S, Pryor D, Thompson SR. The benefit for radiotherapy at specialised sarcoma centres: A systematic review and clinical practice guidelines from the Australia and New Zealand Sarcoma Association. *Radiother Oncol* 2022;177:158-62.
36. Hyatt A, Chung H, Aston R, Gough K, Krishnasamy M. Social return on investment economic evaluation of supportive care for lung cancer patients in acute care settings in Australia. *BMC Health Serv Res* 2022;22:1399.
37. Inderjeeth AJ, Topp M, Sanij E, Castro E, Sandhu S. Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer. *Cancers* 2022;14:5922.
38. Ishizawa T, McCulloch P, Stassen L, van den Bos J, Regimbeau JM, Dembinski J, Schneider-Koriath S, Boni L, Aoki T, Nishino H, Hasegawa K, Sekine Y, Chen-Yoshikawa T, Yeung T, Berber E, Kahramangil B, Bouvet M, Diana M, Kokudo N, Dip F, White K, Rosenthal RJ. Assessing the development status of intraoperative fluorescence imaging for anatomy visualisation, using the IDEAL framework. *BMJ Surg Interv Health Technol* 2022;4:e000156.
39. Itchins M, Ainsworth H, Alexander M, Dean S, Dharmaraj D, Pavlakis N, Clarke SJ, Brown C, Torres J, Saqib A, Ladwa R, O'Byrne K, Moore M, Yip PY, Solomon B, John T, Kao S, Mitchell P, Parakh S. A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases. *Clin Lung Cancer* 2022;23:702-8.
40. Jameson MB, Stevenson ARL, Ngan SY. TNT: Raising more questions than answers? *Asia Pac J Clin Oncol* 2022;18:489-92.
41. Kang YJ, O'Haire S, Franchini F, IJerman M, Zalcborg J, Macrae F, Canfell K, Steinberg J. A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours. *Sci Rep* 2022;12:20495.
42. Kok PS, Antill YC, Scott CL, Lee CK. The impact of single agent PD-1 or PD-L1 inhibition on advanced endometrial cancers: meta-analysis. *ESMO Open* 2022;7:100635.
43. Kostos L, Buteau JP, Yeung T, Iulio JD, Xie J, Cardin A, Chin KY, Emmerson B, Owen KL, Parker BS, Fettke H, Furic L, Azad AA, Hofman MS. AlphaBet: Combination of Radium-223 and [¹⁷⁷Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol). *Front Med* 2022;9:1059122.
44. Kuypers J, Simmance N, Quach H, Hastie K, Kiss N. Nutrition support use and clinical outcomes in patients with multiple myeloma undergoing autologous stem cell transplant. *Support Care Cancer* 2022;30:9341-50.
45. Lasocki A, Abdalla G, Chow G, Thust SC. Imaging features associated with H3 K27-altered and H3 G34-mutant gliomas: a narrative systematic review. *Cancer Imaging* 2022;22:63.
46. Lasocki A, Buckland ME, Drummond KJ, Wei H, Xie J, Christie M, Neal A, Gaillard F. Conventional MRI features can predict the molecular subtype of adult grade 2-3 intracranial diffuse gliomas. *Neuroradiology* 2022;64:2295-305.
47. Lawrentschuk N. Funding of all issues related to prostate cancer treatment should be a priority and have equal access - a key to survivorship. *BJU Int* 2022;130 Suppl 3:4.
48. Leal JL, John T. Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options. *Clin Lung Cancer* 2022;23:643-58.
49. Lee PW, Marshall AC, Knott GJ, Kobelke S, Martelotto L, Cho E, McMillan PJ, Lee M, Bond CS, Fox AH. Paraspeckle subnuclear bodies depend on dynamic heterodimerisation of DBHS RNA-binding proteins via their structured domains. *J Biol Chem* 2022;298:102563.

50. Loi S, Karapetis CS, McCarthy N, Oakman C, Redfern A, White M, Khasraw M, Doval DC, Gore V, Alam M, Binko J, Lu DR, Kim S, Boyle F. Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India. *Asia Pac J Clin Oncol* 2022;18:560-9.
51. Loo S, Dillon R, Ivey A, Anstee NS, Othman J, Tiong IS, Potter N, Jovanovic J, Runglall M, Chong CC, Bajel A, Ritchie D, Gray K, Yeoh ZH, McBean M, Gilkes A, Thomas I, Johnson S, Russell NH, Wei AH. Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome. *Blood* 2022;140:2407-11.
52. Lourenco RA, Khoo T, Crothers A, Haas M, Montgomery R, Ball D, Bressel M, Siva S. Cost-Effectiveness of Single Versus Multifraction SABR for Pulmonary Oligometastases: The SAFRON II Trial. *Int J Radiat Oncol Biol Phys* 2022;114:968-76.
53. Martin JM, Richardson M, Siva S, Cardoso M, Handmer M, Sidhom M. Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy. *Lancet Oncol* 2022;23:e534-43.
54. Mazieres J, Iadecola L, Shaw AT, Solomon BJ, Bauer TM, de Marinis F, Felip E, Goto Y, Kim DW, Mok T, Reisman A, Thurm H, Polli AM, Liu G. Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer. *Lung Cancer* 2022;174:146-56.
55. McDonald J, O'Brien J, Kostos L, Lawrentschuk N, Azad AA, Murphy D, Chen K. Systemic therapy in metastatic hormone-sensitive prostate cancer. *Curr Opin Support Palliat Care* 2022;16:234-9.
56. Meagher NS, Hamilton P, Milne K, Thornton S, Harris B, Weir A, Alsop J, Bisinoto C, Brenton JD, Brooks-Wilson A, Chiu DS, Cushing-Haugen KL, Fereday S, Garsed DW, Gayther SA, Gentry-Maharaj A, Gilks B, Jimenez-Linan M, Kennedy CJ, Le ND, Piskorz AM, Riggan MJ, Shah M, Singh N, Talhouk A, Widschwendter M, Bowtell DDL, Candido Dos Reis FJ, Cook LS, Fortner RT, Garcia MJ, Harris HR, Huntsman DG, Karnezis AN, Köbel M, Menon U, Pharoah PDP, Doherty JA, Anglesio MS, Pike MC, Pearce CL, Friedlander ML, DeFazio A, Nelson BH, Ramus SJ. Profiling the immune landscape in mucinous ovarian carcinoma. *Gynecol Oncol* 2022;168:23-31.
57. Mohan H. Advanced pelvic malignancy: The dawn of precision surgery. *Eur J Surg Oncol* 2022;48:2237.
58. Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank CU, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel JC, Ugurel S, Zimmer L, Banks P, Spain L, Soon JA, Enokida T, Tahara M, Kähler KC, Seggewiss-Bernhardt R, Harvey C, Long GV, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French LE, Knauss S, Heinzerling LM. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study. *Eur J Cancer* 2022;175:224-35.
59. Müller-Jensen L, Zierold S, Versluis JM, Boehmerle W, Huehnchen P, Endres M, Mohr R, Compter A, Blank CU, Hagenacker T, Meier F, Reinhardt L, Gesierich A, Salzmann M, Hassel JC, Ugurel S, Zimmer L, Banks P, Spain L, Soon JA, Enokida T, Tahara M, Kähler KC, Seggewiss-Bernhardt R, Harvey C, Long GV, Schöberl F, von Baumgarten L, Hundsberger T, Schlaak M, French LE, Knauss S, Heinzerling LM. Dataset of a retrospective multicenter cohort study on characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis. *Data Brief* 2022;45:108649.
60. Murphy D, Herrmann K, Hofman M. Leading in Urology and Pioneering in Social Media Outreach: A Conversation Among Declan Murphy, Ken Herrmann, and Michael Hofman. *J Nucl Med* 2022;63:1783-5.
61. Nguyen D, Kleeman NJ, Yager Z, Parker AG, Shean MB, Jefferies W, Wilson-Evered E, Pucinischi CP, Pascoe MC. Identifying barriers and facilitators to implementing mindfulness-based programmes into schools: A mixed methods study. *Appl Psychol Health Well Being* 2022;14:1172-88.
62. Nguyen JK, Routledge D, van Der Weyden C, Blombery P, Angel CM, Johnson D, Goh MS, Lee A. VEXAS syndrome: A dermatological perspective. *Australas J Dermatol* 2022;63:488-92.

63. Nowatzke J, Guedeney P, Palaskas N, Lehmann L, Ederhy S, Zhu H, Cautela J, Francis S, Courand PY, Deswal A, Ewer SM, Aras M, Arangalage D, Ghafourian K, Fenioux C, Finke D, Peretto G, Zaha V, Itzhaki Ben Zadok O, Tajiri K, Akhter N, Levenson J, Baldassarre L, Power J, Huang S, Collet JP, Moslehi J, Salem JE, International ICI-myocarditis registry contributors. Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry. *Eur J Cancer* 2022;177:197-205.
64. Nüssing S, Sutton VR, Trapani JA, Parish IA. Beyond target cell death - Granzyme serine proteases in health and disease. *Mol Aspects Med* 2022;88:101152.
65. O'Brien JS, McVey A, Kelly BD, Jenjitrant P, Buteau J, Hofman MS, Kasivisvanithan V, Eapen R, Moon D, Murphy DG, Lawrentschuk N. Prostate-specific membrane antigen positron emission tomography/computed tomography funding grants free access to superior staging for Australian men with prostate cancer. *BJU Int* 2022;130 Suppl 3:8-10.
66. Othman B, Huang D, Rajkomar A, Pham T, Smart P, Warriar S. Robotic retroperitoneal lymph node dissection in colorectal cancer. *ANZ J Surg* 2022;92:3037-9.
67. Papa N, Perera M, Bensley JG, Evans M, Millar J, Frydenberg M, Murphy DG, Bolton D. A decade of declining prostatectomy margin positivity within a prostate cancer clinical quality registry. *Urol Oncol* 2022;40:537.e19-537.e24.
68. Phung MT, Webb PM, DeFazio A, Fereday S, Lee AW, Bowtell DDL, Fasching PA, Goode EL, Goodman MT, Karlan BY, Lester J, Matsuo K, Modugno F, Brenton JD, Van Gorp T, Pharoah PDP, Schildkraut JM, McLean K, Meza R, Mukherjee B, Richardson J, Grout B, Chase A, McKinnon Deurloo C, Terry KL, Hanley GE, Pike MC, Berchuck A, Ramus SJ, Pearce CL. Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery. *Gynecol Oncol* 2022;168:68-75.
69. Plunkett KR, Armitage JD, Inderjeeth AJ, McDonnell AM, Waithman J, Lau PKH. Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management. *Front Immunol* 2022;13:1048758.
70. Ptasznik G, Papa N, Kelly BD, Thompson J, Stricker P, Roberts MJ, Hofman MS, Buteau J, Murphy DG, Emmett L, Moon D. High prostate-specific membrane antigen (PSMA) positron emission tomography (PET) maximum standardized uptake value in men with PI-RADS score 4 or 5 confers a high probability of significant prostate cancer. *BJU Int* 2022;130 Suppl 3:5-7.
71. Ramsey I, Chan A, Charalambous A, Cheung YT, Darling HS, Eng L, Grech L, Hart NH, Kirk D, Mitchell SA, Poprawski D, Rammant E, Fitch MI, Chan RJ. Exercise counselling and referral in cancer care: an international scoping survey of health care practitioners' knowledge, practices, barriers, and facilitators. *Support Care Cancer* 2022;30:9379-91.
72. Rasheduzzaman M, Murugan AVM, Zhang X, Oliveira T, Dolcetti R, Kenny L, Johnson NW, Kolarich D, Punyadeera C. Head and neck cancer N-glycome traits are cell line and HPV status-dependent. *Anal Bioanal Chem* 2022;414:8401-11.
73. Ryan JT, Nakayama M, Gleeson I, Mannion L, Geso M, Kelly J, Ng SP, Hardcastle N. Functional brain imaging interventions for radiation therapy planning in patients with glioblastoma: a systematic review. *Radiat Oncol* 2022;17:178.
74. Ryckman JM, Thomas TV, Wang M, Wu X, Siva S, Spratt DE, Slotman B, Pal S, Chapin BF, Fitzal F, Soran A, Bex A, Louie AV, Lehrer EJ, Zaorsky NG. Local Treatment of the Primary Tumor for Patients With Metastatic Cancer (PRIME-TX): A Meta-Analysis. *Int J Radiat Oncol Biol Phys* 2022;114:919-35.
75. Salles G, Schuster SJ, Dreyling M, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith SM, Jimenez-Ubieto A, Davis KL, Anjos C, Chu J, Zhang J, Lobetti Bodoni C, Thieblemont C, Fowler NH, Dickinson M, Martinez-Lopez J, Wang Y, Link BK. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. *Blood Adv* 2022;6:5835-43.
76. See D, Le B, Gorelik A, Eastman P. Symptom burden in malignant and non-malignant disease on admission to a palliative care unit. *BMJ Support Palliat Care* 2022;12:e792-7.

77. Sheehan B, Guo C, Neeb A, Paschalis A, Sandhu S, de Bono JS. Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications. *Eur Urol Focus* 2022;8:1157-68.
78. Silva SM, Langley DP, Cossins LR, Samudra AN, Quigley AF, Kapsa RMI, Tothill RW, Greene GW, Moulton SE. Rapid Point-of-Care Electrochemical Sensor for the Detection of Cancer Tn Antigen Carbohydrate in Whole Unprocessed Blood. *ACS Sens* 2022;7:3379-88.
79. Sim BZ, Yong KY, Slavin MA, Yong MK. Risk factors and outcome of concurrent and sequential multiviral cytomegalovirus, Epstein-Barr virus, BK virus, adenovirus and other viral reactivations in transplantation. *Curr Opin Infect Dis* 2022;35:536-44.
80. Siva S, Ali M, Correa RJM, Muacevic A, Ponsky L, Ellis RJ, Lo SS, Onishi H, Swaminath A, McLaughlin M, Morgan SC, Cury FL, Teh BS, Mahadevan A, Kaplan ID, Chu W, Grubb W, Hannan R, Staehler M, Warner A, Louie AV. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). *Lancet Oncol* 2022;23:1508-16.
81. Siva S, Jones G, Bressel M, Shaw M, Chander S, Chu J, Plumridge N, Byrne K, Kothari G, Hardcastle N, Gaudreault M, Kron T, Wheeler G, MacManus M, Hanna GG, Ball DL, David S. Impact of Medical Operability and Total Metastatic Ablation on Outcomes After SABR for Oligometastases. *Int J Radiat Oncol Biol Phys* 2022;114:862-70.
82. Spicer JA, Huttunen KM, Jose J, Dimitrov I, Akhlaghi H, Sutton VR, Voskoboinik I, Trapani J. Small Molecule Inhibitors of Lymphocyte Perforin as Focused Immunosuppressants for Infection and Autoimmunity. *J Med Chem* 2022;65:14305-25.
83. Tedjaseputra A, Kuzich JA, Thiagarajah N, Teh TC, McClelland J, Rahman M, Brook R, Chua CC, Ong DM, Tan SY, Filshie R, Fong CY, Fedele P, Bajel A, Shortt J, Wei AH. Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic. *Leuk Lymphoma* 2022;63:2731-4.
84. Thijssen R, Tian L, Anderson MA, Flensburg C, Jarratt A, Garnham AL, Jabbari JS, Peng H, Lew TE, Teh CE, Gouil Q, Georgiou A, Tan T, Djajawi TM, Tam CS, Seymour JF, Blombery P, Gray DHD, Majewski IJ, Ritchie ME, Roberts AW, Huang DCS. Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy. *Blood* 2022;140:2127-41.
85. Tower H, Dall G, Davey A, Stewart M, Lanteri P, Ruppert M, Lambouras M, Nasir I, Yeow S, Darcy PK, Ingman WV, Parker B, Haynes NM, Britt KL. Estrogen-induced immune changes within the normal mammary gland. *Sci Rep* 2022;12:18986.
86. Tudini E, Andrews J, Lawrence DM, King-Smith SL, Baker N, Baxter L, Beilby J, Bennetts B, Beshay V, Black M, Boughtwood TF, Brion K, Cheong PL, Christie M, Christodoulou J, Chong B, Cox K, Davis MR, Dejong L, Dinger ME, Doig KD, Douglas E, Dubowsky A, Ellul M, Fellowes A, Fisk K, Fortuno C, Friend K, Gallagher RL, Gao S, Hackett E, Hadler J, Hipwell M, Ho G, Hollway G, Hooper AJ, Kassahn KS, Krishnaraj R, Lau C, Le H, San Leong H, Lundie B, Lunke S, Marty A, McPhillips M, Nguyen LT, Nones K, Palmer K, Pearson JV, Quinn MCJ, Rawlings LH, Sadedin S, Sanchez L, Schreiber AW, Sigalas E, Simsek A, Soubrier J, Stark Z, Thompson BA, U J, Vakulin CG, Wells AV, Wise CA, Woods R, Ziolkowski A, Brion MJ, Scott HS, Thorne NP, Spurdle AB. Shariant platform: Enabling evidence sharing across Australian clinical genetic-testing laboratories to support variant interpretation. *Am J Hum Genet* 2022;109:1960-73.
87. Viljoen B, Hofman MS, Chambers SK, Dunn J, Dhillon HM, Davis ID, Ralph N. Experiences of participants in a clinical trial of a novel radioactive treatment for advanced prostate cancer: A nested, qualitative longitudinal study. *PLoS One* 2022;17:e0276063.
88. Vu TM, Loveday BPT, Behrenbruch C, Hollande F, Heriot AG. Theranostics: a fifth pillar of contemporary cancer care? *ANZ J Surg* 2022;92:2782-3.
89. Walker H, Shanthikumar S, Cole T, Neeland M, Hanna D, Haeusler GM. Novel approaches to the prediction and diagnosis of pulmonary complications in the paediatric haematopoietic stem cell transplant patient. *Curr Opin Infect Dis* 2022;35:493-9.

90. Wang J, Prabhakaran S, Larach T, Warriar SK, Bednarski BK, Ngan SY, Leong T, Rodriguez-Bigas M, Peacock O, Chang G, Heriot AG, Kong JC. Treatment strategies for locally recurrent rectal cancer. *Eur J Surg Oncol* 2022;48:2292-8.
91. Wierda WG, Kipps TJ, Al-Sawaf O, Chyla B, Biondo JML, Mun Y, Jiang Y, Seymour JF. Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. *Leuk Lymphoma* 2022;63:2765-84.
92. Wolyniec K, Sharp J, Fisher K, Tothill RW, Bowtell D, Mileskin L, Schofield P. Psychological distress, understanding of cancer and illness uncertainty in patients with Cancer of Unknown Primary. *Psychooncology* 2022;31:1869-76.
93. Wong AK, Grobler A, Le B. ENhANCE trial protocol: A multi-centre, randomised, phase IV trial comparing the efficacy of oxycodone/naloxone prolonged release (OXN PR) versus oxycodone prolonged release (Oxy PR) tablets in patients with advanced cancer. *Contemp Clin Trials Commun* 2022;30:101036.
94. Wong V, de Boer R, Baron-Hay S, Blum R, Boyle F, Chua S, Clarke K, Cuff K, Green M, Lim E, Mok K, Nott L, Nottage M, Tafreshi A, Tsoi D, Uccellini A, Hong W, Gibbs P, Lok SW. Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer. *Clin Breast Cancer* 2022;22:792-800.
95. Zeidan AM, Bewersdorf JP, Buckstein R, Sekeres MA, Steensma DP, Platzbecker U, Loghavi S, Boultonwood J, Bejar R, Bennett JM, Borate U, Brunner AM, Carraway H, Churpek JE, Daver NG, Della Porta M, DeZern AE, Efficace F, Fenaux P, Figueroa ME, Greenberg P, Griffiths EA, Halene S, Hasserjian RP, Hourigan CS, Kim N, Kim TK, Komrokji RS, Kutchroo V, List AF, Little RF, Majeti R, Nazha A, Nimer SD, Odenike O, Padron E, Patnaik MM, Roboz GJ, Sallman DA, Sanz G, Stahl M, Starczynowski DT, Taylor J, Xie Z, Xu M, Savona MR, Wei AH, Abdel-Wahab O, Santini V. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes. *Leukemia* 2022;36:2939-46.
96. Zomerdijk N, Panozzo S, Mileskin L, Yoong J, Nowak AK, Stockler MR, Philip J. Palliative care facilitates the preparedness of caregivers for thoracic cancer patients. *Eur J Cancer Care* 2022;31:e13716.

December

1. Amador C, Bouska A, Wright G, Weisenburger DD, Feldman AL, Greiner TC, Lone W, Heavican T, Smith L, Pileri S, Tabanelli V, Ott G, Rosenwald A, Savage KJ, Slack G, Kim WS, Hye Y, Li Y, Dong G, Song J, Ondrejka S, Cook JR, Barrionuevo C, Lim ST, Ong CK, Chapman J, Inghirami G, Raess PW, Bhagavathi S, Gould C, Blombery P, Jaffe E, Morris SW, Rimsza LM, Vose JM, Staudt L, Chan WC, Iqbal J. Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical Practice. *J Clin Oncol* 2022;40:4261-75.
2. Andritsos LA, Anghelina M, Neal J, Blachly JS, Mathur P, Lele O, Dearden C, Iyengar S, Cross M, Zent CS, Rogers KA, Epperla N, Lozanski G, Oakes CC, Kraut E, Ruppert AS, Zhao Q, Bhat SA, Forconi F, Banerji V, Handunnetti S, Tam CS, Seymour JF, Else M, Kreitman RJ, Saven A, Call T, Parikh SA, Ravandi F, Johnston JB, Tiacci E, Troussard X, Tallman MS, Dietrich S, Tadmor T, Gozzetti A, Zinzani PL, Robak T, Quest G, Demeter J, Rai K, Fernandez SA, Grever M. Development of a distributed international patient data registry for hairy cell leukemia. *Leuk Lymphoma* 2022;63:3021-31.
3. Au L, Larkin J, Turajlic S. Relatlimab and nivolumab in the treatment of melanoma. *Cell* 2022;185:4866-9.
4. Ayton D, Watson E, Betts JM, Doyle J, Teh B, Valoppi G, Cotta M, Robertson M, Peel T. Implementation of an antimicrobial stewardship program in the Australian private hospital system: qualitative study of attitudes to antimicrobial resistance and antimicrobial stewardship. *BMC Health Serv Res* 2022;22:1554.

5. Beatty L, Kemp E, Butow P, Girgis A, Hulbert-Williams N, Kaambwa B, Schofield P, Turner J, Woodman R, Boyle F, Daly A, Jones A, Kiely B, Zdenkowski N, Koczwara B. Finding My Way-Advanced: can a web-based psychosocial intervention improve the mental quality of life for women with metastatic breast cancer vs attention-control? Study protocol of a randomised controlled trial. *BMC Cancer* 2022;22:1353.
6. Blight TJ, Choong PFM. No consistent association between patient-reported outcome measures and coronal alignment following total knee arthroplasty: a narrative review. *ANZ J Surg* 2022;92:3176-81.
7. Bui J, Gellatly R, Othman J, Lindsay J. Subtherapeutic concentrations of posaconazole tablet: determining risk factors and effectiveness of a standardized dose adjustment in hematology inpatients. *Leuk Lymphoma* 2022;63:3418-25.
8. Casarotto M, Lupato V, Giurato G, Guerrieri R, Sulfaro S, Salvati A, D'Angelo E, Furlan C, Menegaldo A, Baboci L, Montico B, Turturici I, Dolcetti R, Romeo S, Baggio V, Corrado S, Businello G, Guido M, Weisz A, Giacomarra V, Franchin G, Steffan A, Sigalotti L, Vaccher E, Boscolo-Rizzo P, Jerry P, Fanetti G, Fratta E. LINE-1 hypomethylation is associated with poor outcomes in locoregionally advanced oropharyngeal cancer. *Clin Epigenetics* 2022;14:171.
9. Chau TCY, Keyser MS, Da Silva JA, Morris EK, Yordanov TE, Dusczyk KP, Paterson S, Yap AS, Hogan BM, Legendijk AK. Dynamically regulated focal adhesions coordinate endothelial cell remodelling in developing vasculature. *Development* 2022;149:dev200454.
10. Chazan G, Jupp J, Bauters T, Duncan N, Weddle KJ, Nomura H, O'Connor S, Chan A, Alkhdair N, Alshamrani M, Buie LW, Chambers P, Chieh TW, DeRemer DL, Duvivier F, Katabalo D, McFarlane T, Mckavanagh D, Mensah K, Martinez EM, Rowan G, Sae-Teaw M, Tadesse TA, Weru I, Alexander M. Impact of coronavirus of 2019 on the delivery of pharmacy services to patients with cancer: An international survey of oncology pharmacy practitioners. *J Oncol Pharm Pract* 2022;28:1832-1847.
11. Chee LYS, Sia J, Milne RL, Foroudi F, Millar JL, Ong WL. Variations in whole brain radiation therapy fractionation for brain metastases in Victoria. *J Med Imaging Radiat Oncol* 2022;66:1106-14.
12. Chen V, Jones M, Cohen L, Yang W, Bedi J, Mohan HM, Apte SS, Larach JT, Flood M, Heriot A, Kong J, Warriar S. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in small bowel adenocarcinoma with peritoneal metastasis: a systematic review. *Pleura Peritoneum* 2022;7:159-167.
13. Claridge Mackonis E, Sykes J, Hardcastle N, Espinoza A, Brown A, Perez G, Evans B, Sheehan H, Haworth A. A comparison of in-house and shared RapidPlan models for prostate radiation therapy planning. *Phys Eng Sci Med* 2022;45:1029-1041.
14. Collins A, Gurren L, McLachlan SA, Wawryk O, Philip J. Communication about early palliative care: A qualitative study of oncology providers' perspectives of navigating the artful introduction to the palliative care team. *Front Oncol* 2022;12:1003357.
15. Cui W, Phillips KA, Anderson RA, Francis PA, Loi S, Loibl S, Partridge AH, Keogh LA. Selection of endpoints in breast cancer clinical trials: a qualitative study of key trial stakeholders. *Am J Cancer Res* 2022;12:5599-612.
16. Day F, Sridharan S, Lynam J, Gedye C, Johnson C, Fraser A, Thompson SR, Michael M, Leong T, Roy A, Kumar M, van der Westhuizen A, Quah GT, Mandaliya H, Mallesara G, Sappiatzer J, Oldmeadow C, Martin J. Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group). *BMC Cancer* 2022;22:1324.
17. Dempsey K, Saw R, Bartula I, Lo S, Lawn C, Pennington T, Spillane A, Boyle F, Dong S, Dieng M, Milne D, Seaman L, Saks D, Lai-Kwon J, Thompson JR, Morton R. Embedding electronic patient-reported outcome measures into routine care for patients with stage III MELanoma (ePROMs-MEL): protocol for a prospective, longitudinal, mixed-methods pilot study. *BMJ Open* 2022;12:e066852.

18. Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, Khan C, Wróbel T, Offner F, Trněný M, Wu SJ, Cartron G, Hertzberg M, Sureda A, Perez-Callejo D, Lundberg L, Relf J, Dixon M, Clark E, Humphrey K, Hutchings M. Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med* 2022;387:2220-31.
19. Donald JS, Yeoh D, McCarthy HJ, Larkins NG. Successful Kidney Transplantation for Children Within 3 Weeks of COVID-19 Infection. *Transplantation* 2022;106:e515-e516.
20. Foley DA, Wong JWS, Keane A, Ramachandran S, Blyth CC, Yeoh DK. Assessing the utility of routine viral surveillance performed in children undergoing autologous stem cell transplantation at a single centre. *Pediatr Blood Cancer* 2022;69:e30012.
21. Garsed DW, Pandey A, Fereday S, Kennedy CJ, Takahashi K, Alsop K, Hamilton PT, Hendley J, Chiew YE, Traficante N, Provan P, Ariyaratne D, Au-Yeung G, Bateman NW, Bowes L, Brand A, Christie EL, Cunningham JM, Friedlander M, Grout B, Harnett P, Hung J, McCauley B, McNally O, Piskorz AM, Saner FAM, Vierkant RA, Wang C, Winham SJ, Pharoah PDP, Brenton JD, Conrads TP, Maxwell GL, Ramus SJ, Pearce CL, Pike MC, Nelson BH, Goode EL, DeFazio A, Bowtell DDL. The genomic and immune landscape of long-term survivors of high-grade serous ovarian cancer. *Nat Genet* 2022;54:1853-64.
22. George ES, Sood S, Kiss N, Daly RM, Nicoll AJ, Roberts SK, Baguley BJ. The Evidence Surrounding Non-Alcoholic Fatty Liver Disease in Individuals with Cancer: A Systematic Literature Review. *Curr Oncol* 2022;30:48-74.
23. Goel S, Tan AR, Rugo HS, Aftimos P, Andric Z, Beelen A, Zhang J, Yi JS, Malik R, O'Shaughnessy J. Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2. *Future Oncol* 2022;18:3701-11.
24. Goff Z, Abbotsford J, Yeoh DK, Bowen AC, Campbell AJ, Foley DA, Ford TJ, Hazelton B, Thu Le H, McLeod C, Ware B, Snelling T, Blyth CC. The Impact of a Multifaceted Tertiary Pediatric Hospital's Antimicrobial Stewardship Service. *Pediatr Infect Dis J* 2022;41:959-966.
25. Hurvitz SA, Bachelot T, Bianchini G, Harbeck N, Loi S, Park YH, Prat A, Gilham L, Boulet T, Gochitashvili N, Monturus E, Lambertini C, Nyawira B, Knott A, Restuccia E, Schmid P. ASTEFANIA: adjuvant adotrastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer. *Future Oncol* 2022;18:3563-72.
26. Jain A, Flood MP, Ramsay R, Michael M, Kong JCH, Heriot AG. Appendiceal pseudomyxoma peritonei: unmasking the indolent invader. *ANZ J Surg* 2022;92:3135-3136.
27. Kaushik AK, Tarangelo A, Boroughs LK, Ragavan M, Zhang Y, Wu CY, Li X, Ahumada K, Chiang JC, Tcheuyap VT, Saatchi F, Do QN, Yong C, Rosales T, Stevens C, Rao AD, Faubert B, Pachnis P, Zacharias LG, Vu H, Cai F, Mathews TP, Genovese G, Slusher BS, Kapur P, Sun X, Merritt M, Brugarolas J, DeBerardinis RJ. In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma. *Sci Adv* 2022;8:eabp8293.
28. Kieu V, Stern C, Harris J, Jayasinghe Y, Bradford N, Cui W, Deans R, Hunter T, Allingham C, Kane SC, Lau LS, Logan S, McLachlan R, Neville K, Peate M, Phillips M, Saunders C, Tome M, Upreti R, White K, Anazodo A, Hart RJ. Australian fertility preservation guidelines for people with cancer 2022: review and recommendations. *Med J Aust* 2022;217:564-9.
29. Kiss N, Curtis A. Current Insights in Nutrition Assessment and Intervention for Malnutrition or Muscle Loss in People with Lung Cancer: A Narrative Review. *Adv Nutr* 2022;13:2420-32.
30. Kong G, Hicks RJ. PRRT for higher-grade neuroendocrine neoplasms: What is still acceptable? *Curr Opin Pharmacol* 2022;67:102293.
31. Kong IY, Trezise S, Light A, Todorovski I, Arnau GM, Gadipally S, Yoannidis D, Simpson KJ, Dong X, Whitehead L, Tempny JC, Farchione AJ, Sheikh AA, Groom JR, Rogers KL, Herold MJ, Bryant VL, Ritchie ME, Willis SN, Johnstone RW, Hodgkin PD, Nutt SL, Vervoort SJ, Hawkins ED. Epigenetic modulators of B cell fate identified through coupled phenotype-transcriptome analysis. *Cell Death Differ* 2022;29:2519-30.

32. Krishnasamy M, Hyatt A, Chung H, Gough K, Fitch M. Refocusing cancer supportive care: a framework for integrated cancer care. *Support Care Cancer* 2022;31:14.
33. Lacey JR, Dubowitz JA, Riedel B. Asystole following spinal anaesthesia: the hazards of intrinsic cardiac reflexes. *Anaesth Rep* 2022;10:e12198.
34. Ligorio F, Di Cosimo S, Verderio P, Ciniselli CM, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, Michiels S, Triulzi T, Tagliabue E, El-Abed S, Izquierdo M, de Azambuja E, Nuciforo P, Huober J, Moscetti L, Janni W, Coccia-Portugal MA, Corsetto PA, Belfiore A, Lorenzini D, Daidone MG, Vingiani A, Gianni L, Pupa SM, Bianchini G, Pruneri G, Vernieri C. Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab. *J Natl Cancer Inst* 2022;114:1720-7.
35. Lin MY, Mileskin L, McNally O, Kondalsamy-Chennakesavan S, Narayan K. Prognostic significance of FIGO 2018 staging of loco-regionally advanced cervical cancer (LRACC) with the use of MRI and PET and implications for treatment selection. *Gynecol Oncol* 2022;169:91-7.
36. Meagher NS, Gorringer KL, Wakefield M, Bolithon A, Pang CNI, Chiu DS, Anglesio MS, Mallitt KA, Doherty JA, Harris HR, Schildkraut JM, Berchuck A, Cushing-Haugen KL, Chezar K, Chou A, Tan A, Alsop J, Barlow E, Beckmann MW, Boros J, Bowtell DDL, AOCs Group, Brand AH, Brenton JD, Campbell I, Cheasley D, Cohen J, Cybulski C, Elishaev E, Erber R, Farrell R, Fischer A, Fu Z, Gilks B, Gill AJ, Australian Pancreatic Genome Initiative, Gourley C, Grube M, Harnett PR, Hartmann A, Hettiaratchi A, Høgdall CK, Huzarski T, Jakubowska A, Jimenez-Linan M, Kennedy CJ, Kim BG, Kim JW, Kim JH, Klett K, Koziak JM, Lai T, Laslavic A, Lester J, Leung Y, Li N, Liauw W, Lim BWX, Linder A, Lubiński J, Mahale S, Mateoiu C, McInerney S, Menkiszak J, Minoo P, Mittelstadt S, Morris D, Orsulic S, Park SY, Pearce CL, Pearson JV, Pike MC, Quinn CM, Mohan GR, Rao J, Riggan MJ, Ruebner M, Salfinger S, Scott CL, Shah M, Steed H, Stewart CJR, Subramanian D, Sung S, Tang K, Timpson P, Ward RL, Wiedenhofer R, Thorne H, kConFab Investigators, Cohen PA, Crowe P, Fasching PA, Gronwald J, Hawkins NJ, Høgdall E, Huntsman DG, James PA, Karlan BY, Kelemen LE, Kommoss S, Konecny GE, Modugno F, Park SK, Staebler A, Sundfeldt K, Wu AH, Talhouk A, Pharoah PDP, Anderson L, DeFazio A, Köbel M, Friedlander ML, Ramus SJ. Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes. *Clin Cancer Res* 2022;28:5383-95.
37. Miligy IM, Toss MS, Gorringer KL, Ellis IO, Green AR, Rakha EA. Aurora Kinase A Is an Independent Predictor of Invasive Recurrence in Breast Ductal Carcinoma in situ. *Pathobiology* 2022;89:382-92.
38. Nelson N, Feurstein S, Niaz A, Truong J, Holien JK, Lucas S, Fairfax K, Dickinson J, Bryan TM. Functional genomics for curation of variants in telomere biology disorder associated genes: A systematic review. *Genet Med* 2022;25:100354.
39. Nolan MT, Creati L, Koczwara B, Kritharides L, Lynam J, Lyon AR, Negishi K, Ngo DTM, Thomas L, Vardy J, Sverdlov AL. First European Society of Cardiology Cardio-Oncology Guidelines: A Big Leap Forward for an Emerging Specialty. *Heart Lung Circ* 2022;31:1563-1567.
40. Ong S, Pascoe C, Kelly BD, Ballok Z, Webb D, Bolton D, Murphy D, Sengupta S, Bowden P, Lawrentschuk N. Distant Nodes Seen on PSMA PET-CT Staging Predicts Post-Treatment Progression in Men with Newly Diagnosed Prostate Cancer-A Prospective Cohort Study. *Cancers* 2022;14:6134.
41. Pollyea DA, Pratz KW, Wei AH, Pullarkat V, Jonas BA, Recher C, Babu S, Schuh AC, Dail M, Sun Y, Potluri J, Chyla B, DiNardo CD. Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine. *Clin Cancer Res* 2022;28:5272-9.
42. Ravandi F, Kreitman RJ, Tiacci E, Andritsos L, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call T, Chihara D, Dearden C, Demeter J, Dietrich S, Else M, Epperla N, Falini B, Forconi F, Gladstone DE, Gozzetti A, Iyengar S, Johnston JB, Jorgensen J, Juliusson G, Lauria F, Lozanski G, Parikh SA, Park JH, Polliack A, Quest G, Robak T, Rogers KA, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam CS, Thompson PA, Troussard X, Zent CS, Zenz T, Zinzani PL, Wörmann B, Rai K, Grever M. Consensus

opinion from an international group of experts on measurable residual disease in hairy cell leukemia. *Blood Cancer J* 2022;12:165.

43. Reynolds HM, Tadimalla S, Wang YF, Montazerolghaem M, Sun Y, Williams S, Mitchell C, Finnegan ME, Murphy DG, Haworth A. Semi-quantitative and quantitative dynamic contrast-enhanced (DCE) MRI parameters as prostate cancer imaging biomarkers for biologically targeted radiation therapy. *Cancer Imaging* 2022;22:71.
44. Rudd-Schmidt JA, Laine RF, Noori T, Brennan AJ, Voskoboinik I. ALFA-PRF: a novel approach to detect murine perforin release from CTLs into the immune synapse. *Front Immunol* 2022;13:931820.
45. Ruecker K, Gill P, Marascia D, Loveday BP, Pang JB. Locally invasive squamous cell carcinoma of the pancreas requiring multivisceral resection. *ANZ J Surg* 2022;92:3366-8.
46. Rugo HS, Im SA, Joy AA, Shparyk Y, Walshe JM, Sleckman B, Loi S, Theall KP, Kim S, Huang X, Bananis E, Mahtani R, Finn RS, Diéras V. Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3. *Breast* 2022;66:324-331.
47. Sigurdson S, Marom EM, Rimner A, Shepherd A, Szolkowska M, Roden AC, Marino M, Tomiyama N, Ball D, Falkson C, Rajan A. The therapeutic relevance of a BRCA2 mutation in a patient with recurrent thymoma: a case report. *Mediastinum* 2022;6:40.
48. Smith D, Robledo KP, Yip S, Cummins MM, Kok PS, Lee YC, Friedlander M, Baron-Hay S, Shannon C, Coward J, Beale P, Goss G, Meniawy T, Lombard J, Spurdle AB, Andrews J, Stockler MR, Mileskin L, Antill Y. Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA). *Cancers* 2022;15:254.
49. Tapia M, Chia C, Manji J, Magarey MJR, Flatman S. Surgeon-performed ultrasound changes surgical management in patients with thyroid cancer. *ANZ J Surg* 2022;92:3268-72.
50. Tee QX, Wong A, Nambiar M, Lau KK. Granulomatosis with polyangiitis: Common and uncommon presentations. *J Med Imaging Radiat Oncol* 2022;66:1089-1096.
51. Thomassen M, Mesman RLS, Hansen TVO, Menendez M, Rossing M, Esteban-Sanchez A, Tudini E, Tornngren T, Parsons MT, Pedersen IS, Teo SH, Kruse TA, Moller P, Borg A, Jensen UB, Christensen LL, Singer CF, Muhr D, Santamarina M, Brandao R, Andresen BS, Feng BJ, Canson D, Richardson ME, Karam R, Pesaran T, LaDuca H, Conner BR, Abualkheir N, Hoang L, Calleja F, Andrews L, James PA, Bunyan D, Hamblett A, Radice P, Goldgar DE, Walker LC, Engel C, Claes KBM, Machackova E, Baralle D, Viel A, Wappenschmidt B, Lazaro C, Vega A, Consortium E, Vreeswijk MPG, de la Hoya M, Spurdle AB. Clinical, splicing, and functional analysis to classify BRCA2 exon 3 variants: Application of a points-based ACMG/AMP approach. *Hum Mutat* 2022;43:1921-44.
52. Watson LR, Lew TE, Fox LC, Khot A, van der Weyden C. Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma. *Leuk Lymphoma* 2022;63:3217-21.
53. Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Champion R, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Jiang Q, Sun Y, Chyla B, Mendes W, DiNardo CD. Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. *Blood* 2022;140:2754-6.
54. Welarathna S, Velautham S, Wanninayake M, Sarasanandarajah S. Evaluation of patient doses for routine digital radiography procedures toward establishing an institutional diagnostic reference levels: A case study in Sri Lanka. *J Appl Clin Med Phys* 2022;23:e13852.
55. Wong J, Khan A, Kong J, Warriar S, Heriot A. Sarcopenia: the 'hidden' marker of surgical outcome. *ANZ J Surg* 2022;92:3128-3129.

56. Wu Y, Clark KC, Nguyen EV, Niranjana B, Horvath LG, Taylor RA, Daly RJ. Proteomic characterisation of prostate cancer intercellular communication reveals cell type-selective signalling and TMSB4X-dependent fibroblast reprogramming. *Cell Oncol* 2022;45:1311-28.
57. Ye Z, Lin S, Zhao X, Bennett MF, Brown NJ, Wallis M, Gao X, Sun L, Wu J, Vedururu R, Witkowski T, Gardiner F, Stutterd C, Duan J, Mullen SA, McGillivray G, Bodek S, Valente G, Reagan M, Yao Y, Li L, Chen L, Boys A, Adikari TN, Cao D, Hu Z, Beshay V, Zhang VW, Berkovic SF, Scheffer IE, Liao J, Hildebrand MS. Mosaicism in tuberous sclerosis complex: Lowering the threshold for clinical reporting. *Hum Mutat* 2022;43:1956-69.